{"PMC7194728": [["Related linksLei Fang and colleagues1 extrapolated results from a molecular study of coronaviruses, which showed that this group of viruses uses angiotensin-converting enzyme 2 (ACE2) to target cells on the epithelium of the lungs, intestine, kidneys, and blood vessels.2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), would probably share these properties.Related linksACE2 is upregulated by antagonists along the renin\u2013angiotensin system, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which are common antihypertensive drugs used to treat patients with hypertension and diabetes.", [["cells", "ANATOMY", 194, 199], ["epithelium", "ANATOMY", 207, 217], ["lungs", "ANATOMY", 225, 230], ["intestine", "ANATOMY", 232, 241], ["kidneys", "ANATOMY", 243, 250], ["blood vessels", "ANATOMY", 256, 269], ["angiotensin", "CHEMICAL", 145, 156], ["acute respiratory syndrome coronavirus", "DISEASE", 279, 317], ["coronavirus disease", "DISEASE", 347, 366], ["COVID-19", "CHEMICAL", 373, 381], ["angiotensin", "CHEMICAL", 514, 525], ["angiotensin", "CHEMICAL", 567, 578], ["ARBs", "CHEMICAL", 598, 602], ["hypertension", "DISEASE", 673, 685], ["diabetes", "DISEASE", 690, 698], ["coronaviruses", "ORGANISM", 85, 98], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 145, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["cells", "CELL", 194, 199], ["epithelium", "TISSUE", 207, 217], ["lungs", "ORGAN", 225, 230], ["intestine", "ORGAN", 232, 241], ["kidneys", "ORGAN", 243, 250], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 256, 269], ["Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 272, 319], ["SARS-CoV-2", "ORGANISM", 321, 331], ["linksACE2", "GENE_OR_GENE_PRODUCT", 430, 439], ["renin\u2013angiotensin", "GENE_OR_GENE_PRODUCT", 480, 497], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 514, 543], ["ACEIs", "SIMPLE_CHEMICAL", 556, 561], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 567, 596], ["ARBs", "SIMPLE_CHEMICAL", 598, 602], ["patients", "ORGANISM", 659, 667], ["angiotensin-converting enzyme 2", "PROTEIN", 145, 176], ["ACE2", "PROTEIN", 178, 182], ["linksACE2", "DNA", 430, 439], ["patients", "SPECIES", 659, 667], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 272, 317], ["SARS-CoV-2", "SPECIES", 321, 331], ["a molecular study", "TEST", 64, 81], ["coronaviruses", "PROBLEM", 85, 98], ["angiotensin", "TREATMENT", 145, 156], ["converting enzyme", "TEST", 157, 174], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 272, 317], ["SARS-CoV", "TEST", 321, 329], ["coronavirus disease", "PROBLEM", 347, 366], ["COVID", "TEST", 373, 378], ["Related linksACE2", "PROBLEM", 422, 439], ["antagonists", "TREATMENT", 458, 469], ["angiotensin", "TREATMENT", 514, 525], ["enzyme inhibitors", "TREATMENT", 537, 554], ["ACEIs", "TREATMENT", 556, 561], ["angiotensin receptor blockers", "TREATMENT", 567, 596], ["ARBs", "TREATMENT", 598, 602], ["common antihypertensive drugs", "TREATMENT", 615, 644], ["hypertension", "PROBLEM", 673, 685], ["diabetes", "PROBLEM", 690, 698], ["viruses", "OBSERVATION", 132, 139], ["epithelium", "ANATOMY_MODIFIER", 207, 217], ["lungs", "ANATOMY", 225, 230], ["intestine", "ANATOMY", 232, 241], ["kidneys", "ANATOMY", 243, 250], ["blood vessels", "ANATOMY", 256, 269], ["acute", "OBSERVATION_MODIFIER", 279, 284], ["respiratory syndrome", "OBSERVATION", 285, 305], ["coronavirus disease", "OBSERVATION", 347, 366], ["upregulated", "OBSERVATION_MODIFIER", 443, 454], ["hypertension", "OBSERVATION", 673, 685], ["diabetes", "OBSERVATION", 690, 698]]], ["Whether an association exists between increased ACE2 expression and risk of infection with SARS-CoV-2 or severity of COVID-19 is currently not understood.", [["infection", "DISEASE", 76, 85], ["SARS", "DISEASE", 91, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["SARS-CoV-2", "ORGANISM", 91, 101], ["COVID-19", "GENE_OR_GENE_PRODUCT", 117, 125], ["ACE2", "PROTEIN", 48, 52], ["SARS-CoV", "SPECIES", 91, 99], ["increased ACE2 expression", "PROBLEM", 38, 63], ["infection", "PROBLEM", 76, 85], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["COVID", "TEST", 117, 122], ["infection", "OBSERVATION", 76, 85]]], ["Nevertheless, Fang and colleagues1 suggested alternative treatment could be sought for those at high risk of infection, and broader public knowledge of this hypothesis has led to increasing uncertainty and concern.Related linksClinical societies have reinforced that there is currently not enough information to make recommendations and have reiterated that patients should not discontinue treatment.", [["infection", "DISEASE", 109, 118], ["patients", "ORGANISM", 358, 366], ["patients", "SPECIES", 358, 366], ["colleagues1", "TREATMENT", 23, 34], ["alternative treatment", "TREATMENT", 45, 66], ["infection", "PROBLEM", 109, 118], ["this hypothesis", "PROBLEM", 152, 167], ["treatment", "TREATMENT", 390, 399], ["infection", "OBSERVATION", 109, 118]]], ["Regardless, many patients are seeking strategies to reduce their risk and might discontinue treatment with or without direction from their care providers.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["treatment", "TREATMENT", 92, 101]]], ["In response to this action, it is prudent to consider whether discontinuation of ACEIs and ARBs is safe in such patients and if alternative drugs are needed.", [["ACEIs", "CHEMICAL", 81, 86], ["ARBs", "CHEMICAL", 91, 95], ["ACEIs", "SIMPLE_CHEMICAL", 81, 86], ["ARBs", "SIMPLE_CHEMICAL", 91, 95], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["ACEIs", "TREATMENT", 81, 86], ["ARBs", "TREATMENT", 91, 95], ["alternative drugs", "TREATMENT", 128, 145]]], ["This information is intended not to supersede clinical society statements but, rather, supply information in situations in which patients are adamant in their desire to discontinue ACEIs or ARBs.Related linksDiscontinuation of antihypertensive drugs in response to pathogens and pandemics has not been recorded in published work.", [["ACEIs", "CHEMICAL", 181, 186], ["patients", "ORGANISM", 129, 137], ["ACEIs", "SIMPLE_CHEMICAL", 181, 186], ["ARBs", "SIMPLE_CHEMICAL", 190, 194], ["patients", "SPECIES", 129, 137], ["ACEIs", "TREATMENT", 181, 186], ["ARBs", "TREATMENT", 190, 194], ["antihypertensive drugs", "TREATMENT", 227, 249], ["pathogens", "PROBLEM", 265, 274], ["pandemics", "PROBLEM", 279, 288]]], ["Thus, a review of studies investigating general discontinuation of antihypertensive drugs is warranted, including results from population-based hypertension studies that include washout periods.", [["hypertension", "DISEASE", 144, 156], ["a review of studies", "TEST", 6, 25], ["antihypertensive drugs", "TREATMENT", 67, 89], ["based hypertension studies", "PROBLEM", 138, 164], ["washout periods", "TREATMENT", 178, 193], ["hypertension", "OBSERVATION", 144, 156]]], ["Although specific antihypertensive agents were not reported in a cohort of patients with previous cardiovascular disease,3 discontinuation of antihypertensive drugs was well tolerated.", [["cardiovascular", "ANATOMY", 98, 112], ["cardiovascular disease", "DISEASE", 98, 120], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["specific antihypertensive agents", "TREATMENT", 9, 41], ["previous cardiovascular disease", "PROBLEM", 89, 120], ["discontinuation of antihypertensive drugs", "TREATMENT", 123, 164], ["cardiovascular", "ANATOMY", 98, 112], ["disease", "OBSERVATION", 113, 120]]], ["However, 14% (82 of 604) of patients in that study had side-effects and needed so-called escape treatment to avoid dangerous blood pressure levels (>180/110 mm Hg) or other disorders.", [["blood", "ANATOMY", 125, 130], ["Hg", "CHEMICAL", 160, 162], ["patients", "ORGANISM", 28, 36], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["patients", "SPECIES", 28, 36], ["that study", "TEST", 40, 50], ["so-called escape treatment", "TREATMENT", 79, 105], ["dangerous blood pressure levels", "TEST", 115, 146], ["other disorders", "PROBLEM", 167, 182]]], ["Common adverse events associated with discontinuation include some cardiovascular side-effects, headache, anxiety, chest pain, dizziness, and malaise.3, 4 In a study in which ACEIs were discontinued,5 the effect on blood pressure was paradoxical, with an immediate increase over 48 h and then a return to baseline or even lower levels.", [["cardiovascular", "ANATOMY", 67, 81], ["chest", "ANATOMY", 115, 120], ["blood", "ANATOMY", 215, 220], ["headache", "DISEASE", 96, 104], ["anxiety", "DISEASE", 106, 113], ["chest pain", "DISEASE", 115, 125], ["dizziness", "DISEASE", 127, 136], ["ACEIs", "CHEMICAL", 175, 180], ["chest", "ORGANISM_SUBDIVISION", 115, 120], ["ACEIs", "SIMPLE_CHEMICAL", 175, 180], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["Common adverse events", "PROBLEM", 0, 21], ["discontinuation", "TREATMENT", 38, 53], ["some cardiovascular side-effects", "PROBLEM", 62, 94], ["headache", "PROBLEM", 96, 104], ["anxiety", "PROBLEM", 106, 113], ["chest pain", "PROBLEM", 115, 125], ["dizziness", "PROBLEM", 127, 136], ["malaise", "PROBLEM", 142, 149], ["a study", "TEST", 158, 165], ["ACEIs", "TREATMENT", 175, 180], ["blood pressure", "TEST", 215, 229], ["chest", "ANATOMY", 115, 120], ["dizziness", "OBSERVATION", 127, 136], ["malaise", "OBSERVATION", 142, 149], ["increase", "OBSERVATION_MODIFIER", 265, 273]]], ["Long-term effects on blood pressure after discontinuation might depend on patient factors, and as far as we know no studies have assessed long-term outcomes.Related linksCaution must be practiced when recommending discontinuation or alternative treatment.", [["blood", "ANATOMY", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["blood pressure", "TEST", 21, 35], ["discontinuation", "TREATMENT", 42, 57], ["discontinuation", "TREATMENT", 214, 229], ["alternative treatment", "TREATMENT", 233, 254], ["-term", "OBSERVATION_MODIFIER", 4, 9]]], ["For patients on multidrug therapy, other antihypertensive agents might not be safe to discontinue and should be continued, particularly central-acting agents such as \u03b2-blockers and \u03b12-agonists, which can have severe withdrawal syndromes.", [["patients", "ORGANISM", 4, 12], ["\u03b2-blockers", "SIMPLE_CHEMICAL", 166, 176], ["\u03b12-agonists", "SIMPLE_CHEMICAL", 181, 192], ["patients", "SPECIES", 4, 12], ["multidrug therapy", "TREATMENT", 16, 33], ["other antihypertensive agents", "TREATMENT", 35, 64], ["central-acting agents", "TREATMENT", 136, 157], ["\u03b2-blockers", "TREATMENT", 166, 176], ["\u03b12-agonists", "TREATMENT", 181, 192], ["severe withdrawal syndromes", "PROBLEM", 209, 236], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["withdrawal syndromes", "OBSERVATION", 216, 236]]], ["Second, if alternative agents are to be suggested, clinical guidelines for selection of these treatments should be followed.Related links", [["alternative agents", "TREATMENT", 11, 29], ["these treatments", "TREATMENT", 88, 104]]]], "PMC7454910": [["IntroductionThe first case of a new coronavirus, COVID-19, was first reported in the USA on 21 January 2020.", [["coronavirus", "DISEASE", 36, 47], ["coronavirus", "ORGANISM", 36, 47], ["a new coronavirus", "PROBLEM", 30, 47], ["COVID", "TEST", 49, 54]]], ["In just 3 months, there were over 1 million cases in the USA with more than 57,000 deaths attributed to the virus (Hauck et al., 2020).", [["deaths", "DISEASE", 83, 89], ["the virus", "PROBLEM", 104, 113]]], ["Popular media outlets reported disturbing headlines linking the pandemic to a \u2018mental health crisis\u2019, noting that \u2018The U.S. is ill-prepared, with some clinics already on the brink of collapse\u2019 (Wan, 2020).", [["crisis\u2019", "DISEASE", 93, 100], ["collapse", "PROBLEM", 183, 191], ["collapse", "OBSERVATION", 183, 191]]], ["Celebrities also focused on the link between the coronavirus and mental health issues through various social media platforms, noting increased levels of anxiety and depression (Macke, 2020).", [["coronavirus", "DISEASE", 49, 60], ["anxiety", "DISEASE", 153, 160], ["depression", "DISEASE", 165, 175], ["the coronavirus and mental health issues", "PROBLEM", 45, 85], ["anxiety", "PROBLEM", 153, 160], ["depression", "PROBLEM", 165, 175], ["coronavirus", "OBSERVATION", 49, 60]]], ["Academic researchers also warned of a \u2018considerable increase\u2019 in anxiety and depressive symptoms, even among those individuals who did not have a previously diagnosed mental health condition (Cullen et al., 2020).", [["anxiety", "DISEASE", 65, 72], ["depressive symptoms", "DISEASE", 77, 96], ["anxiety", "PROBLEM", 65, 72], ["depressive symptoms", "PROBLEM", 77, 96], ["considerable", "OBSERVATION_MODIFIER", 39, 51], ["increase", "OBSERVATION_MODIFIER", 52, 60]]], ["But is there empirical evidence to support a link between the pandemic and an increase in reported mental health issues?", [["the pandemic", "PROBLEM", 58, 70], ["an increase in reported mental health issues", "PROBLEM", 75, 119], ["increase", "OBSERVATION_MODIFIER", 78, 86]]], ["The purpose of this article is to examine the relationship between the COVID-19 pandemic and the number, type, and locations of 911 mental health calls reported in the City of Detroit, one of the areas that has been particularly hard-hit by the virus.Mental health in times of crisisWhile the global impacts of the COVID-19 pandemic have been unprecedented, the study of mental health in times of crisis has a rich history.", [["COVID-19", "ORGANISM", 315, 323], ["the virus", "PROBLEM", 241, 250], ["crisis", "PROBLEM", 277, 283], ["the study", "TEST", 358, 367], ["crisis", "PROBLEM", 397, 403], ["crisis", "OBSERVATION", 277, 283], ["global", "OBSERVATION_MODIFIER", 293, 299], ["impacts", "OBSERVATION_MODIFIER", 300, 307]]], ["The psychological impacts of tragic events such as the World Trade Center terrorist attacks, hurricanes, earthquakes, fires, and mass shootings on the general public as well as first responders have been examined (Gard and Ruzek, 2006; Jones et al., 2012; Shultz et al., 2013).", [["terrorist attacks", "DISEASE", 74, 91], ["hurricanes", "DISEASE", 93, 103], ["earthquakes", "DISEASE", 105, 116], ["tragic events", "PROBLEM", 29, 42], ["mass shootings", "PROBLEM", 129, 143]]], ["These events may result in heightened levels of fear, anxiety, helplessness, post-traumatic stress disorder (PTSD), and depression.Mental health in times of crisisSimilarly, researchers have examined the relationship between mental health and public health emergencies, such as the severe acute respiratory syndrome epidemic in 2003 and the human immunodeficiency virus and acquired immune deficiency syndrome (AIDs/HIV) epidemic (which began in 1982) (Ho et al., 2020; Lau et al., 2008; KFF.org, 2019).", [["anxiety", "DISEASE", 54, 61], ["helplessness", "DISEASE", 63, 75], ["traumatic stress disorder", "DISEASE", 82, 107], ["PTSD", "DISEASE", 109, 113], ["depression", "DISEASE", 120, 130], ["acute respiratory syndrome", "DISEASE", 289, 315], ["human immunodeficiency virus", "DISEASE", 341, 369], ["acquired immune deficiency syndrome", "DISEASE", 374, 409], ["AIDs/HIV) epidemic", "DISEASE", 411, 429], ["human immunodeficiency virus", "ORGANISM", 341, 369], ["human", "SPECIES", 341, 346], ["immunodeficiency virus", "SPECIES", 347, 369], ["human immunodeficiency virus", "SPECIES", 341, 369], ["HIV", "SPECIES", 416, 419], ["heightened levels of fear", "PROBLEM", 27, 52], ["anxiety", "PROBLEM", 54, 61], ["helplessness", "PROBLEM", 63, 75], ["post-traumatic stress disorder", "PROBLEM", 77, 107], ["PTSD", "PROBLEM", 109, 113], ["depression", "PROBLEM", 120, 130], ["the severe acute respiratory syndrome", "PROBLEM", 278, 315], ["the human immunodeficiency virus", "PROBLEM", 337, 369], ["acquired immune deficiency syndrome", "PROBLEM", 374, 409], ["HIV", "PROBLEM", 416, 419], ["severe", "OBSERVATION_MODIFIER", 282, 288], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["respiratory syndrome", "OBSERVATION", 295, 315], ["immune deficiency", "OBSERVATION", 383, 400]]], ["These impacts may be further exacerbated by extended quarantines, closures of non-essential businesses, and the impact on the economy, as individuals struggle with social isolation and fear of unemployment and financial ruin (Ho et al., 2020).", [["social isolation", "TREATMENT", 164, 180], ["may be", "UNCERTAINTY", 14, 20], ["non-essential", "OBSERVATION_MODIFIER", 78, 91], ["businesses", "OBSERVATION", 92, 102]]], ["Reger et al. (2020) further note the potential impacts of stay-at-home orders, lack of ability to participate in religious services, and reduced access to mental health care professionals on the suicide rate.", [["the suicide rate", "TREATMENT", 191, 207]]], ["The very measures that have been taken to prevent the spread of COVID-19 (i.e. closures of schools, businesses, community centres) may ultimately lead to a heightened level of suicide risk.Mental health in times of crisisIn response to the COVID-19 pandemic, a survey was launched on 23 April 2020 to measure the impact on mental health.", [["COVID", "TEST", 64, 69], ["suicide risk", "PROBLEM", 176, 188], ["crisis", "PROBLEM", 215, 221], ["crisis", "OBSERVATION", 215, 221]]], ["Conducted by the US Census Bureau and the National Center for Health Statistics, the results indicated that between 23 April 2020 and 19 May 2020, approximately one-third of respondents reported symptoms of anxiety or depressive disorders.", [["anxiety", "DISEASE", 207, 214], ["depressive disorders", "DISEASE", 218, 238], ["symptoms", "PROBLEM", 195, 203], ["anxiety", "PROBLEM", 207, 214], ["depressive disorders", "PROBLEM", 218, 238]]], ["In contrast, the results of a comparable survey found that from January to June 2019, only 11% of respondents indicated that they had experienced symptoms of anxiety or depressive disorder (Centers for Disease Control and Prevention, 2020).", [["anxiety", "DISEASE", 158, 165], ["depressive disorder", "DISEASE", 169, 188], ["symptoms", "PROBLEM", 146, 154], ["anxiety", "PROBLEM", 158, 165], ["depressive disorder", "PROBLEM", 169, 188], ["Disease Control", "TREATMENT", 202, 217]]], ["Other researchers have focused on the psychiatric consequences of the COVID-19 virus itself on those infected, such as inflammation of the brain, damage to nerve cell direct infection of the brain, and other acute neuropsychiatric symptoms (Brenner, 2020; Troyer et al., 2020).", [["brain", "ANATOMY", 139, 144], ["nerve cell", "ANATOMY", 156, 166], ["brain", "ANATOMY", 191, 196], ["psychiatric", "DISEASE", 38, 49], ["inflammation of the brain", "DISEASE", 119, 144], ["infection of the brain", "DISEASE", 174, 196], ["COVID-19 virus", "ORGANISM", 70, 84], ["brain", "ORGAN", 139, 144], ["nerve cell", "CELL", 156, 166], ["brain", "ORGAN", 191, 196], ["COVID-19 virus", "SPECIES", 70, 84], ["the COVID", "TEST", 66, 75], ["inflammation of the brain", "PROBLEM", 119, 144], ["damage to nerve cell direct infection of the brain", "PROBLEM", 146, 196], ["other acute neuropsychiatric symptoms", "PROBLEM", 202, 239], ["inflammation", "OBSERVATION", 119, 131], ["brain", "ANATOMY", 139, 144], ["nerve cell", "OBSERVATION", 156, 166], ["infection", "OBSERVATION", 174, 183], ["brain", "ANATOMY", 191, 196], ["acute", "OBSERVATION_MODIFIER", 208, 213]]], ["While individuals may report heightened levels of mental distress, do increased levels of anxiety and depression result in greater numbers of emergency calls for service to the police for mental health-related issues?The police and mental health calls for serviceIt is not uncommon for the police to come in to contact with mentally ill citizens.", [["anxiety", "DISEASE", 90, 97], ["depression", "DISEASE", 102, 112], ["mentally ill", "DISEASE", 324, 336], ["mental distress", "PROBLEM", 50, 65], ["anxiety", "PROBLEM", 90, 97], ["depression", "PROBLEM", 102, 112]]], ["194), law enforcement officers \u2018are often the first and only community resource to respond to a situation where a person is having a mental health crisis (emphasis added)\u2019.", [["person", "SPECIES", 114, 120], ["a mental health crisis", "PROBLEM", 131, 153]]], ["Surveys have noted that individuals with mental illnesses are painted as violent, dangerous, and unpredictable, leading to fear of those with disorders.", [["mental illnesses", "PROBLEM", 41, 57], ["disorders", "PROBLEM", 142, 151]]], ["This trepidation often leads to calls for service to the police to control the \u2018problem\u2019, whether it be complaints of homelessness; panhandling; disturbing the peace; or, in some cases, valid concerns regarding the behaviour of a violent person struggling with their disorder.", [["problem\u2019", "DISEASE", 80, 88], ["homelessness", "DISEASE", 118, 130], ["panhandling", "DISEASE", 132, 143], ["person", "SPECIES", 238, 244], ["homelessness", "PROBLEM", 118, 130], ["their disorder", "PROBLEM", 261, 275]]], ["Serving in the peace-keeping role, law enforcement officers are often transformed into \u2018street-corner psychiatrists\u2019 and act as gatekeepers for both the criminal justice and mental health care systems (Teplin, 2000; Lersch and Chakraborty, 2020).The police and mental health calls for serviceIn the special cases of suicide and suicide threats, the police may be called either to protect the individual-threatening suicide or to investigate the circumstances surrounding the death.", [["death", "DISEASE", 475, 480], ["the death", "PROBLEM", 471, 480]]], ["The police must respond to all incidents involving reported deaths and treat the location of a suicide as a crime scene until the official cause of death is determined.", [["deaths", "DISEASE", 60, 66], ["death", "DISEASE", 148, 153], ["death", "PROBLEM", 148, 153]]], ["The exact criteria for this process may vary based on jurisdiction (Sheehan, 2009).", [["this process", "PROBLEM", 23, 35]]], ["In the USA, most states require the presence of dangerousness in order to initiate compulsory confinement.", [["dangerousness", "PROBLEM", 48, 61]]], ["That is, a person must pose an imminent threat to either self (suicide) or others (homicide) in order to be taken into custody (Testa and West, 2010).The geography of mental healthAs a field of inquiry within academic geography, mental health geography is a relatively small, but growing, area of research (Philo, 2005; Lersch and Christy, 2020).", [["person", "SPECIES", 11, 17], ["mental healthAs", "OBSERVATION", 167, 182], ["relatively", "OBSERVATION_MODIFIER", 258, 268], ["small", "OBSERVATION_MODIFIER", 269, 274], ["growing", "OBSERVATION_MODIFIER", 280, 287]]], ["Faris and Dunham (1939) conducted one of the first studies in the USA that examined the spatial epidemiology of mental illness.", [["mental illness", "DISEASE", 112, 126], ["mental illness", "PROBLEM", 112, 126]]], ["Without the aid of sophisticated software, the home addresses of 34,864 people admitted to hospitals and sanatoriums in Chicago from 1922 to 1934 were mapped.", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78]]], ["Definite ecological patterns were found between the rates of admissions and the structure of the city, especially with respect to schizophrenia.", [["schizophrenia", "DISEASE", 130, 143], ["schizophrenia", "PROBLEM", 130, 143], ["ecological patterns", "OBSERVATION", 9, 28], ["schizophrenia", "OBSERVATION", 130, 143]]], ["Overall, the rates of admissions in the more socially disorganized central areas of the city were the highest; the rates steadily decreased as one moved farther into the outskirts in the suburban areas.", [["socially", "OBSERVATION_MODIFIER", 45, 53], ["disorganized", "OBSERVATION_MODIFIER", 54, 66], ["central", "OBSERVATION_MODIFIER", 67, 74], ["areas", "OBSERVATION_MODIFIER", 75, 80], ["highest", "OBSERVATION_MODIFIER", 102, 109], ["steadily", "OBSERVATION_MODIFIER", 121, 129], ["decreased", "OBSERVATION_MODIFIER", 130, 139], ["suburban", "ANATOMY_MODIFIER", 187, 195]]], ["Similarly, Shaw and McKay (1942) explored relationships between the distributions of juvenile delinquency and other social problems, including infant mortality, tuberculosis, and mental health disorders.", [["juvenile delinquency", "DISEASE", 85, 105], ["infant mortality", "DISEASE", 143, 159], ["tuberculosis", "DISEASE", 161, 173], ["mental health disorders", "DISEASE", 179, 202], ["infant", "SPECIES", 143, 149], ["juvenile delinquency", "PROBLEM", 85, 105], ["infant mortality", "PROBLEM", 143, 159], ["tuberculosis", "PROBLEM", 161, 173], ["mental health disorders", "PROBLEM", 179, 202], ["juvenile delinquency", "OBSERVATION", 85, 105], ["tuberculosis", "OBSERVATION", 161, 173]]], ["Not surprisingly, the rates for these various measures all decreased as one moved out of the central cities.The geography of mental healthContemporary studies continue to advance knowledge of the relationship between neighbourhood characteristics and mental health issues.", [["mental healthContemporary studies", "TEST", 125, 158], ["mental health issues", "PROBLEM", 251, 271], ["decreased", "OBSERVATION_MODIFIER", 59, 68], ["central", "ANATOMY_MODIFIER", 93, 100]]], ["Employing more and more sophisticated statistical analyses (see, e.g. Jones, 2007; Chang et al., 2011; Kirchner and Shiffman, 2016), many researchers utilize data from the Census to measure social indicators at the tract, city, county, state, or other areal unit thought to represent neighbourhoods.", [["tract", "ORGANISM_SUBDIVISION", 215, 220]]], ["Social disorganization, urbanization, poverty, unemployment, lack of stable housing, level of education, and median income are frequently used socio-demographic predictors of mental illness (Stack, 2000a, 2000b; Rehkopf and Buka, 2006; Trgovac et al., 2015; Vaughan et al., 2019).", [["poverty", "DISEASE", 38, 45], ["mental illness", "PROBLEM", 175, 189], ["disorganization", "OBSERVATION", 7, 22], ["stable", "OBSERVATION_MODIFIER", 69, 75]]], ["Interestingly, demographers have shown that many of these same predictors are associated with higher risk of death from COVID-19 (Drefahl et al., 2020).The geography of mental healthIn recent studies of the geography of mental health in the City of Detroit, results of optimized hot spot analysis revealed statistically significant areas with higher and lower numbers of calls for service related to mental health issues.", [["death", "DISEASE", 109, 114], ["death", "PROBLEM", 109, 114], ["COVID", "TEST", 120, 125], ["optimized hot spot analysis", "TEST", 269, 296], ["statistically significant areas", "PROBLEM", 306, 337], ["mental health issues", "PROBLEM", 400, 420], ["significant", "OBSERVATION_MODIFIER", 320, 331], ["areas", "OBSERVATION_MODIFIER", 332, 337]]], ["This concentration of calls was especially pronounced with cases of suicide, where only 6.5% of the City\u2019s total area was identified as a hot spot.", [["a hot spot", "PROBLEM", 136, 146]]], ["The total area for statistically significant hot spots for all mental health calls was 165.64 km2; the City of Detroit encompasses 254.92 square miles (see Lersch, 2020; Lersch and Christy, 2020).", [["statistically significant hot spots", "PROBLEM", 19, 54], ["total", "OBSERVATION_MODIFIER", 4, 9], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["hot spots", "OBSERVATION", 45, 54]]], ["Other researchers have reported similar concentrations of mental health calls for service (see, e.g. Hodgkinson and Andresen, 2019; White and Goldberg, 2018) While areal concentrations have been previously reported, what impact (if any) does the COVID-19 crisis have on the geography of mental health calls for service?Purpose of the present studyThe purpose of the present study was to explore the relationship between the COVID-19 pandemic and the number and type of 911 mental health calls to the Detroit Police Department.", [["the present study", "TEST", 330, 347], ["the present study", "TEST", 362, 379]]], ["Given the results of previous studies, one might suspect that as the COVID-19 crisis unfolded, individuals would experience heightened levels of anxiety, depression, and other mental health maladies, which may result in higher numbers of calls for service to the police for intervention and assistance.", [["anxiety", "DISEASE", 145, 152], ["depression", "DISEASE", 154, 164], ["previous studies", "TEST", 21, 37], ["the COVID", "TEST", 65, 74], ["crisis unfolded", "PROBLEM", 78, 93], ["anxiety", "PROBLEM", 145, 152], ["depression", "PROBLEM", 154, 164], ["other mental health maladies", "PROBLEM", 170, 198], ["intervention", "TREATMENT", 274, 286]]], ["Additionally, given the previous literature on mental health and geography, neighbourhoods with higher levels of reported COVID-19 cases and deaths may experience increased levels of mental health crises, resulting in geographic clustering of both COVID-19 cases and police calls for service due to mental health issues.", [["deaths", "DISEASE", 141, 147], ["increased levels of mental health crises", "PROBLEM", 163, 203], ["mental health issues", "PROBLEM", 299, 319]]], ["According to the United States Census Bureau (2019), the estimated population in 2017 was 679,865 persons.", [["persons", "SPECIES", 98, 105]]], ["First and foremost is the catastrophic reduction in population.", [["the catastrophic reduction", "TREATMENT", 22, 48], ["catastrophic", "OBSERVATION_MODIFIER", 26, 38], ["reduction", "OBSERVATION_MODIFIER", 39, 48]]], ["The population of the city dropped from nearly two million residents in 1950 to its current level of under 700,000 residents (Binelli, 2013).", [["population", "OBSERVATION_MODIFIER", 4, 14]]], ["A number of reasons have been given for the decline.", [["the decline", "PROBLEM", 40, 51]]], ["Describing Detroit as \u2018one of the most notorious examples of severe decline in North America\u2019, Xie et al. (2018, p.", [["severe decline", "PROBLEM", 61, 75], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["decline", "OBSERVATION", 68, 75]]], ["350) noted the impact of urban sprawl, a history of racial segregation, and persistently high levels of poverty.", [["poverty", "DISEASE", 104, 111], ["urban sprawl", "TREATMENT", 25, 37], ["racial segregation", "PROBLEM", 52, 70], ["racial segregation", "OBSERVATION", 52, 70]]], ["Others (Beyer, 2018; Binelli, 2013) have pointed to the decline of the automotive industry, race riots, years of municipal corruption resulting in bankruptcy, poor urban planning, and high tax rates coupled with poor municipal services as key factors.The setting: Detroit, Michigan, USAThis mass exodus from the city resulted in a second unique attribute: the proliferation of abandoned and demolished structures.", [["tax", "PROTEIN", 189, 192], ["USAThis mass", "PROBLEM", 283, 295], ["the proliferation of abandoned and demolished structures", "PROBLEM", 356, 412]]], ["At the peak of the city\u2019s decline, nearly 100,000 structures stood empty and abandoned.", [["peak", "OBSERVATION_MODIFIER", 7, 11]]], ["The city encompasses an area of 139 square miles with nearly 40 square miles of vacant land due to demolitions and property abandonment (Binelli, 2013).The setting: Detroit, Michigan, USAFinally, Detroit is unique due to its consistently high crime rate.", [["demolitions", "DISEASE", 99, 110], ["demolitions", "PROBLEM", 99, 110], ["area", "OBSERVATION_MODIFIER", 24, 28]]], ["The violent crime rate in Detroit was 2,057 violent crimes per 100,000 people, which was much higher than the national level of 383 violent offences per 100,000 (FBI, 2018).Detroit and COVID-19The City of Detroit was thrust into the national spotlight on 5 April 2020 when the metropolitan area was identified as an outbreak hotspot during a COVID-19 Task Force briefing.", [["people", "SPECIES", 71, 77], ["The violent crime rate", "TEST", 0, 22], ["COVID", "TEST", 185, 190], ["a COVID", "TREATMENT", 340, 347], ["violent", "OBSERVATION_MODIFIER", 4, 11]]], ["According to the New York Times (2020), the Detroit metropolitan area has been described as a \u2018hardest hit place\u2019, ranked seventh highest in the USA with respect to the rate of cumulative confirmed deaths, behind New York City and New Orleans.Detroit and COVID-19The unique characteristics of the City of Detroit make the area particularly vulnerable to the spread of COVID-19.", [["deaths", "DISEASE", 198, 204], ["COVID-19", "CHEMICAL", 255, 263], ["COVID-19", "CHEMICAL", 368, 376], ["COVID-19", "DNA", 255, 263], ["COVID", "TEST", 255, 260], ["COVID", "TEST", 368, 373]]], ["Along with the high poverty rate, residents report higher levels of obesity, diabetes, hypertension, and a lack of access to health insurance and reliable transportation (Abdalla, 2020).", [["obesity", "DISEASE", 68, 75], ["diabetes", "DISEASE", 77, 85], ["hypertension", "DISEASE", 87, 99], ["obesity", "PROBLEM", 68, 75], ["diabetes", "PROBLEM", 77, 85], ["hypertension", "PROBLEM", 87, 99], ["obesity", "OBSERVATION", 68, 75], ["diabetes", "OBSERVATION", 77, 85], ["hypertension", "OBSERVATION", 87, 99]]], ["Additionally, Detroit is home to one of the largest African American populations in the USA.", [["largest", "OBSERVATION_MODIFIER", 44, 51]]], ["Nationally, the COVID-19 rate is disproportionately higher among African Americans.", [["the COVID", "TEST", 12, 21], ["disproportionately", "OBSERVATION_MODIFIER", 33, 51], ["higher", "OBSERVATION_MODIFIER", 52, 58]]], ["In the state of Michigan, African Americans account for 40% of the deaths due to the coronavirus, but only 14% of the state-wide population is African American (Shau, 2020).Mental health-related calls for service ::: MethodsThe City of Detroit maintains a robust open data portal that provides access to maps and data sets focused on a variety of government services, including public safety, health, transportation, and land use (City of Detroit, n.d.).", [["deaths", "DISEASE", 67, 73], ["coronavirus", "DISEASE", 85, 96], ["coronavirus", "ORGANISM", 85, 96], ["the deaths", "PROBLEM", 63, 73], ["the coronavirus", "PROBLEM", 81, 96], ["Methods", "TREATMENT", 217, 224], ["maps", "TEST", 304, 308], ["coronavirus", "OBSERVATION", 85, 96], ["portal", "ANATOMY", 273, 279]]], ["Launched in 2015, the portal was funded through a grant from the Socrata Foundation in an effort to assist in the redevelopment efforts (Shueh, 2015).Mental health-related calls for service ::: MethodsOne of the data sets maintained in the Open Data Portal contains all 911 calls to the Detroit Police Department (DPD) for emergency police services and officer-initiated calls, which includes traffic stops, street stops, and observations of crimes in progress.", [["the Socrata Foundation", "TREATMENT", 61, 83], ["portal", "ANATOMY", 22, 28], ["Portal", "ANATOMY", 250, 256]]], ["Data collection began on 20 September 2016 and continues to the present, with data updated on a daily basis.", [["Data collection", "TEST", 0, 15]]], ["Along with the description of the call, day, time, and other basic information, the DPD also includes latitude and longitude of the incident.", [["DPD", "PROTEIN", 84, 87]]], ["To protect the identity of those involved, the DPD randomly offsets the coordinates by up to 180 feet along the street segment.Mental health-related calls for service ::: MethodsFor this analysis, the calls for service were limited to non-officer-initiated events (i.e. a 911 call was placed by a citizen requesting police services).", [["DPD", "GENE_OR_GENE_PRODUCT", 47, 50], ["DPD", "PROTEIN", 47, 50], ["this analysis", "TEST", 182, 195], ["street", "ANATOMY", 112, 118], ["segment", "ANATOMY_MODIFIER", 119, 126]]], ["26 February was selected as the start date as this was the first reported case of COVID-19 in the City of Detroit.1 During this time frame, there were 1,552 were mental health-related calls.", [["COVID", "TEST", 82, 87]]], ["Using ArcGIS 10.7, these incidents were geocoded based on the provided XY coordinates.Mental health-related calls for service ::: MethodsThe DPD has several different classifications that were grouped into three categories used in this analysis:COVID 19 casesTwo sources for the COVID-19 cases were used.", [["DPD", "GENE_OR_GENE_PRODUCT", 141, 144], ["XY coordinates", "DNA", 71, 85], ["DPD", "PROTEIN", 141, 144], ["ArcGIS", "TEST", 6, 12], ["Methods", "TREATMENT", 130, 137], ["several different classifications", "PROBLEM", 149, 182], ["this analysis", "TEST", 231, 244], ["the COVID-19 cases", "TREATMENT", 275, 293], ["several", "OBSERVATION_MODIFIER", 149, 156], ["different", "OBSERVATION_MODIFIER", 157, 166], ["classifications", "OBSERVATION", 167, 182]]], ["The daily number of deaths was also reported, with the first COVID-19 death in the City of Detroit noted on 18 March.COVID 19 casesThe second source was from the Detroit Health Department in which the total number of cases was reported by ZIP code.", [["deaths", "DISEASE", 20, 26], ["death", "DISEASE", 70, 75], ["ZIP", "CHEMICAL", 239, 242]]], ["As of this writing, the cases are updated twice a week; the totals used in this analysis were as of 3 May 2020.", [["this analysis", "TEST", 75, 88]]], ["The cases reflect Detroit residents only that had a known ZIP code.", [["ZIP", "CHEMICAL", 58, 61], ["ZIP code", "OBSERVATION", 58, 66]]], ["Given the rapidly evolving nature of the pandemic, the totals were preliminary and could change as new information is/was made available.", [["the pandemic", "PROBLEM", 37, 49], ["pandemic", "OBSERVATION_MODIFIER", 41, 49]]], ["Due to confidentiality concerns, the exact address of individuals diagnosed with COVID-19 is not made available for analysis.COVID 19 casesThe City of Detroit completely encompasses two distinct municipalities that support their own police departments: Hamtramck and Highland Park.", [["individuals", "ORGANISM", 54, 65], ["COVID", "TEST", 81, 86], ["analysis", "TEST", 116, 124]]], ["Comparable data were unavailable for these two cities, which were excluded from the analyses.", [["the analyses", "TEST", 80, 92]]], ["There were five zip codes (48203, 48211, 48212, 48236, and 48239) that were split between neighbouring cities.", [["five", "OBSERVATION_MODIFIER", 11, 15], ["zip codes", "OBSERVATION", 16, 25]]], ["The 48212 ZIP code includes the city of Hamtramck, which covers an area of 2.1 square miles and had an estimated population of 21,716 in 2018 (US Census Bureau, 2020).", [["an estimated population", "TEST", 100, 123]]], ["As the total population of the ZIP code was 39,222 residents, the total number of cases in this ZIP code was reduced by 45%, which was proportionate to the excluded residents of Hamtramck.Geographic concentrations ::: ResultsThe second research question explored in this analysis focused on the geography of the mental health calls for service and the rate of COVID-19 cases by ZIP code.", [["ZIP", "CHEMICAL", 378, 381], ["this analysis", "TEST", 266, 279], ["COVID", "TREATMENT", 360, 365]]], ["Specifically, is there evidence of a spatial relationship between the locations of 911 mental health calls for service and areas with the higher rates of reported cases of COVID-19?Geographic concentrations ::: ResultsZIP Code Boundaries and demographics were downloaded from Esri\u2019s ArcGIS Online Living Atlas.", [["COVID", "TEST", 172, 177]]], ["The layer contains the ZIP Code and 2018 population counts for all US ZIP code polygons.", [["layer", "OBSERVATION_MODIFIER", 4, 9], ["ZIP Code", "OBSERVATION", 23, 31]]], ["This layer was then clipped to the City of Detroit boundary to include only the relevant ZIP codes.", [["ZIP", "CHEMICAL", 89, 92], ["layer", "OBSERVATION_MODIFIER", 5, 10], ["ZIP codes", "OBSERVATION", 89, 98]]], ["The counts per ZIP code were converted to a rate per 100,000.", [["ZIP", "CHEMICAL", 15, 18], ["a rate", "TEST", 42, 48]]], ["There were 27 ZIP codes with a mean of 1,237 COVID-19 cases per 100,000 (SD = 401.21; range = 529\u20132,008 cases per 100,000).", [["COVID", "TEST", 45, 50], ["SD", "TEST", 73, 75], ["cases", "TEST", 104, 109]]], ["Figure 5 displays the COVID-19 rate by ZIP code symbolized by standard deviation values.", [["COVID-19", "DNA", 22, 30], ["the COVID", "TEST", 18, 27]]], ["Darker colours indicate ZIP codes with higher COVID-19 rates.", [["COVID", "PROTEIN", 46, 51], ["ZIP codes", "TEST", 24, 33], ["higher COVID", "TREATMENT", 39, 51], ["ZIP codes", "OBSERVATION", 24, 33]]], ["Additionally, the locations of the 911 calls for service from 26 February 2020 to 26 April 2020 by type are also displayed by call type for each ZIP code.", [["ZIP", "CHEMICAL", 145, 148]]], ["These calls were clipped to the ZIP code boundary for the City of Detroit, reducing the total number of calls from 1,552 to 1,535.Geographic concentrations ::: ResultsTo determine if the reported cases were clustered within the ZIP codes, a Global Moran\u2019s I test for autocorrelation was conducted using ArcGIS 10.7.", [["ZIP", "DNA", 228, 231], ["ArcGIS", "TEST", 303, 309]]], ["The Moran\u2019s I was not significant (I = 0.101, p > 0.05), which means that the pattern of higher and lower rates was not significantly different than random.", [["The Moran\u2019s I", "TEST", 0, 13], ["higher", "OBSERVATION_MODIFIER", 89, 95], ["lower", "OBSERVATION_MODIFIER", 100, 105], ["significantly different", "OBSERVATION_MODIFIER", 120, 143]]], ["This result must be interpreted with caution, given the number of ZIP codes; a minimum of 30 features is idea for analysis.", [["analysis", "TEST", 114, 122]]], ["While some ZIP codes were found to have higher rates than others, there does not appear to be evidence of statistically spatial clustering of reported rates of COVID-19 within the City of Detroit.Optimized hot spot analysis ::: ResultsFinally, the pattern of 911 calls for service was compared to the distribution of COVID-19 rates by ZIP code.", [["ZIP", "GENE_OR_GENE_PRODUCT", 11, 14], ["COVID", "TEST", 160, 165], ["Optimized hot spot analysis", "TEST", 196, 223], ["COVID", "TEST", 317, 322]]], ["This analysis used optimized hot spot analysis.", [["This analysis", "TEST", 0, 13], ["hot spot analysis", "TEST", 29, 46]]], ["This tool uses the Getis-Ord Gi* statistic, which identifies areas where a feature has a high (or low) number of incidents and is surrounded by other features that similarly have high (or low) values (Lentz, 2009).", [["high (or low) values", "PROBLEM", 179, 199], ["high", "OBSERVATION_MODIFIER", 89, 93], ["high", "OBSERVATION_MODIFIER", 179, 183]]], ["The optimized hot spot analysis tool mines the data in order to obtain parameters that will yield optimal hot spot results (Esri, 2018).", [["The optimized hot spot analysis", "TEST", 0, 31]]], ["The tool aggregates the point data, identifies the correct scale of analysis, and automatically corrects for multiple testing and spatial dependence.", [["analysis", "TEST", 68, 76], ["multiple testing", "TEST", 109, 125], ["spatial dependence", "PROBLEM", 130, 148], ["spatial dependence", "OBSERVATION", 130, 148]]], ["Statistically significant results indicate the locations where point clusters are unusually intense or sparse.Optimized hot spot analysis ::: ResultsOptimized hot spot analysis was conducted for four classifications of 911 calls for service: suicides in progress, suicide threats, mentally ill person, and the total number of 911 calls, regardless of type.", [["mentally ill", "DISEASE", 281, 293], ["person", "SPECIES", 294, 300], ["Optimized hot spot analysis", "TEST", 110, 137], ["hot spot analysis", "TEST", 159, 176], ["unusually", "OBSERVATION_MODIFIER", 82, 91], ["intense", "OBSERVATION_MODIFIER", 92, 99]]], ["Only two of the analyses found statistically significant hot spot locations; no cold spots were identified.", [["the analyses", "TEST", 12, 24], ["significant hot spot locations", "PROBLEM", 45, 75], ["cold spots", "PROBLEM", 80, 90], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["hot spot", "OBSERVATION", 57, 65], ["no", "UNCERTAINTY", 77, 79], ["cold spots", "OBSERVATION", 80, 90]]], ["Figure 6 displays the optimized hot spot results for all 911 calls, regardless of classification type.Optimized hot spot analysis ::: ResultsAs can be seen in Figure 6, the hot spot areas for all 911 mental health calls were located in the south-central area of the city, in the downtown area.", [["Optimized hot spot analysis", "TEST", 102, 129], ["the hot spot areas", "PROBLEM", 169, 187], ["central", "ANATOMY_MODIFIER", 246, 253]]], ["These hot spots coincided with ZIP codes that had both below and above the mean COVID-19 rate for all ZIP codes.", [["These hot spots", "PROBLEM", 0, 15], ["ZIP codes", "TEST", 31, 40], ["the mean COVID", "TEST", 71, 85]]], ["The hot spots were not located in the areas with the highest rate of COVID-19 cases.Optimized hot spot analysis ::: ResultsStatistically significant hot spots were also identified for the suicide threats.", [["The hot spots", "PROBLEM", 0, 13], ["COVID", "TEST", 69, 74], ["Optimized hot spot analysis", "TEST", 84, 111], ["significant hot spots", "PROBLEM", 137, 158], ["the suicide threats", "PROBLEM", 184, 203], ["hot", "OBSERVATION_MODIFIER", 4, 7], ["spots", "OBSERVATION", 8, 13], ["significant", "OBSERVATION_MODIFIER", 137, 148], ["hot spots", "OBSERVATION", 149, 158]]], ["In the case of suicide threats, some of the hot spot areas were found in areas with higher rates of COVID-19 cases.Optimized hot spot analysis ::: ResultsAs a point of comparison, Figure 8 displays the results of the optimized hot spot analysis using the locations of all mental health-related calls for service that occurred within the same time frame (2/26\u20134/26) for the previous 3 years.4 Interestingly, the dispersion of mental health calls was markedly different for the 2017\u20132019 COVID-19 time frame when compared to the 2020 results.", [["suicide threats", "PROBLEM", 15, 30], ["the hot spot areas", "PROBLEM", 40, 58], ["COVID", "TEST", 100, 105], ["Optimized hot spot analysis", "TEST", 115, 142], ["the optimized hot spot analysis", "TEST", 213, 244], ["COVID", "TEST", 486, 491]]], ["As can be seen in Figure 8, there were several larger areas identified as statistically significant hot spots.", [["several larger areas", "PROBLEM", 39, 59], ["significant hot spots", "PROBLEM", 88, 109], ["several", "OBSERVATION_MODIFIER", 39, 46], ["larger", "OBSERVATION_MODIFIER", 47, 53], ["statistically", "OBSERVATION_MODIFIER", 74, 87], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["hot spots", "OBSERVATION", 100, 109]]], ["While no cold spots were identified during the COVID-19 time frame in 2020, there were several areas in the previous years that had lower concentrations of mental health calls for service.DiscussionThe purpose of this study was to explore the rate and geographic distribution of 911 calls for service related to mental health issues during the COVID-19 pandemic in the City of Detroit, MI, USA.", [["MI", "DISEASE", 386, 388], ["COVID-19 time frame", "DNA", 47, 66], ["cold spots", "PROBLEM", 9, 19], ["this study", "TEST", 213, 223], ["mental health issues", "PROBLEM", 312, 332], ["the COVID", "TEST", 340, 349], ["MI", "PROBLEM", 386, 388], ["several", "OBSERVATION_MODIFIER", 87, 94], ["areas", "OBSERVATION_MODIFIER", 95, 100]]], ["This study is similar to other recent attempts to explore the relationship between the COVID-19 pandemic and levels of crime and police calls for service (see, for example, Ashby, 2020a, 2020b; Felson et al., 2020; Hodgkinson and Andresen, 2019, 2020; Mohler et al., 2020; Stickle and Felson, 2020).", [["This study", "TEST", 0, 10], ["the COVID", "TEST", 83, 92]]], ["The results of the instant study were somewhat counterintuitive in that the total number of calls for mental health issues was at the lowest level when compared to the same time period for the previous 3 years.", [["the instant study", "TEST", 15, 32], ["mental health issues", "PROBLEM", 102, 122]]], ["Furthermore, as both the daily reported cases and deaths increased over time, there was a significant decline in both suicide threats and suicides in progress.", [["deaths", "DISEASE", 50, 56], ["a significant decline", "PROBLEM", 88, 109], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["decline", "OBSERVATION_MODIFIER", 102, 109]]], ["This finding suggests that while individuals may be experiencing heightened levels of depression and anxiety, the police are not being called in to assist with the matter.DiscussionThis may be related to a similar phenomenon, where the number of individuals found dead in their homes experienced a dramatic spike during the pandemic.", [["depression", "DISEASE", 86, 96], ["anxiety", "DISEASE", 101, 108], ["depression", "PROBLEM", 86, 96], ["anxiety", "PROBLEM", 101, 108], ["a similar phenomenon", "PROBLEM", 204, 224], ["a dramatic spike", "PROBLEM", 296, 312], ["the pandemic", "PROBLEM", 320, 332], ["depression", "OBSERVATION", 86, 96], ["dramatic", "OBSERVATION_MODIFIER", 298, 306], ["spike", "OBSERVATION_MODIFIER", 307, 312]]], ["A report by Fox 2 Detroit noted increases as high as 400 per cent for Priority 4 emergency medical service calls in the South-eastern Michigan region, which are calls for people dead in their homes (Fox 2, 2020).", [["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177]]], ["People may be fearful of seeking help for their condition, whether it be for chronic physical or be mental conditions.DiscussionWith respect to the geographic distribution of 911 mental health-related calls for service, significant hot spots were found for the total calls as well as for threats of suicide.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["chronic physical or be mental conditions", "PROBLEM", 77, 117], ["significant hot spots", "PROBLEM", 220, 241]]], ["These hot spots did not coincide with the spatial distribution of the reported cases of COVID-19 by ZIP code.", [["COVID-19", "CHEMICAL", 88, 96], ["ZIP", "CHEMICAL", 100, 103], ["COVID-19", "DNA", 88, 96], ["These hot spots", "PROBLEM", 0, 15], ["COVID", "TEST", 88, 93]]], ["While higher and lower areas of reported cases were found, these differences by ZIP code were not found to be significant.", [["ZIP", "CHEMICAL", 80, 83], ["higher", "OBSERVATION_MODIFIER", 6, 12], ["lower", "OBSERVATION_MODIFIER", 17, 22]]], ["This result may have been different if the number of cases was known for smaller geographic areas, such as census tracts or blocks.", [["smaller geographic areas", "PROBLEM", 73, 97], ["smaller", "OBSERVATION_MODIFIER", 73, 80], ["geographic", "OBSERVATION_MODIFIER", 81, 91], ["areas", "OBSERVATION", 92, 97]]], ["Given the rapidly evolving nature of the pandemic, perhaps these data will become available for future analyses.DiscussionOf particular interest was the comparison of the geographic clusters of the 911 calls for service during the initial COVID-19 crisis with the locations for the same time period for the previous 3 years.", [["the pandemic", "PROBLEM", 37, 49], ["these data", "TEST", 59, 69], ["future analyses", "TEST", 96, 111], ["pandemic", "OBSERVATION", 41, 49]]], ["The 2020 calls were more evenly spread throughout the city, with relatively small areas identified as hot spots; only 1.84 square miles of the City were identified as a hot spot (out of a total are of 254.82 sq. miles).", [["hot spots", "PROBLEM", 102, 111], ["a hot spot", "PROBLEM", 167, 177], ["small", "OBSERVATION_MODIFIER", 76, 81], ["hot spots", "OBSERVATION_MODIFIER", 102, 111]]], ["No cold spots were found.", [["cold spots", "PROBLEM", 3, 13], ["cold spots", "OBSERVATION", 3, 13]]], ["Conversely, the calls that occurred for the previous 3 years in the same time frame demonstrated definite areas of clustering and dispersion.", [["definite", "UNCERTAINTY", 97, 105], ["areas", "OBSERVATION_MODIFIER", 106, 111], ["clustering", "OBSERVATION", 115, 125], ["dispersion", "OBSERVATION_MODIFIER", 130, 140]]], ["The total area of the hot spots was 24.05 square miles, and the total area of the cold spots was 22.81 square miles.", [["the hot spots", "PROBLEM", 18, 31], ["the cold spots", "PROBLEM", 78, 92], ["total", "OBSERVATION_MODIFIER", 4, 9], ["area", "OBSERVATION_MODIFIER", 10, 14], ["hot", "OBSERVATION_MODIFIER", 22, 25], ["spots", "OBSERVATION_MODIFIER", 26, 31], ["total", "OBSERVATION_MODIFIER", 64, 69], ["area", "OBSERVATION_MODIFIER", 70, 74], ["cold spots", "OBSERVATION", 82, 92]]], ["This lack of statistically significant hot and cold spots during the COVID-19 pandemic makes targeted prevention strategies more difficult.DiscussionThis study focused on a single city with rather unique characteristics.", [["statistically significant hot and cold spots", "PROBLEM", 13, 57], ["the COVID", "TEST", 65, 74], ["targeted prevention strategies", "TREATMENT", 93, 123], ["This study", "TEST", 149, 159], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["hot", "OBSERVATION", 39, 42]]], ["It would be of interest for future researchers to replicate this study in other urban areas to see if similar results are found.", [["this study", "TEST", 60, 70]]], ["It should also be noted that the time frame for this analysis was prior to the death of George Floyd in Minneapolis, Minnesota, on 25 May 2020 while in police custody.", [["death", "DISEASE", 79, 84], ["this analysis", "TEST", 48, 61]]], ["While the purpose of this study was to explore the impact of the COVID-19 pandemic on mental health-related calls for service, future researchers may wish to expand the time frame for analysis in order to examine the continuing influence of the COVID-19 pandemic as well as the civil unrest on mental health.DiscussionArguably, the greatest weakness of this study is the reliability and validity of the COVID-19 reported cases and deaths.", [["deaths", "DISEASE", 431, 437], ["this study", "TEST", 21, 31], ["the COVID", "TEST", 61, 70], ["analysis", "TEST", 184, 192], ["the COVID", "TREATMENT", 241, 250], ["the greatest weakness", "PROBLEM", 328, 349], ["this study", "TEST", 353, 363], ["the COVID", "TEST", 399, 408], ["greatest", "OBSERVATION_MODIFIER", 332, 340], ["weakness", "OBSERVATION", 341, 349]]], ["It should be noted that the Detroit Health Department reports the daily totals based on the date of the onset of the disease.", [["the disease", "PROBLEM", 113, 124], ["disease", "OBSERVATION", 117, 124]]], ["It is unknown what impact these data reporting issue may have on the results.DiscussionAdditionally, several caveats were noted with respect to the reported ZIP code of the COVID-19 case totals.", [["ZIP", "CHEMICAL", 157, 160], ["COVID", "DNA", 173, 178]]], ["Further, the counts reported by the City of Detroit may be slightly different than those from the Michigan Department of Health and Human Services depending on the exact time of day that the data were accessed.DiscussionWhile the results of this study did not find an increase in 911 calls for service during the height of the COVID-19 pandemic, police agencies should not assume that all is well in their communities.", [["Human", "ORGANISM", 132, 137], ["Human", "SPECIES", 132, 137], ["the counts", "TEST", 9, 19], ["this study", "TEST", 241, 251], ["slightly", "OBSERVATION_MODIFIER", 59, 67], ["different", "OBSERVATION", 68, 77], ["increase", "OBSERVATION_MODIFIER", 268, 276]]], ["In fact, the opposite may be true, given the heightened levels of unemployment, anxiety, isolation, and depression that many citizens report.", [["anxiety", "DISEASE", 80, 87], ["depression", "DISEASE", 104, 114], ["anxiety", "PROBLEM", 80, 87], ["isolation", "TREATMENT", 89, 98], ["depression", "PROBLEM", 104, 114], ["may be", "UNCERTAINTY", 22, 28]]]], "443525ce62c805128c2cec1f773ae6b992406f83": [["IntroductionIn an article published by Fuchs in Nature in 2002 we read \"Future generations may be able to determine whether the sequencing of the human genome in 2001 indeed led to a paradigm shift in biology and biomedicine as some predicted, or whether the impact of this event was more gradual instead\" [1] .", [["human", "ORGANISM", 146, 151], ["human genome", "DNA", 146, 158], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151]]], ["The author observes that \"so far, the history of biology has been characterized by a continous shift from the whole organism down to the molecular level, from the descriptive characterization of species over macroscopic observations and morphological and physiological studies to today's molecular dissection of individual genes\".IntroductionNovel experimental techniques require new computational methods.", [["a continous shift", "PROBLEM", 83, 100], ["the whole organism", "PROBLEM", 106, 124], ["macroscopic observations", "TEST", 208, 232], ["physiological studies", "TEST", 255, 276], ["new computational methods", "TREATMENT", 380, 405], ["dissection", "OBSERVATION", 298, 308]]], ["As a consequence, a new interdisciplinary field adapting methods from many different branches of mathematics, physics, chemistry, and computer science emerged.IntroductionA fundamental task coming from sequencing is to understand the code written in the sequence of four letters.", [["new", "OBSERVATION_MODIFIER", 20, 23], ["branches", "OBSERVATION_MODIFIER", 85, 93]]], ["A lot has been done to reveal some global characteristics of long DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["long DNA sequences", "DNA", 61, 79], ["long DNA sequences", "PROBLEM", 61, 79]]], ["For example Herzel et al. [2] created a model that describes thousands of nearly identical dispersed repetitive sequences present in DNA sequences of higher organisms.", [["DNA", "CELLULAR_COMPONENT", 133, 136], ["DNA sequences", "DNA", 133, 146], ["DNA sequences", "TEST", 133, 146], ["higher organisms", "PROBLEM", 150, 166]]], ["The hypothetical model sequences consist of independent equidistributed symbols with randomly interspersed repeats.", [["The hypothetical model sequences", "TEST", 0, 32]]], ["The model that can be analyzed analytically predicts that the entropy of DNA sequences measuring the information content is much lower than suggested by earlier empirical studies.IntroductionA systematic analysis of statistical properties of coding and noncoding DNA sequences has been performed by Mantegna et al. [3] .", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["DNA", "CELLULAR_COMPONENT", 263, 266], ["DNA sequences", "DNA", 73, 86], ["noncoding DNA sequences", "DNA", 253, 276], ["DNA sequences", "TEST", 73, 86], ["earlier empirical studies", "TEST", 153, 178], ["IntroductionA systematic analysis", "TEST", 179, 212], ["noncoding DNA sequences", "TEST", 253, 276]]], ["The authors compared the statistical behavior of coding and noncoding regions in eukaryotic and viral DNA sequences by adapting two tests developed for the analysis of natural languages and symbolic sequences.", [["DNA", "CELLULAR_COMPONENT", 102, 105], ["noncoding regions", "DNA", 60, 77], ["eukaryotic and viral DNA sequences", "DNA", 81, 115], ["coding and noncoding regions in eukaryotic and viral DNA sequences", "PROBLEM", 49, 115], ["adapting two tests", "TEST", 119, 137], ["the analysis", "TEST", 152, 164]]], ["The authors analyzed some similarities and dissimilarities of statistical properties of coding and noncoding regions.", [["coding and noncoding regions", "DNA", 88, 116], ["coding and noncoding regions", "PROBLEM", 88, 116]]], ["In particular they found that for the three chromosomes they studied, the statistical properties of noncoding regions appear to be closer to those observed in natural languages than those of the coding regions.IntroductionStatistical studies aiming at characterization of correlation structures of DNA sequences has been a subject of many studies (for review see [4, 5] ).", [["chromosomes", "CELLULAR_COMPONENT", 44, 55], ["DNA", "CELLULAR_COMPONENT", 298, 301], ["chromosomes", "DNA", 44, 55], ["noncoding regions", "DNA", 100, 117], ["coding regions", "DNA", 195, 209], ["DNA sequences", "DNA", 298, 311], ["the three chromosomes", "PROBLEM", 34, 55], ["IntroductionStatistical studies", "TEST", 210, 241], ["DNA sequences", "TEST", 298, 311], ["many studies", "TEST", 334, 346]]], ["In particular Foss [6] using spectral density of individual base positions demonstrated long-range fractal correlations as well as short-range periodicities.", [["individual base positions", "TEST", 49, 74], ["base", "ANATOMY_MODIFIER", 60, 64]]], ["Arneodo et al. [7] used the wavelet transform to demonstrate the existence of long-correlations in genes containing introns and noncoding regions.", [["introns", "DNA", 116, 123], ["noncoding regions", "DNA", 128, 145], ["the wavelet transform", "TREATMENT", 24, 45], ["long-correlations in genes containing introns and noncoding regions", "PROBLEM", 78, 145]]], ["Buldyrev et al. [8] in order to answer the question in computational molecular biology whether long-range correlations are present in both coding and noncoding DNA sequences have used standard Fourier transform analysis and detrended fluctuation analysis.", [["DNA", "CELLULAR_COMPONENT", 160, 163], ["coding and noncoding DNA sequences", "DNA", 139, 173], ["noncoding DNA sequences", "TEST", 150, 173], ["standard Fourier transform analysis", "TEST", 184, 219], ["detrended fluctuation analysis", "TEST", 224, 254]]], ["For that purpose, the authors performed analysis of the sequences available in GenBank in 1995.", [["the sequences", "TEST", 52, 65]]], ["For noncoding sequences, they obtained the presence of long-range correlations.", [["noncoding sequences", "DNA", 4, 23], ["noncoding sequences", "TEST", 4, 23]]], ["Azbel in his work [9] demonstrated a universality in a DNA statistical structure using an autocorrelation function.", [["Azbel", "CHEMICAL", 0, 5], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["an autocorrelation function", "TEST", 87, 114]]], ["However, no long-range correlations have been found in any of the studied DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA sequences", "DNA", 74, 87], ["the studied DNA sequences", "TEST", 62, 87]]], ["[10] studied long-range correlations by constructing a map of the nucleotide sequence onto a walk which they referred to as a DNA walk.", [["nucleotide", "CHEMICAL", 66, 76], ["nucleotide", "CHEMICAL", 66, 76], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["nucleotide sequence", "DNA", 66, 85]]], ["Using such an approach they found long-range correlations in intron-containing genes and in nontranscribed regulatory DNA sequences, but not in complementary DNA sequence or intron-less genes.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["intron-containing genes", "DNA", 61, 84], ["nontranscribed regulatory DNA sequences", "DNA", 92, 131], ["complementary DNA sequence", "DNA", 144, 170], ["intron", "DNA", 174, 180], ["nontranscribed regulatory DNA sequences", "TEST", 92, 131], ["complementary DNA sequence", "PROBLEM", 144, 170]]], ["Visualization technique proposed by Peng et al. is based on a one dimensional DNA walk showing the relative occurrence of purines and pyrimidynes along the sequence.", [["purines", "CHEMICAL", 122, 129], ["pyrimidynes", "CHEMICAL", 134, 145], ["purines", "CHEMICAL", 122, 129], ["pyrimidynes", "CHEMICAL", 134, 145], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["purines", "SIMPLE_CHEMICAL", 122, 129], ["pyrimidynes", "SIMPLE_CHEMICAL", 134, 145], ["Visualization technique", "TREATMENT", 0, 23], ["purines and pyrimidynes along the sequence", "PROBLEM", 122, 164]]], ["Silverman and Linsker introduced vectorial representation of the bases in three dimensions [11] .", [["Silverman", "TREATMENT", 0, 9], ["Linsker", "TREATMENT", 14, 21], ["bases", "ANATOMY_MODIFIER", 65, 70]]], ["They used the unit vectors of 3D space to construct a Fourier transform.", [["the unit vectors of 3D space", "TREATMENT", 10, 38], ["a Fourier transform", "TREATMENT", 52, 71]]], ["Such Fourier transform graphs representing the sequences were used as measures of DNA periodicity.", [["DNA", "CELLULAR_COMPONENT", 82, 85], ["Fourier transform graphs", "TEST", 5, 29], ["the sequences", "TEST", 43, 56], ["DNA periodicity", "PROBLEM", 82, 97]]], ["Another visualization technique based on DNA walk plotted in three-dimensional Cartesian coordinate system has been introduced by Berger [5] .", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["Another visualization technique", "TEST", 0, 31], ["DNA walk plotted", "TEST", 41, 57]]], ["In his work Berger gave also a good review of visualization techniques based on DNA walk and their applications for an analysis of DNA sequences i.e. a study of correlation information, sequence periodicities, and other sequence characteristics.", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA sequences", "DNA", 131, 144], ["visualization techniques", "TEST", 46, 70], ["DNA walk", "TREATMENT", 80, 88], ["an analysis", "TEST", 116, 127], ["DNA sequences", "TEST", 131, 144], ["a study", "TEST", 150, 157], ["sequence periodicities", "TEST", 186, 208], ["other sequence characteristics", "TEST", 214, 244]]], ["More examples of studies focused on statistical properties of DNA sequences and also on their biological interpretation may be found in [12, 13] .IntroductionAnother class of studies is developing methods aiming at detailed sequence comparisons.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["DNA sequences", "DNA", 62, 75], ["studies", "TEST", 17, 24], ["DNA sequences", "TEST", 62, 75], ["detailed sequence comparisons", "TEST", 215, 244]]], ["Most commonly used in computational biology and medical sciences are global and local alignment methods, for example Clustal W [14] , Blast [15] , Needleman-Wunsch algorithm [16] , and T-Coffee [17] (for review see [18, 19] ).IntroductionAn alternative to the alignment methods are alignment-free methods that can be divided into two groups: numerical similarity/dissimilarity analysis of DNA sequences and similarity/dissimilarity analysis based on graphical representations of DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 389, 392], ["DNA", "CELLULAR_COMPONENT", 479, 482], ["DNA sequences", "DNA", 389, 402], ["DNA sequences", "DNA", 479, 492], ["numerical similarity/dissimilarity analysis", "TEST", 342, 385], ["DNA sequences", "TEST", 389, 402], ["similarity/dissimilarity analysis", "TEST", 407, 440], ["DNA sequences", "TEST", 479, 492]]], ["There is a variety of numerical alignment-free methods (for a review up to 2003 see [20] ).", [["variety", "OBSERVATION_MODIFIER", 11, 18]]], ["Recently new numerical alternative methods have been developed, as for example [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .", [["[21] [22] [23] [24] [25] [26] [27] [28] [29] [30]", "CHEMICAL", 79, 128], ["[21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 79, 133]]], ["In particular 4D numerical representations [32] [33] [34] , 5D representation [35] , 6D representation [36] have been introduced.IntroductionDue to interdisciplinary character of research on DNA, many groups of methods have been developed independently and very often without any knowledge about analogous results obtained in different groups of scientists.", [["DNA", "CELLULAR_COMPONENT", 191, 194]]], ["In particular, DNA walk has been independently discovered by the scientists working on statistical properties of DNA sequences [5] and by scientists working on graphical representations.", [["DNA", "CELLULAR_COMPONENT", 15, 18], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["DNA sequences", "DNA", 113, 126]]], ["Even among researchers working on graphical representations one can find analogous visualization tools discovered independently (see subsequent chapters).IntroductionThis work is focused on graphical representations of DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 219, 222], ["DNA sequences", "DNA", 219, 232], ["DNA sequences", "TEST", 219, 232]]], ["Biological sequences are often very long, and it is not obvious how to represent them graphically in an easy way that shows the main features of these objects.", [["Biological sequences", "TEST", 0, 20], ["main", "OBSERVATION_MODIFIER", 128, 132]]], ["The size of the plots is restricted by the human abilities of perception.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["size", "OBSERVATION_MODIFIER", 4, 8], ["plots", "OBSERVATION", 16, 21]]], ["How to restrict the graphs representing the sequences to two-dimensional plots and how to avoid degeneracies has been the subject of numerous studies which resulted in many graphical representations (see subsequent chapters).", [["degeneracies", "DISEASE", 96, 108], ["the graphs", "TEST", 16, 26], ["numerous studies", "TEST", 133, 149]]], ["Graphical representations offer both numerical and visualization tool for similarity/dissimilarity analysis.", [["visualization tool", "TEST", 51, 69], ["similarity/dissimilarity analysis", "TEST", 74, 107]]], ["Computing codes calculating optimal sequence alignment are implemented using dynamic programming and are freely accessible in the internet and that makes them attractive for potential users.", [["Computing codes calculating optimal sequence alignment", "TEST", 0, 54], ["dynamic programming", "TREATMENT", 77, 96]]], ["However, they are computationally expensive, and methodologically offer too simplistic similarity/dissimilarity analysis.", [["dissimilarity analysis", "TEST", 98, 120]]], ["They restrict the multidimensional similarity space of complex objects and show only one aspect of similarity.", [["complex objects", "OBSERVATION", 55, 70]]], ["In particular, H\u00f6nl and Ragan consider numerical alignment-free methods that can replace multiple-sequence alignment to infer a phylogenetic tree that represents the history of a set of molecular sequences [37] .", [["free methods", "TREATMENT", 59, 71], ["multiple-sequence alignment", "TEST", 89, 116]]], ["Since multiple alignment strategy does not work for all types of data, Liao et al. [38] proposed to use the similarity matrix based on their 2D graphical representation of DNA sequences [39] to construct phylogenetic tree.", [["DNA", "CELLULAR_COMPONENT", 172, 175], ["DNA sequences", "DNA", 172, 185], ["DNA sequences", "TEST", 172, 185]]], ["The authors consider mitochondrial sequences belonging to different species.", [["mitochondrial", "ANATOMY", 21, 34], ["mitochondrial", "CELLULAR_COMPONENT", 21, 34], ["mitochondrial sequences", "TEST", 21, 44]]], ["The same graphical representation has been also used by the authors to obtain the phylogenetic relationships of H5N1 avian influenza virus [40] and the phylogenetic relationships of coronaviruses [41] .", [["influenza virus", "DISEASE", 123, 138], ["H5N1", "ORGANISM", 112, 116], ["avian influenza virus", "ORGANISM", 117, 138], ["coronaviruses", "ORGANISM", 182, 195], ["H5N1", "SPECIES", 112, 116], ["avian influenza virus", "SPECIES", 117, 138], ["H5N1 avian influenza virus", "SPECIES", 112, 138], ["H5N1 avian influenza virus", "PROBLEM", 112, 138], ["coronaviruses", "PROBLEM", 182, 195]]], ["Another 2D graphical representation [42] has been used by Yu et al. to construct the phylogenetic tree of coronaviruses and lentiviruses [43] .", [["coronaviruses", "ORGANISM", 106, 119], ["lentiviruses", "ORGANISM", 124, 136], ["coronaviruses", "PROBLEM", 106, 119], ["tree", "OBSERVATION_MODIFIER", 98, 102]]], ["Wang and Zhang studied molecular phylogeny of H5N1 avian influenza viruses in Asia using 2D and 3D graphical representations of DNA sequences [45] .", [["influenza viruses", "DISEASE", 57, 74], ["H5N1", "ORGANISM", 46, 50], ["avian influenza viruses", "ORGANISM", 51, 74], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["DNA sequences", "DNA", 128, 141], ["H5N1 avian influenza", "SPECIES", 46, 66], ["H5N1 avian influenza viruses", "SPECIES", 46, 74], ["H5N1 avian influenza viruses", "PROBLEM", 46, 74], ["DNA sequences", "TEST", 128, 141]]], ["Graphical representations of DNA sequences have been also generalized for the analysis of similarity/dissimilarity between RNA secondary structures, as for example [46, 47] .", [["DNA", "CELLULAR_COMPONENT", 29, 32], ["DNA sequences", "DNA", 29, 42], ["DNA sequences", "TEST", 29, 42], ["the analysis", "TEST", 74, 86], ["dissimilarity between RNA secondary structures", "PROBLEM", 101, 147]]], ["2D graphical representation has been used for the characterization of the neuraminidase RNA sequences of H5N1 [48, 49] and of H1N1 [50] strains.", [["H5N1", "DISEASE", 105, 109], ["H5N1", "ORGANISM", 105, 109], ["neuraminidase RNA sequences", "DNA", 74, 101], ["the characterization", "TEST", 46, 66], ["the neuraminidase RNA sequences", "TEST", 70, 101], ["H5N1", "PROBLEM", 105, 109], ["H1N1", "PROBLEM", 126, 130], ["strains", "PROBLEM", 136, 143]]], ["Also graphical representations of the proteins have been created [51] [52] [53] [54] .IntroductionGraphical representations of the biological sequences (DNA, RNA, proteins) can be applied to all problems that require similarity/dissimilarity analysis.", [["[51] [52] [53] [54]", "SIMPLE_CHEMICAL", 65, 84], ["DNA", "CELLULAR_COMPONENT", 153, 156], ["biological sequences", "DNA", 131, 151], ["DNA, RNA, proteins", "PROTEIN", 153, 171], ["the proteins", "TEST", 34, 46], ["the biological sequences", "TEST", 127, 151], ["RNA, proteins", "TREATMENT", 158, 171], ["similarity/dissimilarity analysis", "TEST", 217, 250]]], ["Similarity analysis is not unique to sequences in biology.", [["Similarity analysis", "TEST", 0, 19]]], ["For instance, the problem of similarity has been developed and applied in computational pharmacology and has resulted in methods such as QSAR, QSPR [55] [56] [57] [58] [59] [60] [61] which aim at the prediction of molecular properties.", [["[55] [56] [57] [58] [59] [60]", "CHEMICAL", 148, 177], ["55] [56] [57] [58] [59] [60", "SIMPLE_CHEMICAL", 149, 176]]], ["The basic paradigm of quantitative structure-property relationship (QSAR) is that compounds with similar structure have similar properties.", [["quantitative structure", "OBSERVATION", 22, 44], ["similar", "OBSERVATION_MODIFIER", 120, 127], ["properties", "OBSERVATION_MODIFIER", 128, 138]]], ["This implies a smooth transient behavior in the relation between structure and property/activity, i.e., for any small change in the structure, the magnitude of the physico-chemical property or biological activity changes smoothly rather than in an abrupt, in all-or-none type, way.", [["a smooth transient behavior", "PROBLEM", 13, 40], ["any small change in the structure", "PROBLEM", 108, 141], ["smooth", "OBSERVATION_MODIFIER", 15, 21], ["transient", "OBSERVATION_MODIFIER", 22, 31], ["behavior", "OBSERVATION_MODIFIER", 32, 40], ["small", "OBSERVATION_MODIFIER", 112, 117], ["change", "OBSERVATION", 118, 124], ["magnitude", "OBSERVATION_MODIFIER", 147, 156], ["biological activity", "OBSERVATION", 193, 212], ["abrupt", "OBSERVATION_MODIFIER", 248, 254]]], ["The molecular similarity measures are based on a large number of descriptors, i.e. of the numerical indices characterizing molecules.", [["molecular", "OBSERVATION_MODIFIER", 4, 13], ["similarity", "OBSERVATION", 14, 24], ["large", "OBSERVATION_MODIFIER", 49, 54], ["number", "OBSERVATION_MODIFIER", 55, 61], ["molecules", "OBSERVATION", 123, 132]]], ["The basis for these studies is the development of various kinds of mathematical descriptors [62, 63] .", [["these studies", "TEST", 14, 27]]], ["In the theory of molecular similarity it is commonly accepted that different descriptors and different similarity measures reveal different aspects of similarity.", [["different", "OBSERVATION_MODIFIER", 130, 139]]], ["A pair of complex objects may be similar in one aspect and not similar in another aspect.", [["A pair of complex objects", "PROBLEM", 0, 25], ["complex", "OBSERVATION_MODIFIER", 10, 17], ["objects", "OBSERVATION", 18, 25], ["may be", "UNCERTAINTY", 26, 32], ["similar", "OBSERVATION_MODIFIER", 33, 40], ["not", "UNCERTAINTY", 59, 62], ["similar", "OBSERVATION_MODIFIER", 63, 70]]], ["The first QSAR studies on biological sequences using graphical representations of sequences have been already performed [64] .IntroductionThe present work describes the development of fundamental studies related to graphical representations of DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 244, 247], ["DNA sequences", "DNA", 244, 257], ["The first QSAR studies", "TEST", 0, 22], ["biological sequences", "TEST", 26, 46], ["fundamental studies", "TEST", 184, 203], ["DNA sequences", "TEST", 244, 257]]], ["New similarity measures are created for the alignment distributions.", [["alignment", "OBSERVATION_MODIFIER", 44, 53], ["distributions", "OBSERVATION_MODIFIER", 54, 67]]], ["Second, a critical review of graphical representations and their numerical characterization is given.IntroductionIn the last chapter, new aspects of four-component spectral representation, graphical representation of DNA sequences, recently introduced by the author of this work [65] , are described.", [["DNA", "CELLULAR_COMPONENT", 217, 220], ["DNA sequences", "DNA", 217, 230], ["their numerical characterization", "TEST", 59, 91], ["DNA sequences", "TEST", 217, 230], ["new", "OBSERVATION_MODIFIER", 134, 137]]], ["It is shown in the last chapter of this work that by using the four-component spectral representation one can recognize the difference in one base between a pair of sequences so it can be used for single nucleotide polymorfism (SNP) analyses which is subject of many investigation, as for example, in a recent work by Bhasi et al. [66] .", [["nucleotide", "CHEMICAL", 204, 214], ["SNP", "CHEMICAL", 228, 231], ["nucleotide", "CHEMICAL", 204, 214], ["single nucleotide polymorfism (SNP)", "TREATMENT", 197, 232]]], ["Another important problem is to identify protein coding regions of genomic sequences [67, 68] .", [["protein coding regions", "DNA", 41, 63], ["genomic sequences", "DNA", 67, 84], ["genomic sequences", "TEST", 67, 84]]], ["First attempts of identifying protein coding genes using graphical representations of DNA sequences based on Z curve [69] or based on trinucleotides [70] have been already performed.", [["DNA", "CELLULAR_COMPONENT", 86, 89], ["protein coding genes", "DNA", 30, 50], ["DNA sequences", "DNA", 86, 99], ["protein coding genes", "TREATMENT", 30, 50], ["DNA sequences", "TEST", 86, 99], ["Z curve", "TEST", 109, 116], ["trinucleotides", "TEST", 134, 148]]], ["It has been shown that the similarity relations are different for exons, and sequences with introns using the four-component spectral representation (see subsequent chapters).", [["exons", "DNA", 66, 71], ["introns", "DNA", 92, 99], ["introns", "TREATMENT", 92, 99]]], ["Such an observation suggests that the four-component spectral representation that reveals detailed aspects of similarity, as for example the comparisons of asymmetry of the gene structure, can be used to study this problem [71] .Corrections to the alignment methodsIn this section I introduce corrections that reveal some aspects of similarity which cannot be identified in the standard alignment methods.", [["an observation", "TEST", 5, 19], ["asymmetry of the gene structure", "PROBLEM", 156, 187], ["cannot be", "UNCERTAINTY", 350, 359]]], ["The similarity space of complex objects is multidimensional.", [["space", "OBSERVATION_MODIFIER", 15, 20], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["objects", "OBSERVATION", 32, 39], ["multidimensional", "OBSERVATION_MODIFIER", 43, 59]]], ["Complex objects may be similar in one aspect and very different in another one.", [["Complex objects", "PROBLEM", 0, 15], ["objects", "OBSERVATION", 8, 15], ["may be", "UNCERTAINTY", 16, 22], ["similar", "OBSERVATION_MODIFIER", 23, 30], ["very", "OBSERVATION_MODIFIER", 49, 53], ["different", "OBSERVATION_MODIFIER", 54, 63]]], ["For example, in the case of atoms, if a similarity measure based on their atomic numbers is considered then the periodic table of elements is obtained.", [["their atomic numbers", "TEST", 68, 88]]], ["A final, single similarity measure is a result of averaging over different aspects of similarity or, a consequence of neglecting most of the aspects of similarity.Corrections to the alignment methodsThe new similarity measures representing different aspects of similarity can be considered separately, or they can be combined in any way to search for their correlations with different biological functions.Inadequacy of the alignment methodsThe information about similarity of the sequences derived from the alignment methods is rather limited.", [["the sequences", "TEST", 477, 490], ["the alignment methods", "TEST", 504, 525], ["averaging", "OBSERVATION_MODIFIER", 50, 59], ["new", "OBSERVATION_MODIFIER", 203, 206], ["different", "OBSERVATION_MODIFIER", 240, 249]]], ["For example, according to the standard alignment methods, in the following two different cases:Inadequacy of the alignment methodsthe similarity value is the same (50%).", [["the standard alignment methods", "TEST", 26, 56], ["the alignment methodsthe similarity value", "TEST", 109, 150], ["alignment", "OBSERVATION_MODIFIER", 113, 122]]], ["In the first case, the A bases are spread over the whole sequence (positions 1, 3 give non-zero contributions).", [["bases", "ANATOMY_MODIFIER", 25, 30], ["spread", "OBSERVATION_MODIFIER", 35, 41]]], ["In the second case, the A bases are cumulated.", [["bases", "ANATOMY_MODIFIER", 26, 31], ["cumulated", "OBSERVATION_MODIFIER", 36, 45]]], ["This is certainly one of the weakest points of the alignment methods.", [["weakest", "OBSERVATION_MODIFIER", 29, 36], ["alignment", "OBSERVATION_MODIFIER", 51, 60]]], ["The degree of degeneracy may be very large and increases with the lengths of the sequences.", [["degeneracy", "PROBLEM", 14, 24], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["degeneracy", "OBSERVATION", 14, 24], ["may be", "UNCERTAINTY", 25, 31], ["very", "OBSERVATION_MODIFIER", 32, 36], ["large", "OBSERVATION", 37, 42]]], ["Obviously, the degree of degeneracy in the model example is larger than 2.", [["degree", "OBSERVATION_MODIFIER", 15, 21], ["degeneracy", "OBSERVATION", 25, 35], ["larger", "OBSERVATION_MODIFIER", 60, 66]]], ["For example, the bases that give non-zero contribution can be also C, T, or G and the positions of the aligned bases can be different.", [["bases", "ANATOMY_MODIFIER", 17, 22], ["non-zero contribution", "OBSERVATION", 33, 54], ["bases", "ANATOMY_MODIFIER", 111, 116], ["different", "OBSERVATION_MODIFIER", 124, 133]]], ["In order to describe different aspects of similarity in more detail, let us define a discrete alignment distribution n p for a pair of DNA sequences:Inadequacy of the alignment methods, if the p-th positions in the two sequences are occupied by two identical bases, 0, otherwise.Inadequacy of the alignment methods(1)Inadequacy of the alignment methodsLet us introduce a variable x p running along the sequenceInadequacy of the alignment methodswhere p = 1, 2, . . .", [["DNA", "CELLULAR_COMPONENT", 135, 138], ["DNA sequences", "DNA", 135, 148], ["p-th positions", "DNA", 193, 207], ["a pair of DNA sequences", "TEST", 125, 148], ["the alignment methods", "TEST", 163, 184], ["a variable x p running along the sequence", "TREATMENT", 369, 410], ["the alignment methodswhere", "TEST", 424, 450], ["bases", "ANATOMY_MODIFIER", 259, 264], ["alignment", "OBSERVATION_MODIFIER", 297, 306]]], ["K is the position in the sequence and r is the resolution that can be selected, depending on the length of the distribution, in a way convenient for the calculations changing the units of lengths.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["the calculations changing the units of lengths", "TREATMENT", 149, 195], ["position", "OBSERVATION_MODIFIER", 9, 17]]], ["K is the length of the sequences or subsequences for which the alignment is calculated.", [["K", "CHEMICAL", 0, 1], ["K", "TEST", 0, 1]]], ["Two bases belonging to different sequences, both located on the p-th positions are represented by a pair of numbers, {x p , n p }.Inadequacy of the alignment methodsLet us consider multiple alignments.", [["p-th positions", "DNA", 64, 78], ["different sequences", "TEST", 23, 42], ["the alignment methods", "TEST", 144, 165], ["bases", "ANATOMY_MODIFIER", 4, 9], ["multiple", "OBSERVATION_MODIFIER", 181, 189], ["alignments", "OBSERVATION", 190, 200]]], ["Analogously, as for a pair of sequences according to the standard alignment methods, in the following two cases 1.Inadequacy of the alignment methodsthe similarity value is the same (50%).", [["a pair of sequences", "TEST", 20, 39], ["the standard alignment methods", "TEST", 53, 83], ["the alignment methodsthe similarity value", "TEST", 128, 169], ["alignment", "OBSERVATION_MODIFIER", 132, 141]]], ["Thus, the alignment method is highly degenerate (different bases on different positions give non-zero contributions and these situations are undistinguishable).", [["the alignment method", "TEST", 6, 26], ["alignment", "OBSERVATION_MODIFIER", 10, 19], ["highly", "OBSERVATION_MODIFIER", 30, 36], ["degenerate", "OBSERVATION", 37, 47]]], ["Analogously, as for a pair of sequences, we can define a discrete alignment distribution n p of several (M) DNA sequences:Inadequacy of the alignment methods, if the p-th positions in allMsequences are occupied by the identical bases, 0, otherwise.Inadequacy of the alignment methodsM bases belonging to different sequences, located on the p-th positions are represented by {x p , n p }, where x p is defined in Eq.", [["DNA", "CELLULAR_COMPONENT", 108, 111], ["DNA sequences", "DNA", 108, 121], ["p-th positions", "DNA", 166, 180], ["alignment methodsM bases", "DNA", 266, 290], ["p-th positions", "DNA", 340, 354], ["a pair of sequences", "TEST", 20, 39], ["several (M) DNA sequences", "TEST", 96, 121], ["the alignment methods", "TEST", 136, 157], ["Inadequacy of the alignment methodsM bases", "PROBLEM", 248, 290], ["bases", "ANATOMY_MODIFIER", 228, 233]]], ["2.Statistical properties of the discrete alignment distributionsAs it is known from the statistics, distributions can be characterized in a convenient way by their moments.", [["the discrete alignment distributions", "PROBLEM", 28, 64], ["discrete", "OBSERVATION_MODIFIER", 32, 40], ["alignment distributions", "OBSERVATION", 41, 64]]], ["Distribution moments are the basic quantities in statistical spectroscopy.", [["statistical spectroscopy", "TEST", 49, 73]]], ["The aim of statistical spectroscopy [72] [73] [74] , is to construct global characteristics of a spectrum.", [["statistical spectroscopy", "TEST", 11, 35]]], ["The individual eigenvalues, the experimental energy levels or the intensities of spectral lines are considered as statistical ensembles.", [["the experimental energy levels", "TEST", 28, 58], ["spectral lines", "TREATMENT", 81, 95], ["individual", "OBSERVATION_MODIFIER", 4, 14], ["eigenvalues", "OBSERVATION_MODIFIER", 15, 26], ["spectral lines", "OBSERVATION", 81, 95]]], ["Let me just mention several applications of statistical spectroscopy.Statistical properties of the discrete alignment distributionsOriginally, methods of statistical spectroscopy were used in nuclear physics [75] where the character of the interparticle interactions is not exactly known.", [["statistical spectroscopy", "TEST", 44, 68], ["the discrete alignment distributions", "PROBLEM", 95, 131], ["statistical spectroscopy", "TEST", 154, 178], ["discrete", "OBSERVATION_MODIFIER", 99, 107], ["alignment distributions", "OBSERVATION", 108, 131], ["interparticle", "OBSERVATION", 240, 253]]], ["Assuming different forms of the Hamiltonian matrix and comparing distributions of the densities of the energy levels derived from this matrix and from the experiment some information about the Hamiltonian may be derived.Statistical properties of the discrete alignment distributionsStatistical spectroscopy may also be used to study the locations of the individual eigenvalues of the Hamiltonian.", [["matrix", "CELLULAR_COMPONENT", 135, 141], ["the Hamiltonian matrix", "TREATMENT", 28, 50], ["the energy levels", "TEST", 99, 116], ["Statistical spectroscopy", "TEST", 282, 306], ["Hamiltonian matrix", "OBSERVATION", 32, 50], ["densities", "OBSERVATION", 86, 95], ["discrete", "OBSERVATION_MODIFIER", 250, 258], ["alignment", "OBSERVATION_MODIFIER", 259, 268]]], ["In a way this is an inverse problem to the one from which the statistical spectroscopy originated: from global characteristics of the eigenvalues one tries to obtain some information about details of the spectrum.", [["the statistical spectroscopy", "TEST", 58, 86]]], ["Examples of generating individual energy levels using methods of statistical spectroscopy may be found in the theory of nuclear, atomic, molecular, and solid-state spectra [76] [77] [78] .", [["nuclear", "ANATOMY", 120, 127], ["nuclear", "CELLULAR_COMPONENT", 120, 127], ["statistical spectroscopy", "TEST", 65, 89]]], ["Approximating the eigenvalues by statistical quantities (spectral density distribution moments) is not limited by dimensions of the matrices and that is an advantage comparing to the standard methods based on diagonalization of the Hamiltonian matrix.", [["matrix", "CELLULAR_COMPONENT", 244, 250], ["the standard methods", "TEST", 179, 199], ["diagonalization of the Hamiltonian matrix", "TREATMENT", 209, 250], ["Hamiltonian matrix", "OBSERVATION", 232, 250]]], ["The distribution of the eigenvalues have been found to be Gaussian-like, well approximated by several-term Gram-Charlier expansions [79] .", [["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["The exact spectra (obtained by the diagonalizations of the Hamiltonian matrices) have been compared with the ones derived from the moment-generated spectral density distributions.", [["spectral density", "OBSERVATION", 148, 164]]], ["It has been observed that the quality of the statistical description improves with an increase of the dimension of the problem and with a lowering of the symmetry of the lattice.Statistical properties of the discrete alignment distributionsAnother attractive application of the statistical spectroscopy is a description of the shapes of molecular electronic bands [80] [81] [82] [83] .", [["[80] [81] [82]", "CHEMICAL", 364, 378], ["the discrete alignment distributions", "PROBLEM", 204, 240], ["the statistical spectroscopy", "TEST", 274, 302], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["discrete", "OBSERVATION_MODIFIER", 208, 216], ["alignment distributions", "OBSERVATION", 217, 240]]], ["Initially, the method of generating of envelopes of the intensities has been introduced for the transitions in crystals [84] and in atoms [85] .", [["the transitions in crystals", "PROBLEM", 92, 119]]], ["Replacing the calculations line by line by the statistical approach with much shorter computing time became also attractive in molecular physics.", [["the calculations line", "TREATMENT", 10, 31], ["calculations line", "OBSERVATION", 14, 31]]], ["The shape of a molecular band may be defined as an envelope of the rovibrational lines which constitute the band.", [["rovibrational lines", "CELL_LINE", 67, 86], ["a molecular band", "PROBLEM", 13, 29], ["the rovibrational lines", "TREATMENT", 63, 86], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["molecular band", "OBSERVATION", 15, 29], ["may be", "UNCERTAINTY", 30, 36], ["envelope", "OBSERVATION_MODIFIER", 51, 59], ["rovibrational lines", "OBSERVATION", 67, 86], ["band", "OBSERVATION_MODIFIER", 108, 112]]], ["The method of determining the shapes of molecular electronic bands consists of several steps.", [["molecular electronic bands", "PROBLEM", 40, 66], ["electronic bands", "OBSERVATION", 50, 66]]], ["Finally, a smooth function for which several lowest moments are equal to the exact ones, is derived.", [["smooth", "OBSERVATION_MODIFIER", 11, 17]]], ["In particular, I have used this algorithm to derive the intensity spectrum corresponding to the transitions in H 2 molecule using 3-moment trial function [86] .", [["H 2", "CHEMICAL", 111, 114], ["H 2 molecule", "PROTEIN", 111, 123], ["this algorithm", "TREATMENT", 27, 41], ["the transitions in H 2 molecule", "TREATMENT", 92, 123]]], ["Adding moments of the order higher than 4 does not improve the results when the Gram-Charlier expansion is taken as the trial function.", [["the Gram", "TEST", 76, 84], ["Charlier expansion", "TEST", 85, 103]]], ["This process may even be divergent.", [["may even be", "UNCERTAINTY", 13, 24]]], ["In the case of H 2 molecule a non-standard 3-moment trial function has to be applied in order to get a high quality approximation of the spectrum (treated as a statistical distribution).Statistical properties of the discrete alignment distributionsDistributions are commonly, and very conveniently, characterized by their moments.", [["H 2", "CHEMICAL", 15, 18], ["H 2 molecule", "PROTEIN", 15, 27], ["a non-standard 3-moment trial function", "TREATMENT", 28, 66], ["the discrete alignment distributions", "PROBLEM", 212, 248], ["discrete", "OBSERVATION_MODIFIER", 216, 224], ["alignment distributions", "OBSERVATION", 225, 248]]], ["In the present work I describe DNA sequences as distributions and apply the distribution moments to study similarity between these sequences.", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["DNA sequences", "DNA", 31, 44], ["DNA sequences", "TEST", 31, 44], ["these sequences", "TEST", 125, 140]]], ["A similarity measure\u02dc q based on the q-th moment of the discrete alignment distribution n p is defined asStatistical properties of the discrete alignment distributionswhere q = 0, 1, 2, . . . .", [["discrete", "OBSERVATION_MODIFIER", 56, 64], ["alignment", "OBSERVATION_MODIFIER", 65, 74], ["distribution", "OBSERVATION_MODIFIER", 75, 87], ["discrete", "OBSERVATION_MODIFIER", 135, 143], ["alignment", "OBSERVATION_MODIFIER", 144, 153]]], ["The normalization constant c is defined so that the zeroth moment of the distribution is equal to one (\u02dc 0 = 1):Statistical properties of the discrete alignment distributionsComparing sequences, usually one is interested in the quantities that are independent of the lengths of the sequences.", [["normalization", "OBSERVATION", 4, 17], ["constant", "OBSERVATION_MODIFIER", 18, 26], ["equal", "OBSERVATION_MODIFIER", 89, 94], ["discrete", "OBSERVATION_MODIFIER", 142, 150], ["alignment", "OBSERVATION", 151, 160]]], ["For that purpose, moments for which the mean value is equal to 0 ( 1 = 0) and the variance is equal to 1 ( 2 = 1) can be used as similarity measures:Statistical properties of the discrete alignment distributionsTable 1 shows a model example of the alignment distribution n p for a pair of sequences.", [["the mean value", "TEST", 36, 50], ["the variance", "TEST", 78, 90], ["the discrete alignment distributions", "PROBLEM", 175, 211], ["a pair of sequences", "TEST", 279, 298], ["discrete", "OBSERVATION_MODIFIER", 179, 187], ["alignment distributions", "OBSERVATION", 188, 211]]], ["The choice of the query sequence has no influence on the results.", [["the query sequence", "TEST", 14, 32]]], ["The length of sequence 1 is 12 and the length of sequence 2 is 15.", [["The length of sequence", "TEST", 0, 22]]], ["If K = 15 is chosen then for p > 12 the distribution is defined as zeros: n 13 = n 14 = n 15 = 0.", [["K", "CHEMICAL", 3, 4], ["K", "TEST", 3, 4]]], ["Therefore, the Table 1 Model example of alignment distributions (r = 1) Table 2 shows a model example of the multiple alignment distribution for M = 3 (Eq.", [["alignment distributions (r = 1) Table 2", "TEST", 40, 79], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["alignment", "OBSERVATION_MODIFIER", 118, 127], ["distribution", "OBSERVATION_MODIFIER", 128, 140]]], ["Analogously, the value of K may be set equal to the length of any of the three sequences.", [["K", "CHEMICAL", 26, 27]]], ["Thus, independently of the choice of K the moments remain the same.Discrete alignment distribution moments as similarity measuresIn this work,\u02dc q and q are proposed as new similarity measures that can be treated as corrections to the alignment methods.", [["\u02dc q and q", "DNA", 142, 151], ["Discrete alignment distribution moments", "PROBLEM", 67, 106], ["alignment", "OBSERVATION_MODIFIER", 76, 85], ["distribution moments", "OBSERVATION", 86, 106]]], ["They describe such features of similarity that cannot be identified in the alignment methods.", [["cannot be", "UNCERTAINTY", 47, 56]]], ["In particular, the two model cases defined at the beginning of this chapter can be distinguished using the new measures.Discrete alignment distribution moments as similarity measuresThe new numerical characterization of DNA sequences is exemplified using the \u03b2globin gene of different species.", [["DNA", "CELLULAR_COMPONENT", 220, 223], ["\u03b2globin", "GENE_OR_GENE_PRODUCT", 259, 266], ["DNA sequences", "DNA", 220, 233], ["\u03b2globin gene", "DNA", 259, 271], ["Discrete alignment distribution moments", "PROBLEM", 120, 159], ["DNA sequences", "TEST", 220, 233], ["different species", "PROBLEM", 275, 292], ["new", "OBSERVATION_MODIFIER", 107, 110], ["alignment", "OBSERVATION_MODIFIER", 129, 138], ["distribution moments", "OBSERVATION", 139, 159], ["new", "OBSERVATION_MODIFIER", 186, 189], ["different species", "OBSERVATION", 275, 292]]], ["The species and the locations of the sequences in genes as well as the lengths of the sequences, N 1 and N 2 , are listed in Table 3 .", [["N 1 and N 2", "DNA", 97, 108], ["the sequences", "TEST", 82, 95]]], ["Tables 4, 5, 6, 7, 8, 9, 10, 11 show similarity matrices based on the new measures for the sequences listed in Table 3 .", [["4, 5, 6, 7, 8, 9, 10, 11", "DNA", 7, 31]]], ["Tables 4, 5, 6, 7 correspond to the coding sequences of the first exon, Exon 1 C DS , and Tables 8, 9, 10, 11 correspond to the second exon, Exon 2 C DS .", [["4, 5, 6, 7", "DNA", 7, 17], ["exon", "DNA", 66, 70], ["Exon 1 C DS", "DNA", 72, 83], ["Tables 8, 9, 10, 11", "DNA", 90, 109], ["exon", "DNA", 135, 139], ["Exon 2 C DS", "DNA", 141, 152], ["DS", "TEST", 81, 83], ["Tables", "TEST", 90, 96]]], ["The similarity matrices are based on different measures:\u02dc 1 (Tables 4, 8 ), 3 (Tables 5, 9 ), described by x 1 = 1, x 2 = 2, and x 3 = 3.", [["matrices", "OBSERVATION_MODIFIER", 15, 23]]], ["In this case\u02dc 1 = 4/2 = 2 and x 2 = 2 is the middle of the sequence.", [["middle", "ANATOMY_MODIFIER", 45, 51]]], ["One can normalize the similarity matrix based on\u02dc 1 dividing all its elements by K + 1.", [["K", "CHEMICAL", 81, 82], ["matrix", "CELLULAR_COMPONENT", 33, 39], ["K + 1", "GENE_OR_GENE_PRODUCT", 81, 86], ["K", "TEST", 81, 82]]], ["Then one can easily see whether the mean value is larger or smaller than 1/2.", [["the mean value", "TEST", 32, 46], ["larger", "OBSERVATION_MODIFIER", 50, 56], ["smaller", "OBSERVATION_MODIFIER", 60, 67]]], ["If\u02dc 1 is equal to 1/2 then the location of the mean value of the distribution is in the middle.", [["equal", "OBSERVATION_MODIFIER", 9, 14], ["mean", "OBSERVATION_MODIFIER", 47, 51], ["distribution", "OBSERVATION_MODIFIER", 65, 77], ["middle", "ANATOMY_MODIFIER", 88, 94]]], ["If it is greater than 1/2 it is shifted towards the end of the distribution.", [["greater", "OBSERVATION_MODIFIER", 9, 16], ["shifted", "OBSERVATION", 32, 39]]], ["Since q are independent of the lengths of the sequences it is convenient to keep at least one similarity measure (\u02dc 1 ) that carries the information both about the lengths of the sequences and about the distributions of the aligned bases.", [["bases", "ANATOMY_MODIFIER", 232, 237]]], ["Therefore,\u02dc 1 is not normalized in this work.Discrete alignment distribution moments as similarity measuresAn example of the similarity measure independent of the lengths of the sequences is 3 that describes the asymmetry of the aligned distributions.", [["Discrete alignment distribution moments", "PROBLEM", 45, 84], ["normalized", "OBSERVATION", 21, 31], ["alignment", "OBSERVATION_MODIFIER", 54, 63], ["distribution moments", "OBSERVATION", 64, 84], ["asymmetry", "OBSERVATION", 212, 221], ["aligned", "OBSERVATION_MODIFIER", 229, 236], ["distributions", "OBSERVATION_MODIFIER", 237, 250]]], ["It is negative for the left-skewed distributions and positive for right-skewed distributions.", [["right-skewed distributions", "PROBLEM", 66, 92], ["negative", "OBSERVATION", 6, 14], ["left", "ANATOMY_MODIFIER", 23, 27], ["skewed", "OBSERVATION", 28, 34], ["right", "ANATOMY_MODIFIER", 66, 71], ["skewed distributions", "OBSERVATION", 72, 92]]], ["One can observe, that the asymmetry of the aligned distributions for Exon 1 C DS (Table 5) is different from the one for Exon 2 C DS ( Table 9 ).", [["Exon 1 C DS (Table 5", "TREATMENT", 69, 89], ["Exon 2 C DS", "TREATMENT", 121, 132], ["asymmetry", "OBSERVATION_MODIFIER", 26, 35]]], ["The number of the negative values of 3 is 41 for Exon 1 C DS and 21 for Exon 2 C DS .", [["Exon 1 C DS", "TEST", 49, 60], ["Exon 2 C DS", "TREATMENT", 72, 83]]], ["For example, in the case of human-mouse sequences, 3 is negative for Exon 1 C DS and it is positive for Exon 2 C DS .", [["human", "ORGANISM", 28, 33], ["mouse", "ORGANISM", 34, 39], ["human-mouse sequences", "DNA", 28, 49], ["Exon 1 C DS", "DNA", 69, 80], ["Exon 2 C DS", "DNA", 104, 115], ["human", "SPECIES", 28, 33], ["mouse", "SPECIES", 34, 39], ["human", "SPECIES", 28, 33], ["mouse", "SPECIES", 34, 39], ["human-mouse sequences", "TEST", 28, 49], ["Exon 1 C DS", "PROBLEM", 69, 80], ["Exon 2 C DS", "PROBLEM", 104, 115]]], ["This is the kurtosis parameter, that is the measure of the peakedness of the distribution.", [["the kurtosis parameter", "TEST", 8, 30], ["distribution", "OBSERVATION_MODIFIER", 77, 89]]], ["For example, the similarity measure based on 4 for galluslemur sequences is 1.86 for Exon 1 C DS and 1.70 for Exon 2 C DS .", [["galluslemur sequences", "DNA", 51, 72], ["galluslemur sequences", "TEST", 51, 72], ["Exon 1 C DS", "TREATMENT", 85, 96], ["Exon 2 C DS", "TREATMENT", 110, 121]]], ["The horizontal axis represents the values listed in Table 6 Table 5 versus values listed in Table 7 ( Fig. 2, panel b) and the values listed in Table 9 versus values listed in Table 11 means that the information coming from 5 is similar to the one coming from 3 .", [["the values", "TEST", 123, 133]]], ["2 and 3, panels a, where Table 13 Model example of four-component multiple alignment distribution (K = 15, M = 3, r = 1)Discrete alignment distribution moments as similarity measuresIn order to further enrich the information that can be derived from the alignment methods, one can introduce the four-component alignment distributions, separately for A, C, T, and G bases.", [["multiple alignment distribution", "TEST", 66, 97], ["K", "TEST", 99, 100], ["M", "TEST", 107, 108], ["Discrete alignment distribution moments", "PROBLEM", 120, 159], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["alignment", "OBSERVATION_MODIFIER", 75, 84], ["alignment", "OBSERVATION_MODIFIER", 129, 138], ["distribution moments", "OBSERVATION", 139, 159], ["alignment", "OBSERVATION_MODIFIER", 310, 319], ["bases", "ANATOMY_MODIFIER", 365, 370]]], ["A specific \u03b3 -component of this distribution, referred to as \u03b3 -distribution, is defined asDiscrete alignment distribution moments as similarity measureswhere \u03b3 = A, C, T, G denotes one of the bases.", [["\u03b3", "PROTEIN", 11, 12], ["component", "OBSERVATION_MODIFIER", 14, 23], ["alignment", "OBSERVATION_MODIFIER", 100, 109], ["distribution", "OBSERVATION_MODIFIER", 110, 122], ["bases", "ANATOMY_MODIFIER", 193, 198]]], ["Such kind of distributions can be created for a pair of sequences (M = 2) and also for the multiple alignment studies (M \u2265 3).", [["a pair of sequences", "TEST", 46, 65], ["the multiple alignment studies", "TEST", 87, 117]]], ["A model example of the four-component distribution with M = 3 is shown in Table 13 .Discrete alignment distribution moments as similarity measuresThe same definitions of the distributions (Eqs.", [["Discrete alignment distribution moments", "PROBLEM", 84, 123], ["alignment", "OBSERVATION_MODIFIER", 93, 102], ["distribution moments", "OBSERVATION", 103, 123], ["distributions", "OBSERVATION_MODIFIER", 174, 187]]], ["A model example of the optimized multiple alignment distribution based on Eq.", [["multiple", "OBSERVATION_MODIFIER", 33, 41], ["alignment", "OBSERVATION_MODIFIER", 42, 51], ["distribution", "OBSERVATION_MODIFIER", 52, 64]]], ["The maximally scoring alignment is obtained if two gaps are introduced in sequence 3.Discrete alignment distribution moments as similarity measuresObviously, the information is more detailed if four-component optimized distribution is created.", [["Discrete alignment distribution moments", "PROBLEM", 85, 124], ["alignment", "OBSERVATION_MODIFIER", 94, 103], ["distribution moments", "OBSERVATION", 104, 124]]], ["7) for the same sequences as shown in Table 14 .", [["the same sequences", "TEST", 7, 25]]], ["The application of the new similarity measures to all kinds of the distributions is simple and straightforward.", [["new", "OBSERVATION_MODIFIER", 23, 26], ["distributions", "OBSERVATION_MODIFIER", 67, 80], ["simple", "OBSERVATION_MODIFIER", 84, 90]]], ["In this way, different aspects of similarity can be revealed.Graphical representations of DNA sequencesAn attractive, alternative to the time consuming alignment methods, are graphical representations.", [["DNA", "CELLULAR_COMPONENT", 90, 93], ["DNA sequences", "DNA", 90, 103], ["DNA sequences", "TEST", 90, 103]]], ["They reveal different aspects of similarity, offer both numerical characterization of similarity and the visualization.", [["both numerical characterization", "TEST", 51, 82], ["the visualization", "TEST", 101, 118], ["different", "OBSERVATION_MODIFIER", 12, 21]]], ["Also the computing effort is in this case very small.", [["small", "OBSERVATION_MODIFIER", 47, 52]]], ["In this section graphical methods are discussed.Graphical representations of DNA sequencesIn the original approaches, DNA sequences were plotted as either three-dimensional [87] or two-dimensional [88] [89] [90] curves.", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["DNA sequences", "DNA", 77, 90], ["DNA sequences", "DNA", 118, 131], ["DNA sequences", "TEST", 77, 90], ["DNA sequences", "TEST", 118, 131]]], ["The shapes of the curves were determined by a walk in a space spanned by four vectors that represent the four bases.", [["shapes", "OBSERVATION_MODIFIER", 4, 10], ["four", "ANATOMY_MODIFIER", 105, 109], ["bases", "ANATOMY_MODIFIER", 110, 115]]], ["In the first article on this subject, Hamori proposed a graphical representation method in which the information about the DNA sequence has been mapped into a three-dimensionalspace curve.", [["DNA", "CELLULAR_COMPONENT", 123, 126], ["DNA sequence", "DNA", 123, 135], ["the DNA sequence", "TEST", 119, 135]]], ["A unit vector of a characteristic direction has been assigned to each of the four nucleotides: adenine A, cytosine C, thymine T, and guanine G. In this approach the shape of the curve (called H-curve) representing the sequence of nucleotides is obtained by joining the vectors in the order of the nucleotides in the sequence.", [["adenine", "CHEMICAL", 95, 102], ["cytosine", "CHEMICAL", 106, 114], ["thymine", "CHEMICAL", 118, 125], ["guanine", "CHEMICAL", 133, 140], ["nucleotides", "CHEMICAL", 82, 93], ["adenine A", "CHEMICAL", 95, 104], ["cytosine C", "CHEMICAL", 106, 116], ["thymine T", "CHEMICAL", 118, 127], ["guanine", "CHEMICAL", 133, 140], ["nucleotides", "CHEMICAL", 230, 241], ["nucleotides", "CHEMICAL", 297, 308], ["adenine A", "SIMPLE_CHEMICAL", 95, 104], ["cytosine C", "SIMPLE_CHEMICAL", 106, 116], ["thymine T", "SIMPLE_CHEMICAL", 118, 127], ["guanine", "SIMPLE_CHEMICAL", 133, 140], ["A unit vector", "TREATMENT", 0, 13], ["adenine A", "TREATMENT", 95, 104], ["cytosine C", "TREATMENT", 106, 116], ["thymine T", "TREATMENT", 118, 127], ["guanine G.", "TREATMENT", 133, 143]]], ["Changing the resolution one can see short-range details or global trends of the distribution of nucleotides.", [["nucleotides", "CHEMICAL", 96, 107]]], ["For example, H-curve is shifted in characteristic direction if the sequence is rich in certain nucleotides.", [["H-curve", "CHEMICAL", 13, 20], ["nucleotides", "CHEMICAL", 95, 106], ["shifted", "OBSERVATION_MODIFIER", 24, 31]]], ["The first mathematical representation Hamori also published in Nature in 1985 under the title \"Novel DNA sequence representation\" [91] .Graphical representations of DNA sequencesThe same year another article about a new graphical representation titled \"Simpler DNA sequence representations\" has been also published in Nature by Gates [88] .", [["DNA", "CELLULAR_COMPONENT", 101, 104], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["DNA", "CELLULAR_COMPONENT", 261, 264], ["DNA sequences", "DNA", 165, 178], ["Simpler DNA sequence", "DNA", 253, 273], ["DNA sequences", "TEST", 165, 178], ["a new graphical representation", "PROBLEM", 214, 244], ["Simpler DNA sequence representations", "PROBLEM", 253, 289]]], ["In this approach, guanine is represented by a unit vector in the positive x-axis direction, complementary cytosine is represented by a negative x-axis unit vector, and adenine and thymine are represented by unit vectors in the positive and negative y-axis directions, respectively.", [["guanine", "CHEMICAL", 18, 25], ["cytosine", "CHEMICAL", 106, 114], ["adenine", "CHEMICAL", 168, 175], ["thymine", "CHEMICAL", 180, 187], ["guanine", "CHEMICAL", 18, 25], ["cytosine", "CHEMICAL", 106, 114], ["adenine", "CHEMICAL", 168, 175], ["thymine", "CHEMICAL", 180, 187], ["guanine", "SIMPLE_CHEMICAL", 18, 25], ["cytosine", "SIMPLE_CHEMICAL", 106, 114], ["adenine", "SIMPLE_CHEMICAL", 168, 175], ["thymine", "SIMPLE_CHEMICAL", 180, 187], ["negative x-axis unit vector", "DNA", 135, 162], ["a unit vector", "TREATMENT", 44, 57], ["complementary cytosine", "TREATMENT", 92, 114], ["adenine and thymine", "TREATMENT", 168, 187], ["positive x-axis", "OBSERVATION", 65, 80]]], ["Using such an approach all sequences can be represented in two dimensions in a unique manner, while using the Hamori approach, DNA structure may be viewed from any chosen perspective in two-dimensional plots.", [["DNA", "CELLULAR_COMPONENT", 127, 130], ["the Hamori approach", "TREATMENT", 106, 125]]], ["Obviously, a chosen perspective of a 3D curve in 2D space gives only a part of the total information about the sequence.", [["a 3D curve in 2D space", "TREATMENT", 35, 57]]], ["However, also in the graphical representation proposed by Gates some information may be lost, as it is shown in a subsequent part of this work.Graphical representations of DNA sequencesAbout 10 years later, Nandy (independently of Gates) published an article \"A new graphical representation and analysis of DNA sequence structure: I. Methodology and application to globin genes\" [89] .", [["DNA", "CELLULAR_COMPONENT", 172, 175], ["DNA", "CELLULAR_COMPONENT", 307, 310], ["globin", "GENE_OR_GENE_PRODUCT", 365, 371], ["DNA sequences", "DNA", 172, 185], ["globin genes", "DNA", 365, 377], ["DNA sequences", "TEST", 172, 185]]], ["The idea is very similar to the one presented by Gates.", [["very", "OBSERVATION_MODIFIER", 12, 16], ["similar", "OBSERVATION", 17, 24]]], ["In the scientific correspondence [92] , the author explains that he has just brought to his attention that a similar technique was presented by Gates and indicates some advantages of his method: The nontrivial choice of the coordinate system A-G, C-T (purine-pirymidine) instead of the axis system proposed by Gates (C-G, A-T) may give more significant biological information.Graphical representations of DNA sequencesOne year later (independently of Nandy), Leong and Morgenthaler proposed two new graphical representations of DNA sequences [90] .", [["C-T", "CHEMICAL", 247, 250], ["purine-pirymidine", "CHEMICAL", 252, 269], ["purine", "CHEMICAL", 252, 258], ["pirymidine", "CHEMICAL", 259, 269], ["A-G", "SIMPLE_CHEMICAL", 242, 245], ["C-T", "SIMPLE_CHEMICAL", 247, 250], ["purine-pirymidine", "SIMPLE_CHEMICAL", 252, 269], ["DNA", "CELLULAR_COMPONENT", 405, 408], ["DNA", "CELLULAR_COMPONENT", 528, 531], ["DNA sequences", "DNA", 405, 418], ["DNA sequences", "DNA", 528, 541], ["purine-pirymidine", "TREATMENT", 252, 269], ["DNA sequences", "TEST", 405, 418], ["DNA sequences", "TEST", 528, 541]]], ["The first one is a slight modification of the Gates method: they change the unit vectors corresponding to the particular bases.", [["the unit vectors", "TREATMENT", 72, 88], ["slight", "OBSERVATION_MODIFIER", 19, 25], ["modification", "OBSERVATION", 26, 38], ["bases", "ANATOMY_MODIFIER", 121, 126]]], ["The x-axis represents C and A and y-axis G and T. According to the authors such a change allows to exhibit the distribution of purines (A and G) and pyrimidines (C and T).", [["purines", "CHEMICAL", 127, 134], ["pyrimidines", "CHEMICAL", 149, 160], ["purines", "CHEMICAL", 127, 134], ["pyrimidines", "CHEMICAL", 149, 160], ["purines", "SIMPLE_CHEMICAL", 127, 134], ["A", "SIMPLE_CHEMICAL", 136, 137], ["pyrimidines", "SIMPLE_CHEMICAL", 149, 160], ["C", "SIMPLE_CHEMICAL", 162, 163], ["C and A and y-axis G and T.", "PROBLEM", 22, 49], ["A and G)", "TREATMENT", 136, 144], ["pyrimidines (C and T)", "TREATMENT", 149, 170]]], ["However, the authors found a good solution to identify in the plot the regions in which the parts of the sequences are hidden: the scale is visible even for long sequences and the numbers that label the bases in the plot are pointed every one hundred.", [["long sequences", "TEST", 157, 171], ["bases", "ANATOMY_MODIFIER", 203, 208]]], ["Leong and Morgenthaler also proposed another, interesting graphical representation: gap plots that give the information about the distances between particular bases.Graphical representations of DNA sequencesIndependently of the graphical representations introduced by Gates [88], Nandy [89] , Leong and Morgenthaler [90] , similar graphs, also based on vectorial representations of the four bases and constructing 2D DNA walks, have been constructed by Mizraji and Ninio [93] and by Lobry [94] .", [["DNA", "CELLULAR_COMPONENT", 194, 197], ["DNA", "CELLULAR_COMPONENT", 417, 420], ["DNA sequences", "DNA", 194, 207], ["gap plots", "PROBLEM", 84, 93], ["DNA sequences", "TEST", 194, 207], ["constructing 2D DNA walks", "TREATMENT", 401, 426], ["bases", "ANATOMY_MODIFIER", 159, 164], ["bases", "ANATOMY_MODIFIER", 391, 396]]], ["Lobry also used orthogonal directions but his choice of the unit vectors representing the four bases was different than the ones used in refs.", [["unit vectors", "DNA", 60, 72], ["the unit vectors", "TREATMENT", 56, 72], ["bases", "ANATOMY_MODIFIER", 95, 100]]], ["The specific choice of the basis vectors done by Mizraji and Ninio seems to solve many problems.", [["Mizraji", "TREATMENT", 49, 56], ["Ninio", "TREATMENT", 61, 66]]], ["The vectors have been chosen so that it is easy to distinguish between coding and noncoding parts of the sequence and the graphs are nondegenerate.", [["The vectors", "TREATMENT", 0, 11], ["nondegenerate", "OBSERVATION", 133, 146]]], ["Mizraji and Ninio also proposed a graphical representation which shows purine/pirymidyne distributions along the sequence.", [["purine", "CHEMICAL", 71, 77], ["purine", "CHEMICAL", 71, 77], ["pirymidyne", "CHEMICAL", 78, 88], ["purine", "SIMPLE_CHEMICAL", 71, 77], ["pirymidyne", "SIMPLE_CHEMICAL", 78, 88], ["Mizraji", "TREATMENT", 0, 7], ["Ninio", "TREATMENT", 12, 17], ["a graphical representation", "TEST", 32, 58], ["purine/pirymidyne distributions", "PROBLEM", 71, 102]]], ["However, the authors did not propose any numerical representation associated with these graphs.Graphical representations of DNA sequencesAs a consequence, four similar 2D graphical representations have been created.", [["DNA", "CELLULAR_COMPONENT", 124, 127], ["DNA sequencesAs", "DNA", 124, 139], ["these graphs", "TEST", 82, 94]]], ["They differ from each other in the choice of the coordinate systems: x-axis: G-C (Gates), A-G (Nandy), C-A (Leong and Morgenthaler), A-T (Lobry).", [["G-C", "SIMPLE_CHEMICAL", 77, 80], ["A-G", "SIMPLE_CHEMICAL", 90, 93], ["Nandy", "SIMPLE_CHEMICAL", 95, 100], ["C-A", "SIMPLE_CHEMICAL", 103, 106], ["A-T", "GENE_OR_GENE_PRODUCT", 133, 136], ["G", "TEST", 77, 78], ["A", "TEST", 90, 91], ["Nandy", "TEST", 95, 100], ["C", "TEST", 103, 104], ["Leong", "TEST", 108, 113], ["Morgenthaler", "TEST", 118, 130]]], ["The most popular became the graphical representation proposed by Nandy, called Nandy plots.Graphical representations of DNA sequencesHowever, such a two-dimensional representation may lead to some parts of the sequence being hidden if the walk is performed back and forth along the same trace (so called repetitive walks).", [["Nandy", "SIMPLE_CHEMICAL", 65, 70], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["DNA sequences", "DNA", 120, 133], ["DNA sequences", "TEST", 120, 133]]], ["Labeling and coloring only approximately localizes the regions in the sequences where the hidden parts are located.", [["regions", "ANATOMY_MODIFIER", 55, 62]]], ["The advantage is a small size of the graph representing long sequences and very often the information coming from such a plot may be sufficient.", [["small", "OBSERVATION_MODIFIER", 19, 24], ["size", "OBSERVATION_MODIFIER", 25, 29]]], ["In order to eliminate, or to minimize, the degeneracy caused by the repetitive walks, many different methods have been introduced.", [["the degeneracy", "PROBLEM", 39, 53], ["the repetitive walks", "PROBLEM", 64, 84], ["many different methods", "TREATMENT", 86, 108]]], ["For example, Guo et al. [95] introduced a new graphical representation, also based on a walk in 2D space changing the angles between the basis vectors: the four nucleic acid bases are represented by the vectors: A by \u22121, 1 d ; T by 1 d , \u22121 ; G by 1, 1 d ; and C by 1 d , 1 , where d is a positive integer.", [["nucleic acid", "CHEMICAL", 161, 173], ["a walk in 2D space", "TREATMENT", 86, 104], ["a positive integer", "PROBLEM", 287, 305], ["acid bases", "OBSERVATION", 169, 179]]], ["The authors have shown that the degree of degeneracy of the new graphs is lower than for Nandy plots, but it is still present and depends on the value of d.Graphical representations of DNA sequencesA further modification of the graphical representation based on a walk in 2D space has been introduced by changing the vectors in such a way that the basis vectors corresponding to pyrimidines (T, C) are located in the first quadrant of the Cartesian coordinate system and to purines (A, G) in the fourth one [38, 39] .", [["pyrimidines", "CHEMICAL", 379, 390], ["purines", "CHEMICAL", 474, 481], ["pyrimidines", "CHEMICAL", 379, 390], ["C", "CHEMICAL", 395, 396], ["purines", "CHEMICAL", 474, 481], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["T, C", "GENE_OR_GENE_PRODUCT", 392, 396], ["purines", "SIMPLE_CHEMICAL", 474, 481], ["DNA sequences", "DNA", 185, 198], ["Nandy plots", "PROBLEM", 89, 100], ["DNA sequences", "PROBLEM", 185, 198], ["a walk in 2D space", "TREATMENT", 262, 280], ["the vectors", "TREATMENT", 313, 324], ["pyrimidines (T, C)", "TREATMENT", 379, 397], ["degeneracy", "OBSERVATION", 42, 52], ["new", "OBSERVATION_MODIFIER", 60, 63]]], ["The unit vectors representing four nucleotides are as follows: [96] and also H-L curve representation proposed recently by Huang et al. [97, 98] .Graphical representations of DNA sequencesAn interesting 2D ladder-like graphical representation has been also proposed by Li and Wang [99] .", [["Li", "CHEMICAL", 269, 271], ["nucleotides", "CHEMICAL", 35, 46], ["Li", "CHEMICAL", 269, 271], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["The unit vectors", "TREATMENT", 0, 16], ["four nucleotides", "TREATMENT", 30, 46], ["DNA sequencesAn", "TEST", 175, 190], ["2D ladder", "TREATMENT", 203, 212]]], ["Their graphs are based on the division of bases according to their chemical properties.", [["bases", "ANATOMY_MODIFIER", 42, 47]]], ["The four bases can be classified into groups: 1. purine R = A, G, pirymidyne Y = C, T; 2. strong H bond S = C, G, weak H bond W = A, T; and 3. amino M = A, C, keto K = G, T. The method is also based on a walk in 2D space with basis vectors (0,1), (1,0) for characteristic sequences (M, K), (R, Y) and (W, S).Graphical representations of DNA sequencesRecently, we have proposed another method aimed at some improvement of the original 2D walk method (Nandy plots) [100] .", [["purine", "CHEMICAL", 49, 55], ["amino M", "CHEMICAL", 143, 150], ["purine", "CHEMICAL", 49, 55], ["pirymidyne", "CHEMICAL", 66, 76], ["C", "CHEMICAL", 81, 82], ["H", "CHEMICAL", 97, 98], ["C", "CHEMICAL", 108, 109], ["H", "CHEMICAL", 119, 120], ["amino", "CHEMICAL", 143, 148], ["C", "CHEMICAL", 156, 157], ["purine R = A, G, pirymidyne Y = C", "SIMPLE_CHEMICAL", 49, 82], ["H bond S = C, G", "SIMPLE_CHEMICAL", 97, 112], ["H bond W = A", "SIMPLE_CHEMICAL", 119, 131], ["amino", "AMINO_ACID", 143, 148], ["keto K = G", "SIMPLE_CHEMICAL", 159, 169], ["DNA", "CELLULAR_COMPONENT", 337, 340], ["purine R", "TEST", 49, 57], ["A", "TEST", 60, 61], ["G", "TEST", 63, 64], ["pirymidyne", "TEST", 66, 76], ["T", "TEST", 84, 85], ["strong H bond S", "TEST", 90, 105], ["C", "TEST", 108, 109], ["G", "TEST", 111, 112], ["weak H bond W", "TEST", 114, 127], ["amino M", "TEST", 143, 150], ["keto K", "TEST", 159, 165], ["characteristic sequences", "TEST", 257, 281], ["the original 2D walk method", "TREATMENT", 421, 448], ["bases", "ANATOMY_MODIFIER", 9, 14]]], ["This method is based on Nandy plots but it removes the degeneracy coming from the repetitive walks.", [["the degeneracy", "PROBLEM", 51, 65]]], ["The DNA sequence is represented as a set of material points in 2D space.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA sequence", "DNA", 4, 16], ["The DNA sequence", "TEST", 0, 16]]], ["Figure 4 , panel a, shows the method of plotting the 2D-dynamic graph for a model sequence CTC and Fig. 5 , panel a, for CTCT one.", [["a model sequence CTC", "TEST", 74, 94], ["CTCT", "TEST", 121, 125]]], ["The first base in the sequence is C and we make a shift along the vertical axis in the positive direction.", [["base", "ANATOMY_MODIFIER", 10, 14], ["vertical axis", "OBSERVATION_MODIFIER", 66, 79], ["positive direction", "OBSERVATION", 87, 105]]], ["At the end of this vector (position (0,1)) we locate the point with the mass equal to 1.", [["mass", "OBSERVATION", 72, 76]]], ["The second base in the sequence is T and we make the second shift along the vertical axis in the negative direction starting from the end of the last vector.", [["second", "OBSERVATION_MODIFIER", 4, 10], ["base", "ANATOMY_MODIFIER", 11, 15], ["vertical axis", "OBSERVATION_MODIFIER", 76, 89], ["negative", "OBSERVATION", 97, 105]]], ["At the end of the second vector again we locate the point with the mass also 1 (position (0,0)) and so on.", [["the mass", "PROBLEM", 63, 71], ["mass", "OBSERVATION", 67, 71]]], ["If the ends of vectors meet several times at the same point then the mass of this point increases (it is equal to the sum of all masses located in this point).", [["masses", "CANCER", 129, 135], ["the mass", "PROBLEM", 65, 73], ["all masses", "PROBLEM", 125, 135], ["mass", "OBSERVATION", 69, 73], ["masses", "OBSERVATION", 129, 135]]], ["The total mass in the graph is equal to the total number of bases in the sequence (3 in Fig. 4 and 4 in Fig. 5 ).", [["The total mass", "PROBLEM", 0, 14], ["the sequence", "TEST", 69, 81], ["total", "OBSERVATION_MODIFIER", 4, 9], ["mass", "OBSERVATION", 10, 14], ["equal", "OBSERVATION_MODIFIER", 31, 36], ["total", "OBSERVATION_MODIFIER", 44, 49], ["number", "OBSERVATION_MODIFIER", 50, 56], ["bases", "ANATOMY_MODIFIER", 60, 65]]], ["Different masses are represented by different symbols in the plots.", [["Different masses", "PROBLEM", 0, 16], ["masses", "OBSERVATION", 10, 16], ["different symbols", "OBSERVATION", 36, 53]]], ["Please note that both sequences CTC and CTCT are represented by the identical Nandy plots (Figs.", [["CTCT", "DNA", 40, 44], ["both sequences CTC", "TEST", 17, 35], ["CTCT", "TEST", 40, 44]]], ["2D-dynamic graph removes this degeneracy (the masses of the points (0,0) are different: 1 for CTC and 2 for CTCT).", [["this degeneracy", "PROBLEM", 25, 40], ["CTC", "TEST", 94, 97], ["CTCT", "TEST", 108, 112], ["masses", "OBSERVATION", 46, 52]]], ["The difference between the two sequences is also revealed in the mass-density distributions which we create for x and y directions [101] .", [["the two sequences", "TEST", 23, 40], ["the mass-density distributions", "PROBLEM", 61, 91], ["mass", "OBSERVATION", 65, 69], ["density", "OBSERVATION", 70, 77]]], ["The masses are projected onto two orthogonal directions and then summed for each x and y.", [["masses", "ANATOMY", 4, 10], ["masses", "CANCER", 4, 10], ["The masses", "PROBLEM", 0, 10], ["masses", "OBSERVATION", 4, 10]]], ["In the model examples the results of the projection and of the summation of the masses are shown in Figs.", [["masses", "CANCER", 80, 86], ["the masses", "PROBLEM", 76, 86], ["masses", "OBSERVATION", 80, 86]]], ["The mass-density distributions are composed of single lines located at the coordinates corresponding to the projected masses (x = 0 for \u03c1 x and y = 0, y = 1 for \u03c1 y ).", [["The mass-density distributions", "PROBLEM", 0, 30], ["single lines", "TREATMENT", 47, 59], ["mass", "OBSERVATION", 4, 8], ["-density", "OBSERVATION_MODIFIER", 8, 16], ["distributions", "OBSERVATION_MODIFIER", 17, 30], ["single lines", "OBSERVATION", 47, 59], ["masses", "OBSERVATION", 118, 124]]], ["The intensities of the lines correspond to the projected masses.", [["masses", "ANATOMY", 57, 63], ["lines", "CELL", 23, 28], ["masses", "CANCER", 57, 63], ["the lines", "TREATMENT", 19, 28], ["the projected masses", "PROBLEM", 43, 63], ["intensities", "OBSERVATION_MODIFIER", 4, 15], ["lines", "OBSERVATION", 23, 28], ["projected", "OBSERVATION_MODIFIER", 47, 56], ["masses", "OBSERVATION", 57, 63]]], ["The center panels in Figs.", [["The center panels", "TEST", 0, 17]]], ["4 and 5 correspond to mass-density distributions for x direction (\u03c1 x ) and the right ones for y directions (\u03c1 y ).", [["mass-density distributions", "PROBLEM", 22, 48], ["mass", "OBSERVATION", 22, 26], ["density", "OBSERVATION", 27, 34], ["distributions", "OBSERVATION_MODIFIER", 35, 48], ["for x direction", "OBSERVATION_MODIFIER", 49, 64], ["right", "ANATOMY_MODIFIER", 80, 85]]], ["However, the main reason for the creation of the mass-density distributions is deriving new descriptors related to 2D-dynamic graphs (see the subsequent chapter).Graphical representations of DNA sequencesThe modifications of the original 2D walk methods resulted also in graphs which became linear-like representations (1D), extending along one direction in 2D space.", [["DNA", "CELLULAR_COMPONENT", 191, 194], ["DNA sequences", "DNA", 191, 204], ["the mass-density distributions", "PROBLEM", 45, 75], ["2D-dynamic graphs", "TEST", 115, 132], ["DNA sequences", "TEST", 191, 204], ["the original 2D walk methods", "TEST", 225, 253], ["main", "OBSERVATION_MODIFIER", 13, 17], ["mass", "OBSERVATION", 49, 53], ["density", "OBSERVATION", 54, 61], ["linear", "OBSERVATION_MODIFIER", 291, 297]]], ["In such kind of methods only the horizontal axis is associated with the positions of the bases.", [["horizontal axis", "OBSERVATION_MODIFIER", 33, 48], ["bases", "ANATOMY_MODIFIER", 89, 94]]], ["Therefore these methods are free of the effects of self-overlapping of the graphs.", [["free", "OBSERVATION_MODIFIER", 28, 32]]], ["The cost we have to pay for the reduction of the degeneracy, is worse visualization of long sequences.Graphical representations of DNA sequencesA combination of a linear-like method with a DNA walk has recently been proposed by Zhang [102] .", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["long sequences", "DNA", 87, 101], ["DNA sequencesA", "PROBLEM", 131, 145], ["a linear-like method", "TREATMENT", 161, 181], ["a DNA walk", "TREATMENT", 187, 197]]], ["One nucleotide is represented by a pair of basis vectors instead of a single vector: (1, 1),(1, 1) corresponds to A, (1, 1), (1, \u22121) corresponds to T, (1, \u22121), (1, 1) corresponds to C, and (1, \u22121), (1, \u22121) corresponds to G. Since one base is represented by a double vector, the author calls his graphical representation of DNA sequences a DV-curve.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["DNA", "CELLULAR_COMPONENT", 323, 326], ["DNA sequences", "DNA", 323, 336], ["C", "TEST", 182, 183], ["a double vector", "TREATMENT", 257, 272], ["base", "ANATOMY_MODIFIER", 234, 238]]], ["A recently introduced graphical representation of DNA sequences based on the neighboring dual niclueotides (dinucleotides) [103, 104] is another example of a linear representation.", [["niclueotides", "CHEMICAL", 94, 106], ["dinucleotides", "CHEMICAL", 108, 121], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["DNA sequences", "DNA", 50, 63], ["DNA sequences", "TEST", 50, 63], ["a linear representation", "PROBLEM", 156, 179], ["linear", "OBSERVATION_MODIFIER", 158, 164]]], ["The authors plot a dinucleotide (DN) curve representing the distributions of pairs of nucleotides along the sequence.Graphical representations of DNA sequencesSeveral years ago a four-horizontal-line graphical representation has been proposed by Randi\u0107 et al. [105, 106] .", [["dinucleotide", "CHEMICAL", 19, 31], ["dinucleotide", "CHEMICAL", 19, 31], ["nucleotides", "CHEMICAL", 86, 97], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["DNA sequences", "DNA", 146, 159], ["a dinucleotide (DN) curve", "TREATMENT", 17, 42], ["DNA sequences", "TEST", 146, 159]]], ["Each line is associated with one base: A, T, G, and C, from the top.", [["line", "OBSERVATION", 5, 9], ["base", "ANATOMY_MODIFIER", 33, 37]]], ["The sequence is written at the bottom of the lowest line, with unit distances between the neighboring bases.", [["lowest line", "OBSERVATION", 45, 56], ["neighboring", "ANATOMY_MODIFIER", 90, 101], ["bases", "ANATOMY_MODIFIER", 102, 107]]], ["The dots (or rectangles) are put on the lines if a particular base appears in the sequence.", [["The dots (or rectangles)", "TREATMENT", 0, 24]]], ["For a better visualization the adjacent points are connected by a line, and zigzag-like curve is obtained.", [["a line", "TREATMENT", 64, 70], ["zigzag-like curve", "TEST", 76, 93]]], ["The idea proposed by Randi\u0107 of the visualization of DNA sequence by zigzag curves has been extended by different combinations of labeling the lines and by different number of graphs representing one sequence (characteristic graphs).", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["DNA sequence", "DNA", 52, 64], ["DNA sequence", "TEST", 52, 64], ["labeling the lines", "TREATMENT", 129, 147]]], ["Usually, the horizontal lines are not plotted.Graphical representations of DNA sequencesAnother linear graphical representation has been proposed by Li and Wang [108] .", [["horizontal lines", "ANATOMY", 13, 29], ["Li", "CHEMICAL", 149, 151], ["Li", "CHEMICAL", 149, 151], ["horizontal lines", "CELL", 13, 29], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["horizontal lines", "CELL_LINE", 13, 29], ["DNA sequences", "DNA", 75, 88], ["the horizontal lines", "TREATMENT", 9, 29], ["DNA sequences", "TEST", 75, 88], ["horizontal lines", "OBSERVATION", 13, 29], ["linear", "OBSERVATION_MODIFIER", 96, 102]]], ["The graphical representation is composed of three characteristic graphs, each of them consisting of two horizontal lines.", [["horizontal lines", "CELL", 104, 120], ["horizontal lines", "CELL_LINE", 104, 120], ["two", "OBSERVATION_MODIFIER", 100, 103], ["horizontal lines", "OBSERVATION", 104, 120]]], ["Each line in each graph is assigned to more than one base.", [["Each line in each graph", "TREATMENT", 0, 23], ["line", "OBSERVATION", 5, 9], ["base", "ANATOMY_MODIFIER", 53, 57]]], ["The lines in particular graphs are labeled by the following bases: A similar graphical representation has been proposed by Song and Tang [109] .", [["lines", "CELL", 4, 9], ["lines", "OBSERVATION", 4, 9]]], ["Two graphs correspond to one classification.", [["Two graphs", "TEST", 0, 10], ["one", "OBSERVATION_MODIFIER", 25, 28], ["classification", "OBSERVATION", 29, 43]]], ["For example in two graphs corresponding to classification purine (R) -pirymidyne (Y), the middle lines correspond to purines and pirymidynes in the first and in the second graph respectively.", [["middle lines", "ANATOMY", 90, 102], ["purine", "CHEMICAL", 58, 64], ["purines", "CHEMICAL", 117, 124], ["pirymidynes", "CHEMICAL", 129, 140], ["purine (R) -pirymidyne", "CHEMICAL", 58, 80], ["purines", "CHEMICAL", 117, 124], ["pirymidynes", "CHEMICAL", 129, 140], ["purine (R) -pirymidyne", "SIMPLE_CHEMICAL", 58, 80], ["purines", "SIMPLE_CHEMICAL", 117, 124], ["pirymidynes", "SIMPLE_CHEMICAL", 129, 140], ["classification purine", "TEST", 43, 64], ["the middle lines", "TREATMENT", 86, 102], ["purines and pirymidynes", "TEST", 117, 140], ["middle lines", "ANATOMY", 90, 102], ["purines", "OBSERVATION_MODIFIER", 117, 124]]], ["The other two lines correspond to these bases that are not purines or not pirymidynes, respectively, i.e.: A, Y, G label the lines in the first graph (top, middle, and bottom respectively) and C, R, T label the lines in the second graph.Graphical representations of DNA sequencesAnother example of an analogous graphical representation has been proposed by Liao and Wang [110] .", [["purines", "CHEMICAL", 59, 66], ["pirymidynes", "CHEMICAL", 74, 85], ["purines", "CHEMICAL", 59, 66], ["pirymidynes", "CHEMICAL", 74, 85], ["purines", "SIMPLE_CHEMICAL", 59, 66], ["pirymidynes", "SIMPLE_CHEMICAL", 74, 85], ["DNA", "CELLULAR_COMPONENT", 266, 269], ["DNA sequences", "DNA", 266, 279], ["DNA sequences", "TEST", 266, 279], ["two lines", "OBSERVATION", 10, 19], ["bases", "ANATOMY_MODIFIER", 40, 45], ["lines", "OBSERVATION", 125, 130], ["middle", "ANATOMY_MODIFIER", 156, 162], ["lines", "OBSERVATION", 211, 216]]], ["The sequence is represented by three graphs, and each of them is consisting of two horizontal lines.", [["horizontal lines", "CELL", 83, 99], ["horizontal lines", "CELL_LINE", 83, 99], ["two", "OBSERVATION_MODIFIER", 79, 82], ["horizontal lines", "OBSERVATION", 83, 99]]], ["The lines are labeled as follows: In another analogous graphical representation, proposed by Wang and Zhang [111] , also consisting of three characteristic graphs, the lines are labeled by the following bases: graph 1: non-A = G, C, T and A, graph 2: non-G = A, C, T and G, graph 3: non-C = A, G, T and C.Graphical representations of DNA sequencesA slight modification of this method has been proposed by Yao and Wang [112] .", [["lines", "CELL", 4, 9], ["lines", "CELL", 168, 173], ["DNA", "CELLULAR_COMPONENT", 334, 337], ["graph", "TEST", 210, 215], ["non-A", "TEST", 219, 224], ["G", "TEST", 227, 228], ["C", "TEST", 230, 231], ["T", "TEST", 233, 234], ["A", "TEST", 239, 240], ["graph", "TEST", 242, 247], ["non-G", "TEST", 251, 256], ["A", "TEST", 259, 260], ["C", "TEST", 262, 263], ["T", "TEST", 265, 266], ["G", "TEST", 271, 272], ["graph", "TEST", 274, 279], ["non-C", "TEST", 283, 288], ["A", "TEST", 291, 292], ["G", "TEST", 294, 295], ["T", "TEST", 297, 298], ["DNA sequencesA", "TEST", 334, 348], ["this method", "TREATMENT", 372, 383], ["lines", "OBSERVATION", 4, 9]]], ["The authors proposed to use cells instead of horizontal lines.", [["cells", "ANATOMY", 28, 33], ["horizontal lines", "ANATOMY", 45, 61], ["cells", "CELL", 28, 33], ["horizontal lines", "CELL", 45, 61], ["horizontal lines", "CELL_LINE", 45, 61], ["cells", "TREATMENT", 28, 33], ["horizontal lines", "TREATMENT", 45, 61], ["horizontal lines", "OBSERVATION", 45, 61]]], ["They considered different shapes of cells, for example a rectangle.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["different shapes of cells", "PROBLEM", 16, 41], ["different shapes", "OBSERVATION_MODIFIER", 16, 32], ["cells", "OBSERVATION", 36, 41]]], ["Each corner of the rectangle is assigned to a particular base.", [["base", "ANATOMY_MODIFIER", 57, 61]]], ["The cells are placed next to each other.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9]]], ["Particular bases in the sequence are put in a proper corner (each base is located in its own cell).", [["cell", "ANATOMY", 93, 97], ["cell", "CELL", 93, 97], ["bases", "ANATOMY_MODIFIER", 11, 16], ["corner", "OBSERVATION_MODIFIER", 53, 59], ["base", "ANATOMY_MODIFIER", 66, 70]]], ["The adjacent dots are connected by a line and a zigzag curve representing the sequence is obtained.Graphical representations of DNA sequencesThe methods described above, based on several horizontal lines, can be also considered as spectral-like representations (lines with some intensities appear in the positions corresponding to the bases in the sequences).", [["DNA", "CELLULAR_COMPONENT", 128, 131], ["DNA sequences", "DNA", 128, 141], ["The adjacent dots", "TREATMENT", 0, 17], ["a line", "TREATMENT", 35, 41], ["a zigzag curve", "TEST", 46, 60], ["the sequence", "TEST", 74, 86], ["DNA sequences", "TEST", 128, 141], ["several horizontal lines", "TREATMENT", 179, 203], ["some intensities", "PROBLEM", 273, 289], ["dots", "OBSERVATION_MODIFIER", 13, 17], ["line", "OBSERVATION_MODIFIER", 37, 41], ["bases", "ANATOMY_MODIFIER", 335, 340]]], ["The author presents four-horizontal-line graphs and chaos-game 2D maps [114, 115] in the form of spectrum-like graphical representations.Graphical representations of DNA sequencesRecently, I have introduced another spectral-like graphical representation called four-component spectral representation [65] .", [["DNA", "CELLULAR_COMPONENT", 166, 169], ["DNA sequences", "DNA", 166, 179], ["2D maps", "TEST", 63, 70], ["DNA sequences", "TEST", 166, 179], ["graphical representations", "OBSERVATION", 111, 136]]], ["The method is very sensitive.", [["very", "OBSERVATION_MODIFIER", 14, 18], ["sensitive", "OBSERVATION", 19, 28]]], ["By using linear graphical representations of DNA sequences the problem of degeneracy can be overcome.", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["DNA sequences", "DNA", 45, 58], ["DNA sequences", "PROBLEM", 45, 58]]], ["However, in technical terms, the visualization of long sequences is rather inconvenient.", [["long sequences", "DNA", 50, 64], ["the visualization of long sequences", "TEST", 29, 64]]], ["A good solution for this drawback is introducing a resolution parameter for linear representations as it was done for the four-component spectral representations (for details see Sect.", [["this drawback", "TREATMENT", 20, 33]]], ["4).Graphical representations of DNA sequencesAnother solution is to combine the compact form of the plots characteristic for 2D walks and zigzag curve method, as proposed by Randi\u0107 et al. [116, 117] .", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA sequences", "DNA", 32, 45], ["DNA sequences", "TEST", 32, 45], ["2D walks and zigzag curve method", "TREATMENT", 125, 157]]], ["In the last approach, the sequence is represented by a zigzag spiral, known in the literature as the worm curve.", [["a zigzag spiral", "PROBLEM", 53, 68], ["the worm curve", "TEST", 97, 111]]], ["It does not intersect itself and uses a little space for the graphical representations of long sequences.", [["long sequences", "DNA", 90, 104], ["a little space", "PROBLEM", 38, 52]]], ["Another compact graphical representation, Four-color map, has also been proposed by Randi\u0107 et al. [118] .", [["Four-color map", "TEST", 42, 56]]], ["The map is constructed as a spiral of square cells.", [["cells", "ANATOMY", 45, 50], ["square cells", "CELL", 38, 50], ["square cells", "CELL_TYPE", 38, 50], ["The map", "TEST", 0, 7], ["square cells", "OBSERVATION", 38, 50]]], ["The first base is located at the central square of the spiral, and the last base finishes the spiral.", [["first", "ANATOMY_MODIFIER", 4, 9], ["base", "ANATOMY_MODIFIER", 10, 14], ["central", "OBSERVATION_MODIFIER", 33, 40], ["square", "OBSERVATION_MODIFIER", 41, 47], ["spiral", "OBSERVATION_MODIFIER", 55, 61], ["base", "ANATOMY_MODIFIER", 76, 80], ["spiral", "ANATOMY_MODIFIER", 94, 100]]], ["Then four different colors are assigned to particular squares representing different bases: red for G, blue for T, green for C, and yellow for A.Graphical representations of DNA sequencesThe original 3D method proposed by Hamori has been also extended by various authors.", [["green for C", "GENE_OR_GENE_PRODUCT", 115, 126], ["DNA", "CELLULAR_COMPONENT", 174, 177], ["red for G, blue for T, green for C", "PROTEIN", 92, 126], ["DNA sequences", "DNA", 174, 187], ["C", "PROBLEM", 125, 126], ["DNA sequences", "TEST", 174, 187], ["different", "OBSERVATION_MODIFIER", 75, 84], ["bases", "OBSERVATION_MODIFIER", 85, 90]]], ["In particular, a modified Hamori curve representation of DNA sequences has been recently introduced by Pesek and Zerovnik [119] .Graphical representations of DNA sequencesMoreover, methods based on a walk in 3D space with different vectors corresponding to particular bases were introduced: vectors located along tetrahedral directions A(1,\u22121,\u22121), G(\u22121,1,\u22121), C(\u22121,\u22121,1), T(1,1,1) [120] or AGC-T curve, where the vectors are chosen as A(1,0,0), G(0,1,0), C(0,0,1), T(1,1,1) [121, 122] .", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["G(0,1,0)", "SIMPLE_CHEMICAL", 445, 453], ["C(0,0,1", "SIMPLE_CHEMICAL", 455, 462], ["DNA sequences", "DNA", 57, 70], ["DNA sequences", "DNA", 158, 171], ["a modified Hamori curve", "TREATMENT", 15, 38], ["DNA sequences", "PROBLEM", 57, 70], ["DNA sequences", "TEST", 158, 171], ["a walk in 3D space with different vectors", "TREATMENT", 198, 239], ["\u2212", "TEST", 340, 341], ["\u2212", "TEST", 343, 344], ["G", "TEST", 348, 349], ["\u2212", "TEST", 350, 351], ["\u2212", "TEST", 355, 356], ["C", "TEST", 360, 361], ["T", "TEST", 372, 373], ["AGC-T curve", "TEST", 390, 401], ["G", "TEST", 445, 446], ["C", "TEST", 455, 456], ["vectors", "ANATOMY", 413, 420]]], ["Examples of other 3D graphs are representations of one sequence by a set of characteristic 3D curves [123] [124] [125] [126] [127] [128] .", [["characteristic 3D curves", "TEST", 76, 100]]], ["Another 3D graphical representation, called Z curve, combines the properties of several characteristic curves [129] .", [["Z curve", "TEST", 44, 51]]], ["A single Z curve contains the information about the distributions of purine/pirymidyne, amino/keto and strong H bond/weak H bond.Graphical representations of DNA sequencesRecently, new 3D graphical representations based on the frequencies of occurring of pairs of nucleotides (dual nucleotides or dinucleotides) or trinucleotides in DNA sequences have been created.", [["purine", "CHEMICAL", 69, 75], ["pirymidyne", "CHEMICAL", 76, 86], ["amino/keto", "CHEMICAL", 88, 98], ["H", "CHEMICAL", 110, 111], ["H", "CHEMICAL", 122, 123], ["purine", "CHEMICAL", 69, 75], ["pirymidyne", "CHEMICAL", 76, 86], ["amino", "CHEMICAL", 88, 93], ["keto", "CHEMICAL", 94, 98], ["H", "CHEMICAL", 110, 111], ["H", "CHEMICAL", 122, 123], ["nucleotides", "CHEMICAL", 264, 275], ["nucleotides", "CHEMICAL", 282, 293], ["dinucleotides", "CHEMICAL", 297, 310], ["purine", "SIMPLE_CHEMICAL", 69, 75], ["pirymidyne", "SIMPLE_CHEMICAL", 76, 86], ["amino/keto", "SIMPLE_CHEMICAL", 88, 98], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["DNA", "CELLULAR_COMPONENT", 333, 336], ["trinucleotides", "DNA", 315, 329], ["DNA sequences", "DNA", 333, 346], ["A single Z curve", "TREATMENT", 0, 16], ["purine/pirymidyne", "TREATMENT", 69, 86], ["amino/keto", "TREATMENT", 88, 98], ["DNA sequencesRecently", "PROBLEM", 158, 179], ["nucleotides (dual nucleotides or dinucleotides)", "TREATMENT", 264, 311], ["trinucleotides in DNA sequences", "TEST", 315, 346]]], ["Four nucleotides form 16 dinucleotides and 64 trinucleotides.", [["nucleotides", "CHEMICAL", 5, 16], ["dinucleotides", "CHEMICAL", 25, 38], ["trinucleotides", "CHEMICAL", 46, 60], ["Four nucleotides", "TEST", 0, 16], ["trinucleotides", "TREATMENT", 46, 60], ["16 dinucleotides", "OBSERVATION_MODIFIER", 22, 38]]], ["By assigning different vectors to each pair or to each trinucleotide in 3D space, 3D-curves are obtained.", [["trinucleotide", "DNA", 55, 68], ["3D-curves", "TEST", 82, 91]]], ["The curves contain the information about neighboring bases and their distributions along the sequence.", [["bases", "ANATOMY_MODIFIER", 53, 58]]], ["Dual nucleotides can be also divided into groups according to their chemical properties, as for example purine dinucleotides (AG, GA), pirymidyne dinucleotides (CT, TC), amino ones (AC, CA), keto ones (TG, GT), weak H-bond (AT, TA) and strong H-bond (CG, GC).", [["purine", "CHEMICAL", 104, 110], ["AG", "CHEMICAL", 126, 128], ["GA", "CHEMICAL", 130, 132], ["pirymidyne", "CHEMICAL", 135, 145], ["amino ones", "CHEMICAL", 170, 180], ["nucleotides", "CHEMICAL", 5, 16], ["purine dinucleotides", "CHEMICAL", 104, 124], ["pirymidyne dinucleotides", "CHEMICAL", 135, 159], ["amino", "CHEMICAL", 170, 175], ["keto", "CHEMICAL", 191, 195], ["H", "CHEMICAL", 216, 217], ["H", "CHEMICAL", 243, 244], ["purine dinucleotides", "SIMPLE_CHEMICAL", 104, 124], ["AG", "SIMPLE_CHEMICAL", 126, 128], ["GA", "SIMPLE_CHEMICAL", 130, 132], ["pirymidyne dinucleotides", "SIMPLE_CHEMICAL", 135, 159], ["CT", "SIMPLE_CHEMICAL", 161, 163], ["TC", "SIMPLE_CHEMICAL", 165, 167], ["amino ones", "SIMPLE_CHEMICAL", 170, 180], ["AC", "SIMPLE_CHEMICAL", 182, 184], ["keto ones", "SIMPLE_CHEMICAL", 191, 200], ["TG", "SIMPLE_CHEMICAL", 202, 204], ["GT", "SIMPLE_CHEMICAL", 206, 208], ["H-bond", "SIMPLE_CHEMICAL", 216, 222], ["AT", "SIMPLE_CHEMICAL", 224, 226], ["TA", "SIMPLE_CHEMICAL", 228, 230], ["H-bond", "SIMPLE_CHEMICAL", 243, 249], ["Dual nucleotides", "TREATMENT", 0, 16], ["example purine dinucleotides", "TEST", 96, 124], ["AG", "TEST", 126, 128], ["pirymidyne dinucleotides", "TEST", 135, 159], ["CT", "TEST", 161, 163], ["amino ones", "TEST", 170, 180], ["keto ones", "TEST", 191, 200], ["TG", "TEST", 202, 204], ["GT", "TEST", 206, 208]]], ["3D graphical representation of one sequence by four characteristic curves based on dinucletides has been proposed by Cao et al. [130] .", [["dinucletides", "CHEMICAL", 83, 95], ["dinucletides", "TREATMENT", 83, 95]]], ["Other 3D graphical representations based on dinucleotides (PN-curves) [131] , (DN-curves) [132] , (D-curves) [133] , or based on trinucleotides (TN-curves) [134] have been also proposed.Numerical representations of DNA sequencesGraphical representations constitute a tool allowing visual inspection of the sequences.", [["dinucleotides", "CHEMICAL", 44, 57], ["trinucleotides", "CHEMICAL", 129, 143], ["DNA", "CELLULAR_COMPONENT", 215, 218], ["TN", "PROTEIN", 145, 147], ["DNA sequences", "DNA", 215, 228], ["dinucleotides (PN-curves", "TEST", 44, 68], ["DN-curves", "TEST", 79, 88], ["D-curves", "TEST", 99, 107], ["trinucleotides", "TEST", 129, 143], ["TN", "TEST", 145, 147], ["DNA sequences", "TEST", 215, 228], ["visual inspection of the sequences", "TEST", 281, 315]]], ["The descriptors representing numerically some properties of the sequences can be used for similarity/dissimilarity analysis of the sequences.", [["similarity/dissimilarity analysis", "TEST", 90, 123]]], ["The computing time of the calculations of the descriptors is low and the numerical comparison of long sequences becomes attractive.", [["the descriptors", "TEST", 42, 57]]], ["However, each descriptor represents some specific properties of the graphs and it is not obvious how to characterize graphical objects by numerical values (for review of methods related to the creation of mathematical descriptors of DNA sequences up to 2006 see [135] ).Numerical representations of DNA sequencesOne of the methods, most commonly used to describe graphs numerically, is transforming the plots to matrices.", [["DNA", "CELLULAR_COMPONENT", 233, 236], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["DNA sequences", "DNA", 233, 246], ["DNA sequences", "DNA", 299, 312], ["the graphs", "TEST", 64, 74], ["DNA sequences", "TEST", 233, 246], ["DNA sequences", "TEST", 299, 312]]], ["The method has been initially introduced by Randi\u0107 et al. for 3D graphical representations [120] .", [["The method", "TREATMENT", 0, 10]]], ["The authors introduced distance matrices, D/D. The numerator in the matrix element (i, j) stands for the Euclidean distance between vertices i and j, and the denominator stands for the graph theoretical distance (the number of arcs separating the two vertices).", [["matrix element", "DNA", 68, 82]]], ["The normalized leading eigenvalue of a D/D matrix offers a measure of the degree of folding of a chain-like structure or a curve.", [["a D/D matrix", "TREATMENT", 37, 49], ["a chain-like structure", "PROBLEM", 95, 117], ["eigenvalue", "OBSERVATION_MODIFIER", 23, 33], ["folding", "OBSERVATION", 84, 91]]], ["The authors introduced also higher-order matrix k D/ k D that is constructed by taking matrix elements of D/D matrix to power k.", [["matrix k D/ k D", "TREATMENT", 41, 56], ["D/D matrix", "TREATMENT", 106, 116]]], ["In the limit k \u2192 \u221e, the resulting matrix reduces to a binary matrix \u221e D/ \u221e D. As the descriptors the authors also proposed the leading eigenvalues of these matrices.", [["matrix", "CELLULAR_COMPONENT", 34, 40], ["the resulting matrix reduces", "PROBLEM", 20, 48]]], ["Such kind of descriptors can be viewed as an index of flexibility (or stiffness) of the structure.Numerical representations of DNA sequencesThe methods of transforming graphs to matrices stimulated introducing new kinds of matrices.", [["DNA", "CELLULAR_COMPONENT", 127, 130], ["DNA sequences", "DNA", 127, 140], ["stiffness) of the structure", "PROBLEM", 70, 97], ["DNA sequences", "TEST", 127, 140], ["transforming graphs to matrices", "TREATMENT", 155, 186]]], ["Different kinds of matrices associated with the graphs have been introduced by Song and Tang [109] .", [["Different kinds of matrices", "PROBLEM", 0, 27], ["matrices", "OBSERVATION", 19, 27]]], ["The authors introduced the Euclidean matrix E, whose (i, j) element is defined as the Euclidean distance between vertices (dots) i and j of the curve.", [["Euclidean matrix E", "DNA", 27, 45]]], ["They also introduced M/M matrix whose elements are defined as a quotient of the Euclidean distance between two vertices of the curve and the number of arcs between the two vertices.", [["curve", "OBSERVATION_MODIFIER", 127, 132], ["number", "OBSERVATION_MODIFIER", 141, 147], ["arcs", "OBSERVATION_MODIFIER", 151, 155], ["two", "ANATOMY_MODIFIER", 168, 171], ["vertices", "ANATOMY_MODIFIER", 172, 180]]], ["The third kind of matrix introduced by these authors is L/L matrix whose elements are defined as a quotient of the Euclidean distance between two vertices of the curve and the sum of geometrical lengths of arcs between the two vertices.", [["matrix", "CELLULAR_COMPONENT", 18, 24], ["L/L matrix", "TREATMENT", 56, 66], ["matrix", "OBSERVATION", 18, 24], ["vertices", "ANATOMY_MODIFIER", 146, 154], ["curve", "OBSERVATION_MODIFIER", 162, 167], ["geometrical", "OBSERVATION_MODIFIER", 183, 194], ["lengths", "OBSERVATION_MODIFIER", 195, 202], ["arcs", "OBSERVATION_MODIFIER", 206, 210], ["two", "ANATOMY_MODIFIER", 223, 226], ["vertices", "ANATOMY_MODIFIER", 227, 235]]], ["As the descriptors the authors chose the leading eigenvalues of M/M and L/L matrices.", [["L/L matrices", "TREATMENT", 72, 84], ["L", "ANATOMY_MODIFIER", 74, 75]]], ["The authors considered characteristic linear curves and their descriptors characterize the distribution of bases with different chemical structures.", [["linear", "OBSERVATION_MODIFIER", 38, 44], ["distribution", "OBSERVATION_MODIFIER", 91, 103], ["bases", "ANATOMY_MODIFIER", 107, 112], ["different", "OBSERVATION_MODIFIER", 118, 127], ["chemical structures", "OBSERVATION", 128, 147]]], ["The authors also considered higher-order L/L matrices.", [["L/L matrices", "DNA", 41, 53], ["L/L matrices", "TREATMENT", 41, 53]]], ["The authors introduced covariance matrices associated with the graphs.Numerical representations of DNA sequencesUsually, the leading eigenvalues of the matrices are taken as descriptors.", [["DNA", "CELLULAR_COMPONENT", 99, 102], ["DNA sequencesUsually", "PROBLEM", 99, 119], ["DNA", "OBSERVATION", 99, 102]]], ["Some authors propose to consider more eigenvalues or matrix elements as descriptors of the sequences.", [["matrix elements", "DNA", 53, 68], ["the sequences", "TEST", 87, 100]]], ["Wang and Zhang proposed to take as a descriptor the sum of the maximal and minimal eigenvalues for the matrices associated with their graphical representation, called three non-base representation [111] .", [["Zhang", "TREATMENT", 9, 14]]], ["Liao et al. [38] took all (two) eigenvalues of the 2 \u00d7 2 covariance matrices.", [["the 2 \u00d7 2 covariance matrices", "TREATMENT", 47, 76]]], ["Li and Wang proposed as descriptors normalized matrix norms instead of the eigenvalues [99] .", [["Li", "CHEMICAL", 0, 2]]], ["Randi\u0107 et al. considered as the descriptors average matrix elements of the matrices associated with the four-color map representation of DNA sequences [118] .", [["DNA", "CELLULAR_COMPONENT", 137, 140], ["DNA sequences", "DNA", 137, 150], ["DNA sequences", "TEST", 137, 150]]], ["They can be obtained by summing the distance matrix elements along each of the lines parallel to the main diagonal if the matrix is in the canonical form.", [["matrix", "CELLULAR_COMPONENT", 122, 128], ["distance matrix elements", "DNA", 36, 60], ["main diagonal", "ANATOMY", 101, 114]]], ["Qi and Fan took all elements of the matrix as descriptors of the sequences of equal lengths [131] .", [["matrix", "CELLULAR_COMPONENT", 36, 42], ["Fan", "PROTEIN", 7, 10]]], ["Pesek and Zerovnik proposed to take as the numerical characterization of the modified Hamori curve a product of first ten and last ten eigenvalues of the descending ordered eigenvalue list of the matrix L/L [119] .Numerical representations of DNA sequencesNumerical representation of 2D or 3D graphical representations of DNA sequences based on transforming the graphs into matrices and deriving the descriptors from these matrices has been widely used by many authors.", [["DNA", "CELLULAR_COMPONENT", 243, 246], ["DNA", "CELLULAR_COMPONENT", 322, 325], ["DNA sequences", "DNA", 243, 256], ["DNA sequences", "DNA", 322, 335], ["Pesek", "TREATMENT", 0, 5], ["Zerovnik", "TREATMENT", 10, 18], ["DNA sequences", "PROBLEM", 243, 256], ["DNA sequences", "PROBLEM", 322, 335], ["these matrices", "TREATMENT", 417, 431], ["descending", "ANATOMY", 154, 164]]], ["Examples of similarity analysis of DNA sequences using this method may be found in [137, 105, 106, 108, 116, 123, 110, 112, 125, 124, 109, 118, 138, 126, 111] .Numerical representations of DNA sequencesNumerical representation of a graphical representation can be also performed directly from the coordinates or from the properties of the graphs without transforming the graphs to matrices.", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["DNA sequences", "DNA", 35, 48], ["DNA sequences", "DNA", 189, 202], ["similarity analysis", "TEST", 12, 31], ["DNA sequences", "TEST", 35, 48], ["this method", "TEST", 55, 66], ["DNA sequences", "TEST", 189, 202]]], ["As descriptors of the sequences he proposed the means of the Manhattan and Euclidean \"fractal\" dimensions.Numerical representations of DNA sequencesRaychaudhury and Nandy proposed mean x and y coordinate values, and the radius of the graph as descriptors of DNA sequences [140] .", [["DNA", "CELLULAR_COMPONENT", 135, 138], ["DNA", "CELLULAR_COMPONENT", 258, 261], ["DNA sequences", "DNA", 135, 148], ["DNA sequences", "DNA", 258, 271], ["Euclidean \"fractal\" dimensions", "TREATMENT", 75, 105], ["DNA sequences", "TEST", 135, 148], ["DNA sequences", "TEST", 258, 271]]], ["Guo and Nandy introduced also improved mean x and y coordinate values, and the radius of the graph, reducing the degeneracy of the previously defined descriptors of DNA sequences [141] .", [["DNA", "CELLULAR_COMPONENT", 165, 168], ["DNA sequences", "DNA", 165, 178], ["DNA sequences", "TEST", 165, 178], ["improved", "OBSERVATION_MODIFIER", 30, 38], ["mean", "OBSERVATION_MODIFIER", 39, 43], ["radius", "ANATOMY_MODIFIER", 79, 85]]], ["Yao et al. extended these descriptors to three dimensions defining 3D radius and adding mean z-coordinate as a descriptor [122] .Numerical representations of DNA sequencesWe have extended the set of these 2D descriptors to higher-order moments of the mass-density distributions.", [["DNA", "CELLULAR_COMPONENT", 158, 161], ["DNA sequences", "DNA", 158, 171], ["3D radius", "TREATMENT", 67, 76], ["DNA sequences", "TEST", 158, 171], ["the mass-density distributions", "PROBLEM", 247, 277], ["mass", "OBSERVATION", 251, 255], ["density distributions", "OBSERVATION", 256, 277]]], ["The mean x and y coordinate values are equal to the firstorder moments (M x,1 , M y,1 ) of the mass-density distribution, \u03c1 x and \u03c1 y respectively.", [["The mean x and y coordinate values", "TEST", 0, 34], ["the mass-density distribution", "PROBLEM", 91, 120], ["mass", "OBSERVATION", 95, 99], ["density", "OBSERVATION", 100, 107]]], ["In particular, if in a 2D-dynamic graph we put all masses equal to 1, then the 2Ddynamic graph becomes the Nandy plot and all the moments of the two graphs are identical.", [["the 2Ddynamic graph", "TEST", 75, 94], ["masses", "OBSERVATION", 51, 57]]], ["Introducing the masses different than 1, the mean x and y coordinate values become the coordinates of the center of mass of the graph and are different than for the Nandy plot.", [["the masses", "PROBLEM", 12, 22], ["the Nandy plot", "TEST", 161, 175], ["masses", "OBSERVATION", 16, 22], ["different", "OBSERVATION_MODIFIER", 23, 32], ["mass", "OBSERVATION", 116, 120], ["different", "OBSERVATION_MODIFIER", 142, 151]]], ["As the new descriptors we proposed moments of the mass-density distributions \u03c1 x and \u03c1 y up to the sixth order [101] and up to the eighth order [142] .", [["the mass", "PROBLEM", 46, 54], ["mass", "OBSERVATION", 50, 54], ["density", "OBSERVATION", 55, 62]]], ["Higher-order moments give more specific information about the distribution of masses.", [["masses", "ANATOMY", 78, 84], ["masses", "CANCER", 78, 84], ["masses", "PROBLEM", 78, 84], ["masses", "OBSERVATION", 78, 84]]], ["We have shown that the third-(M x,3 ), fourth-(M x,4 ), fifth-(M x,5 ), and sixth-order (M x,6 ) x-moments of the mass-density distributions representing histone H4 coding sequences have different values for plants than for vertebrates [101] .", [["histone H4", "GENE_OR_GENE_PRODUCT", 154, 164], ["histone H4 coding sequences", "DNA", 154, 181], ["the mass-density distributions", "PROBLEM", 110, 140], ["histone H4 coding sequences", "PROBLEM", 154, 181], ["third", "OBSERVATION_MODIFIER", 23, 28], ["mass", "OBSERVATION", 114, 118], ["density distributions", "OBSERVATION", 119, 140], ["histone H4", "OBSERVATION", 154, 164]]], ["In the present work, 2D-plots M x,q \u2212 M x,q are proposed instead of 1D-plots (descriptors versus labels of the sequences) that were shown in [101] .", [["the sequences", "TEST", 107, 120]]], ["In all the plots we observe clusterization of evolutionary similar organisms: plants are located in different parts of the plots than the vertebrates.Numerical representations of DNA sequencesThe differences between histone H4 coding sequences across the species are not big and it is rather difficult to find the descriptors that reveal the clusterization.", [["DNA", "CELLULAR_COMPONENT", 179, 182], ["histone H4", "GENE_OR_GENE_PRODUCT", 216, 226], ["DNA sequences", "DNA", 179, 192], ["histone H4 coding sequences", "DNA", 216, 243], ["evolutionary similar organisms", "PROBLEM", 46, 76], ["DNA sequences", "TEST", 179, 192], ["The differences between histone H4 coding sequences", "PROBLEM", 192, 243]]], ["In particular, this means that using the Nandy plots for which the descriptors are taken as the mean values (first-order moments) of x and y we cannot get the clusterization.", [["the Nandy plots", "PROBLEM", 37, 52], ["the mean values", "TEST", 92, 107]]], ["I have also found another set of descriptors (related to the four-component spectral representation) that reveal clusterization for histone H4 and H1 coding sequences (for details see the subsequent chapter).Numerical representations of DNA sequencesAnalogous (2D visualization) is introduced in the present work for the recently proposed molecular descriptors.", [["histone H4", "GENE_OR_GENE_PRODUCT", 132, 142], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["histone H4 and H1 coding sequences", "DNA", 132, 166], ["DNA sequences", "DNA", 237, 250], ["histone H4 and H1 coding sequences", "PROBLEM", 132, 166], ["DNA sequences", "TEST", 237, 250]]], ["Figure 7 shows moment-based classification of the molecules: M 1 \u2212 M 2 (top), M 3 \u2212 M 4 (middle), and M 5 \u2212 M 6 (bottom).", [["Figure", "TEST", 0, 6], ["middle", "ANATOMY_MODIFIER", 89, 95]]], ["We have shown that the new molecular descriptors (moments of the intensity distributions) have different values for two kinds of molecules: nitriles and amides.", [["nitriles", "CHEMICAL", 140, 148], ["nitriles", "CHEMICAL", 140, 148], ["amides", "CHEMICAL", 153, 159], ["nitriles", "SIMPLE_CHEMICAL", 140, 148], ["amides", "SIMPLE_CHEMICAL", 153, 159], ["nitriles and amides", "TREATMENT", 140, 159], ["new", "OBSERVATION_MODIFIER", 23, 26]]], ["We observe that the descriptors representing nitriles are located in different parts of the plots than those representing amides.", [["nitriles", "CHEMICAL", 45, 53], ["nitriles", "CHEMICAL", 45, 53], ["amides", "CHEMICAL", 122, 128], ["nitriles", "SIMPLE_CHEMICAL", 45, 53], ["amides", "SIMPLE_CHEMICAL", 122, 128], ["nitriles", "TREATMENT", 45, 53]]], ["Figures 6 and 7 represent different objects: DNA sequences and molecules, respectively.", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["DNA sequences", "DNA", 45, 58], ["Figures", "TEST", 0, 7], ["DNA sequences", "TEST", 45, 58]]], ["The clusterization of the descriptors indicates that these descriptors can be a good tool for similarity/dissimilarity analysis.", [["similarity/dissimilarity analysis", "TEST", 94, 127]]], ["Moreover, some of the plots reveal similar shapes, as for example, middle and bottom parts of Fig. 7 .", [["the plots", "TEST", 18, 27], ["middle and bottom parts of Fig", "PROBLEM", 67, 97], ["similar", "OBSERVATION_MODIFIER", 35, 42], ["shapes", "OBSERVATION_MODIFIER", 43, 49], ["middle", "ANATOMY_MODIFIER", 67, 73], ["bottom", "ANATOMY_MODIFIER", 78, 84], ["Fig", "OBSERVATION", 94, 97]]], ["However, the shape is similar but not identical.", [["shape", "OBSERVATION_MODIFIER", 13, 18], ["similar", "OBSERVATION_MODIFIER", 22, 29]]], ["The problem of correlation and extracting the minimal set of moments we studied in ref.", [["minimal", "OBSERVATION_MODIFIER", 46, 53]]], ["Usually 4 lowest moments are sufficient to describe the object but also the information coming from higher-order moments cannot be neglected in some cases.Numerical representations of DNA sequencesAs the new descriptors of DNA sequences we also proposed the angles between the x axis and the principal axis of inertia of the 2D-dynamic graph (axes for which the tensor of moment of inertia is diagonal) [100] .", [["DNA", "CELLULAR_COMPONENT", 184, 187], ["DNA", "CELLULAR_COMPONENT", 223, 226], ["DNA sequences", "DNA", 184, 197], ["DNA sequences", "DNA", 223, 236], ["DNA sequences", "TEST", 184, 197], ["DNA sequences", "TEST", 223, 236], ["x axis", "OBSERVATION_MODIFIER", 277, 283], ["principal", "OBSERVATION_MODIFIER", 292, 301], ["axis", "OBSERVATION_MODIFIER", 302, 306], ["inertia", "OBSERVATION_MODIFIER", 310, 317]]], ["We also introduced the principal moments of inertia as the descriptors of DNA sequences associated with the 2D-dynamic graph [100] .", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA sequences", "DNA", 74, 87], ["DNA sequences", "PROBLEM", 74, 87]]], ["The moment of inertia of an object about a given axis describes how difficult is to induce an angular rotation of the object about this axis.", [["inertia", "OBSERVATION_MODIFIER", 14, 21], ["angular", "OBSERVATION_MODIFIER", 94, 101]]], ["If the mass is concentrated close to the axis of rotation, it is easier to accelerate into spinning fast and the moment of inertia is smaller.", [["the mass", "PROBLEM", 3, 11], ["mass", "OBSERVATION", 7, 11], ["concentrated", "OBSERVATION_MODIFIER", 15, 27], ["inertia", "OBSERVATION", 123, 130], ["smaller", "OBSERVATION_MODIFIER", 134, 141]]], ["As a consequence, these descriptors give the information about the concentrations of masses around the axes.", [["masses", "PROBLEM", 85, 91], ["masses", "OBSERVATION", 85, 91]]], ["Guo and Wang obtained smooth curves from the zigzag curves and took curvatures of the smooth curves as descriptors of the sequences [145] .", [["the zigzag curves", "TEST", 41, 58], ["the sequences", "TEST", 118, 131], ["smooth", "OBSERVATION_MODIFIER", 22, 28], ["curves", "OBSERVATION_MODIFIER", 29, 35]]], ["Yu et al. proposed two kinds of descriptors: a set of coordinates of TN curves, and the probabilities of occurring of particular trinucleotides among all 64 trinucleotides in the sequence [134] .", [["trinucleotides", "CHEMICAL", 129, 143], ["trinucleotides", "CHEMICAL", 157, 171], ["TN", "PROTEIN", 69, 71], ["trinucleotides", "PROTEIN", 129, 143], ["trinucleotides", "PROTEIN", 157, 171], ["TN curves", "TEST", 69, 78], ["particular trinucleotides", "PROBLEM", 118, 143]]], ["Yu et al. composed 6D vector associated with the D-curve as a descriptor of DNA sequences [133] .Numerical representations of DNA sequencesAnother kind of non-standard descriptors has also been introduced for four-component spectral representation (for the details see the next chapter).", [["DNA", "CELLULAR_COMPONENT", 76, 79], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["6D vector", "DNA", 19, 28], ["DNA sequences", "DNA", 76, 89], ["DNA sequences", "DNA", 126, 139], ["the D-curve", "TREATMENT", 45, 56], ["DNA sequences", "TEST", 76, 89], ["DNA sequences", "TEST", 126, 139]]], ["Usually, as the similarity measure the Euclidean distance between the components of the vectors corresponding to a pair of sequences is taken.", [["a pair of sequences", "TEST", 113, 132], ["components", "OBSERVATION_MODIFIER", 70, 80]]], ["In particular, for identical sequences, this similarity measure is equal to zero.Numerical representations of DNA sequencesRecently, non-standard measures have been introduced.", [["DNA", "CELLULAR_COMPONENT", 110, 113], ["DNA sequences", "DNA", 110, 123], ["DNA sequences", "TEST", 110, 123], ["non-standard measures", "TREATMENT", 133, 154], ["equal", "OBSERVATION_MODIFIER", 67, 72]]], ["We have used the Manhattan distance normalized by the mean value of the descriptors for the similarity studies of the sequences represented by the 2D-dynamic graphs [101, 146] .", [["the similarity studies", "TEST", 88, 110]]], ["For identical sequences this measure is equal to zero, as it is assumed for most of similarity studies.", [["similarity studies", "TEST", 84, 102]]], ["Another non-standard similarity measure, also normalized to zero for identical sequences, is introduced in this work for four-component spectral representation (for details see subsequent chapter).Numerical representations of DNA sequencesHowever, in the alignment studies the similarity measure changes from 0 to 100 for identical sequences.", [["DNA", "CELLULAR_COMPONENT", 226, 229], ["DNA sequences", "DNA", 226, 239], ["DNA sequences", "TEST", 226, 239], ["the alignment studies", "TEST", 251, 272]]], ["Such a measure is also defined for four-component spectral representation ( [147] , see next chapter).Numerical representations of DNA sequencesAnother similarity measure, also normalized to 100 for identical sequences, we have used for comparisons of 2D-graphs.", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA sequences", "DNA", 131, 144], ["DNA sequences", "TEST", 131, 144], ["comparisons of 2D-graphs", "TEST", 237, 261]]], ["This similarity measure introduces nonconventional treatment of graphs and their similarity analysis.", [["nonconventional treatment of graphs", "TREATMENT", 35, 70], ["their similarity analysis", "TEST", 75, 100]]], ["We have not calculated the descriptors but the similarity measure has been directly obtained from the graphs.Numerical representations of DNA sequencesIn our studies we treated the graphs as rigid bodies, as in the classical dynamics.", [["DNA", "CELLULAR_COMPONENT", 138, 141], ["DNA sequences", "DNA", 138, 151], ["DNA sequences", "TEST", 138, 151], ["our studies", "TEST", 154, 165], ["rigid bodies", "PROBLEM", 191, 203], ["rigid bodies", "OBSERVATION", 191, 203]]], ["As a similarity measure for a pair of sequences represented by the graphs we took mass overlaps [146] .", [["mass overlaps", "PROBLEM", 82, 95]]], ["Using the genetic methods, very efficient in problems of optimization, we found the locations of a pair of graphs for which their mass overlap reaches maximum.", [["a pair of graphs", "PROBLEM", 97, 113], ["their mass overlap", "PROBLEM", 124, 142], ["mass", "OBSERVATION", 130, 134], ["maximum", "OBSERVATION_MODIFIER", 151, 158]]], ["In this position the similarity measure is defined as a mass overlap of a pair of graphs.", [["mass", "OBSERVATION", 56, 60]]], ["In the process of maximization of the mass overlap we considered shifts and rotations of the graphs.Four-component spectral representationRecently, I have introduced another graphical representation [65] .", [["the mass overlap", "PROBLEM", 34, 50], ["rotations of the graphs", "TEST", 76, 99], ["mass", "OBSERVATION", 38, 42], ["spectral representation", "OBSERVATION", 115, 138]]], ["In this section, the details and new aspects of this representation are described.", [["new", "OBSERVATION_MODIFIER", 33, 36]]], ["The DNA sequence is represented by a four-component function (or, graphically, by a four-component spectrum).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA sequence", "DNA", 4, 16], ["The DNA sequence", "TEST", 0, 16]]], ["A single DNA sequence is represented by four abstract spectra: one for bases A, one for C, one for T and one for G. This means that I decompose each sequence to four components.", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["DNA sequence", "DNA", 9, 21], ["A single DNA sequence", "TEST", 0, 21]]], ["Each \u03b3 -component I call-\u03b3 spectrum where \u03b3 = A, C, T, G denotes one of the bases.", [["bases", "ANATOMY_MODIFIER", 76, 81]]], ["Each \u03b3 -component is given by a function that is a superposition of the Gaussian functions:Four-component spectral representationwhere N is the length of the sequence, andFour-component spectral representationThe parameter r is the resolution of I \u03b3 (x).", [["\u03b3", "PROTEIN", 5, 6], ["I \u03b3", "PROTEIN", 246, 249]]], ["For the visualization of long sequences it is convenient to take small r .", [["long sequences", "DNA", 25, 39]]], ["The resolution parameter r determines the differences between the maxima of the Gaussians.", [["The resolution parameter", "TEST", 0, 24], ["resolution", "OBSERVATION_MODIFIER", 4, 14]]], ["The details of spectra are better visible when r is large, i.e. when the neighboring maxima are well separated.", [["large", "OBSERVATION", 52, 57]]], ["With an increasing r the resolution becomes larger.", [["increasing", "OBSERVATION_MODIFIER", 8, 18], ["r", "OBSERVATION_MODIFIER", 19, 20], ["resolution", "OBSERVATION_MODIFIER", 25, 35], ["larger", "OBSERVATION_MODIFIER", 44, 50]]], ["If r = 1 then the maximum corresponding to the first base ( p = 1) is located at x = 1 = 0 and the maximum corresponding to the last base is located at x = N = N \u2212 1.", [["base", "ANATOMY_MODIFIER", 53, 57], ["base", "ANATOMY_MODIFIER", 133, 137]]], ["If the neighboring \u03b3 bases are closely packed then the intensities (I \u03b3 ) increase.", [["neighboring \u03b3 bases", "DNA", 7, 26], ["bases", "ANATOMY_MODIFIER", 21, 26], ["packed", "OBSERVATION_MODIFIER", 39, 45]]], ["If the sequence does not contain one of \u03b3 bases then the contribution to \u03b3 -component may be zero and all the contributions are located in one of the three other \u03b3 -spectra.", [["\u03b3", "PROTEIN", 73, 74], ["bases", "ANATOMY_MODIFIER", 42, 47], ["may be", "UNCERTAINTY", 86, 92], ["zero", "OBSERVATION_MODIFIER", 93, 97]]], ["Generally, the distributions of particular bases along the sequences are asymmetric and this information is reflected in the form of I \u03b3 (x).", [["I \u03b3", "PROTEIN", 133, 136], ["bases", "ANATOMY_MODIFIER", 43, 48], ["asymmetric", "OBSERVATION_MODIFIER", 73, 83]]], ["In principle, x may change from \u2212\u221e to +\u221e.", [["+\u221e", "SIMPLE_CHEMICAL", 38, 40]]], ["However, in practical terms, I \u03b3 (x) = 0 if x < \u2212r or x > Nr. Therefore one can assume that the graphs extend forFour-component spectral representationx \u2208 \u2212r, Nr .Four-component spectral representationIn this way the first and the last bases are considered in the same way as the other ones.", [["forFour", "PROTEIN", 110, 117], ["\u2212r", "PROTEIN", 155, 157], ["Nr", "PROTEIN", 159, 161], ["the graphs", "TEST", 92, 102]]], ["However, for the numerical characterization related to this graphical representation the range from \u2212\u221e to +\u221e is considered.Four-component spectral representationAs the numerical characterization of the four-component spectral representation I propose the properly scaled distribution moments.Four-component spectral representationAnalogously to the definitions of the moments of a discrete distribution (Eqs.", [["the numerical characterization", "TEST", 13, 43], ["the numerical characterization", "TEST", 164, 194], ["spectral representation", "OBSERVATION", 138, 161], ["discrete", "OBSERVATION_MODIFIER", 381, 389], ["distribution", "OBSERVATION_MODIFIER", 390, 402]]], ["4-6), the q-th moment of the continues distribution I \u03b3 (x) readsFour-component spectral representationwhereFour-component spectral representationis the normalization constant and R(x) is the range of x for which the integrand does not vanish.", [["readsFour", "PROTEIN", 60, 69], ["normalization", "OBSERVATION_MODIFIER", 153, 166], ["constant", "OBSERVATION_MODIFIER", 167, 175]]], ["The normalization has been introduced for the numerical characteristics of the sequences.", [["normalization", "OBSERVATION", 4, 17]]], ["Visualization is independent of the numerical calculations and it is more clear to consider unnormalized plots defined as \u03b3 -spectra in Eq.", [["the numerical calculations", "TEST", 32, 58]]], ["Good descriptors of the distributions are also the centered moments MFour-component spectral representationfor which the first moment is equal to 0, and also M (13) for which the first moment is equal to 0 and the second one is equal to 1.Four-component spectral representationConsidering several lowest moments it is convenient to perform integrations over the whole range of x (from \u2212\u221e to +\u221e).", [["equal", "OBSERVATION_MODIFIER", 137, 142], ["equal", "OBSERVATION", 228, 233], ["spectral representation", "OBSERVATION", 254, 277], ["several", "OBSERVATION_MODIFIER", 289, 296], ["lowest moments", "OBSERVATION_MODIFIER", 297, 311]]], ["The integration can be performed analytically andFour-component spectral representationwhereFour-component spectral representationIn the graphical representation defined in Eq.", [["spectral representation", "OBSERVATION", 107, 130]]], ["Only the terms for which the occupation number is different than zero give non-zero contribution to the \u03b3 -spectrum and their number is N \u03b3 which is the number of \u03b3 bases in the sequence andFour-component spectral representationLet us take an example of a model sequence ATAT.", [["a model sequence ATAT", "TEST", 254, 275]]], ["In case of T-spectrum p = 2, 4 and for G and C-spectra all the contributions are zeros.", [["T-spectrum p", "TEST", 11, 23]]], ["As a consequence, the four-component spectrum isFour-component spectral representationThe descriptors associated with the four-component spectral representation (D \u03b3 q ) have been defined as properly scaled distribution moments [65] .", [["spectral representation", "OBSERVATION", 63, 86]]], ["In this kind of visualization, different types of classified objects are clustered in different areas of the plots.Four-component spectral representationAs a similarity measure between a pair of sequences labeled by i and jFour-component spectral representationis proposed, where q = 1, 2, 3, 4 [147] .", [["visualization", "TEST", 16, 29], ["classified objects", "OBSERVATION", 50, 68], ["different", "OBSERVATION_MODIFIER", 86, 95], ["areas", "OBSERVATION_MODIFIER", 96, 101]]], ["Though q may be easily increased up to higher-orders, as we shall see, the information about similarity sequences is specific enough up to the fourth order.", [["similarity sequences", "TEST", 93, 113], ["increased", "OBSERVATION", 23, 32]]], ["Let us note that d \u03b3 q is consistent with standard measures used in biology: For the identical sequences the similarity value equals 100% and it decreases (approaching 0) if the difference between the two D \u03b3 q increases.", [["decreases", "OBSERVATION_MODIFIER", 145, 154]]], ["The average information about the similarity of a pair of sequences is contained in the measureFour-component spectral representationwhereFour-component spectral representationare referred to as the weights, N \u03b3 (i) is the number of \u03b3 bases in the i-th sequence, andFour-component spectral representationis the length of the i-th sequence.Four-component spectral representationIn order to study the problem of convergence of the method with respect to the higher-order moments I consider, for a pair of sequences labeled by i and j, the similarity measureFour-component spectral representationwhere n is the maximum order of moments taken into account.", [["\u03b3 bases", "RNA", 233, 240], ["the weights", "TEST", 195, 206], ["bases", "ANATOMY_MODIFIER", 235, 240], ["spectral representation", "OBSERVATION", 354, 377]]], ["All definitions may be easily generalized for multiple similarity studies.", [["multiple similarity studies", "TEST", 46, 73]]], ["If J sequences labeled by i \u2261 {i 1 , i 2 , . . . i J } are matched then the measures are defined asFour-component spectral representationandFour-component spectral representationThe weightsFour-component spectral representationare equal to the relative numbers of \u03b3 bases in all the considered sequences andFour-component spectral representationThe measures defined in Eqs.", [["J sequences", "DNA", 3, 14], ["\u03b3 bases", "DNA", 264, 271], ["The weights", "TEST", 178, 189], ["bases", "ANATOMY_MODIFIER", 266, 271]]], ["An alternative similarity measure is defined in this work asFour-component spectral representations \u03b3 q is equal to 0 if the descriptors of the i-th and the j-th sequences are the same (D \u03b3 q (i) = D \u03b3 q ( j)) and approaches 1 if the difference between the two descriptors increases.", [["i-th and the j-th sequences", "DNA", 144, 171], ["the j-th sequences", "TREATMENT", 153, 171]]], ["This similarity measure is analogous to the one that we have introduced in the molecular similarity studies [56] .Four-component spectral representationI also introduce a similarity measure between the sequences labeled by i and j that carries the information about several (n) propertiesFour-component spectral representationwhere i 1 < i 2 < \u00b7 \u00b7 \u00b7 < i n and w i 1 . . . w i n denote the weights.", [["the weights", "PROBLEM", 385, 396]]], ["For example, if we consider similarity of three properties: the width, the asymmetry and the curtosis of the \u03b3 -spectrum that are described by s \u03b3 2 , s \u03b3 3 and s \u03b3 4 respectively, then n = 3, i 1 = 2, i 2 = 3, i 3 = 4 and the similarity measure isFour-component spectral representationIn this work all the weights in Eqs.", [["the asymmetry", "PROBLEM", 71, 84], ["the similarity measure", "TEST", 223, 245], ["asymmetry", "OBSERVATION", 75, 84], ["spectral representation", "OBSERVATION", 263, 286]]], ["As a consequence, for example S 3,4 \u03b3 is a convenient measure for comparison of sequences of different lengths, if we are interested in the similarity information that is not related to the lengths of the sequences.", [["S 3,4 \u03b3", "SIMPLE_CHEMICAL", 30, 37]]], ["If the information about the mean value D 1 or about the width D 2 of \u03b3 -spectra needs to be compared then S i 1 ,i 2 ,...i n \u03b3 , where i k are 1 or 2 may be considered.Four-component spectral representationAll the panels (a-d) in the figure represent the same model sequence.", [["All the panels", "TEST", 207, 221], ["spectral representation", "OBSERVATION", 184, 207]]], ["The particular bases are represented by Gaussians centered at p = ( p \u2212 1)r , where p = 1, 2, . . .", [["bases", "ANATOMY_MODIFIER", 15, 20]]], ["The first base is represented by a Gaussian with the maximum located at 1 = 0 for all the cases and the last one at 50 = 49, 50 = 98, 50 = 147, 50 = 196 for r = 1, r = 2, r = 3, r = 4 respectively.", [["base", "ANATOMY_MODIFIER", 10, 14]]], ["For smaller r the bases are located close to each other and as a consequence the neighboring Gaussian functions overlap and we observe the envelope of the spectrum.", [["smaller r the bases", "PROBLEM", 4, 23], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["bases", "ANATOMY_MODIFIER", 18, 23]]], ["In particular, if all the bases are the same, the spectrum becomes rectangular (Fig. 8, panel a) .", [["bases", "ANATOMY_MODIFIER", 26, 31], ["rectangular", "OBSERVATION_MODIFIER", 67, 78]]], ["Increasing the resolution, the range for which the spectrum is different than zero becomes larger and we have a chance to look into details of the spectra.", [["resolution", "OBSERVATION_MODIFIER", 15, 25], ["different", "OBSERVATION_MODIFIER", 63, 72], ["larger", "OBSERVATION_MODIFIER", 91, 97]]], ["The details are the locations of particular bases along the sequence.", [["bases", "ANATOMY_MODIFIER", 44, 49]]], ["For long sequences, the balance between the details of spectra and the range of the plot determined by the location of the last Gaussian N = (N \u2212 1)r has to be found.", [["long sequences", "TEST", 4, 18]]], ["Theoretically, the resolution may change from a small positive value to infinity.", [["a small positive value to infinity", "PROBLEM", 46, 80], ["small", "OBSERVATION_MODIFIER", 48, 53], ["positive", "OBSERVATION", 54, 62]]], ["For example, if in the model example the resolution is taken as smaller than 1 then also rectangular representation is obtained.", [["smaller", "OBSERVATION_MODIFIER", 64, 71]]], ["For smaller resolution the range of the spectrum is smaller and the neighboring maxima are located close to each other.", [["smaller", "OBSERVATION_MODIFIER", 4, 11], ["resolution", "OBSERVATION_MODIFIER", 12, 22], ["range", "OBSERVATION_MODIFIER", 27, 32], ["spectrum", "OBSERVATION_MODIFIER", 40, 48], ["smaller", "OBSERVATION_MODIFIER", 52, 59], ["neighboring", "OBSERVATION_MODIFIER", 68, 79], ["maxima", "OBSERVATION_MODIFIER", 80, 86]]], ["As a consequence of closely located Gaussian functions exp[\u2212(x \u2212 p ) 2 ], the resulting maxima of spectrum I A are larger (around 3 in Fig. 9 and around 2 in Fig. 8, panel a) .", [["larger", "OBSERVATION_MODIFIER", 115, 121]]], ["However the qualitative information is the same in Fig. 8 , panel a, and in Fig. 9 .Four-component spectral representationIn case of real sequences, there is a natural separation between the neighboring bases.", [["real sequences", "TEST", 133, 147], ["spectral representation", "OBSERVATION", 99, 122], ["natural separation", "OBSERVATION", 160, 178], ["neighboring", "ANATOMY_MODIFIER", 191, 202], ["bases", "ANATOMY_MODIFIER", 203, 208]]], ["Usually the resolution r = 1 and even smaller is sufficient for a good visualization.", [["resolution", "OBSERVATION_MODIFIER", 12, 22], ["smaller", "OBSERVATION_MODIFIER", 38, 45]]], ["In Fig. 10 , spectral representation of histone H1 coding sequence of Arabidopsis thaliana is shown (i = 19, Table 16 ).", [["histone H1", "GENE_OR_GENE_PRODUCT", 40, 50], ["Arabidopsis thaliana", "ORGANISM", 70, 90], ["histone H1 coding sequence", "DNA", 40, 66], ["Arabidopsis thaliana", "SPECIES", 70, 90], ["Arabidopsis thaliana", "SPECIES", 70, 90], ["histone H1", "TREATMENT", 40, 50], ["Arabidopsis thaliana", "PROBLEM", 70, 90], ["Arabidopsis thaliana", "OBSERVATION", 70, 90]]], ["The numbers of particular bases are N A = 259, N C = 167, N T = 188, and N G = 208.", [["A", "TEST", 38, 39], ["N C", "TEST", 47, 50], ["T", "TEST", 60, 61], ["N G", "TEST", 73, 76], ["bases", "ANATOMY_MODIFIER", 26, 31]]], ["The largest number of A bases can be easily seen (large number of lines with large intensities as an effect of overlapping closely located Gaussians representing A bases).", [["large intensities", "PROBLEM", 77, 94], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["bases", "ANATOMY_MODIFIER", 24, 29], ["large", "OBSERVATION_MODIFIER", 50, 55], ["number", "OBSERVATION_MODIFIER", 56, 62], ["lines", "OBSERVATION_MODIFIER", 66, 71], ["large", "OBSERVATION_MODIFIER", 77, 82], ["intensities", "OBSERVATION_MODIFIER", 83, 94], ["bases", "ANATOMY_MODIFIER", 164, 169]]], ["The resolution r = 0.1 seems to be sufficient to distinguish between those ranges of x for which the density of bases is larger comparing to ranges that are poor in the considered bases.Four-component spectral representationA very convenient way of a direct comparison of the difference between a pair of sequences labeled by i and j is plotting the difference I \u03b3 i j .", [["I \u03b3", "PROTEIN", 361, 364], ["resolution", "OBSERVATION_MODIFIER", 4, 14], ["density", "OBSERVATION", 101, 108], ["bases", "ANATOMY_MODIFIER", 112, 117], ["larger", "OBSERVATION_MODIFIER", 121, 127], ["ranges", "OBSERVATION_MODIFIER", 141, 147], ["poor", "OBSERVATION_MODIFIER", 157, 161], ["bases", "ANATOMY_MODIFIER", 180, 185]]], ["Clearly, for both sequences I \u03b3 (x) must be represented with the same resolution in order to compare the distribution of \u03b3 bases along the sequence.", [["\u03b3 bases", "DNA", 121, 128], ["bases", "ANATOMY_MODIFIER", 123, 128]]], ["Figures 12 and 13 show the differences between a pair of sequences.", [["Figures", "TEST", 0, 7]]], ["In Fig. 12 the differences with resolution r = 1 between the spectra representing histone H4 coding sequence of human (i = 9, Table 17 ) and histone H4 coding sequence of maize ( j = 1, Table 17 Table 16 ).Four-component spectral representationthe distributions of particular bases along the sequences.", [["histone H4", "GENE_OR_GENE_PRODUCT", 82, 92], ["human", "ORGANISM", 112, 117], ["histone H4", "GENE_OR_GENE_PRODUCT", 141, 151], ["histone H4 coding sequence", "DNA", 82, 108], ["histone H4 coding sequence", "DNA", 141, 167], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["maize", "SPECIES", 171, 176], ["histone H4 coding sequence", "TEST", 141, 167], ["spectral representationthe", "OBSERVATION", 221, 247], ["bases", "ANATOMY_MODIFIER", 276, 281]]], ["In particular, the number of lines in I A i j , I T i j , I G i j is smaller than for I C i j .", [["I C", "PROTEIN", 86, 89], ["lines", "OBSERVATION", 29, 34], ["smaller", "OBSERVATION_MODIFIER", 69, 76]]], ["This means that the difference of the distributions of C bases along the sequences is the largest comparing to the differences of the distributions of other bases.", [["difference", "OBSERVATION_MODIFIER", 20, 30], ["distributions", "OBSERVATION_MODIFIER", 38, 51], ["bases", "ANATOMY_MODIFIER", 57, 62], ["largest", "OBSERVATION_MODIFIER", 90, 97], ["bases", "ANATOMY_MODIFIER", 157, 162]]], ["Moreover comparing the number of lines that are positive to the ones that are negative, for a particular plot, one can easily estimate the differences between the numbers of the particular bases.", [["lines", "CELL", 33, 38], ["lines", "OBSERVATION", 33, 38], ["negative", "OBSERVATION", 78, 86], ["particular", "ANATOMY_MODIFIER", 178, 188], ["bases", "ANATOMY_MODIFIER", 189, 194]]], ["For example, N C = 79 for the sequence of human and N C = 96 for the sequence of maize so the number of negative lines for I C i j is larger then the number of the positive ones.", [["human", "ORGANISM", 42, 47], ["I C", "PROTEIN", 123, 126], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["maize", "SPECIES", 81, 86], ["N C", "TEST", 13, 16], ["human and N C", "TEST", 42, 55], ["I C i j", "PROBLEM", 123, 130], ["negative lines", "OBSERVATION", 104, 118], ["larger", "OBSERVATION_MODIFIER", 134, 140], ["positive", "OBSERVATION", 164, 172]]], ["Analogously, the Table 16) number of negative lines for I G i j can be seen: N G = 100 for the sequence of human and N G = 111 for the sequence of maize.", [["G i j", "GENE_OR_GENE_PRODUCT", 58, 63], ["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["maize", "SPECIES", 147, 152], ["human and N G", "TEST", 107, 120]]], ["Since the number of A and T bases are larger for the sequence of human then for the sequence of maize, one can observe in I A i j and I T i j plots more positive lines than the negative ones.", [["human", "ORGANISM", 65, 70], ["I A i j and I T i j plots more positive lines", "CELL_LINE", 122, 167], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["maize", "SPECIES", 96, 101], ["larger", "OBSERVATION_MODIFIER", 38, 44], ["positive lines", "OBSERVATION", 153, 167]]], ["In Fig. 13 the differences with the resolution r = 1 between the spectra representing histone H4 coding sequence of human (i = 9, Table 17 ) and histone H4 coding sequence of mouse ( j = 7, Table 17 ) are shown.", [["histone H4", "GENE_OR_GENE_PRODUCT", 86, 96], ["human", "ORGANISM", 116, 121], ["histone H4", "GENE_OR_GENE_PRODUCT", 145, 155], ["mouse", "ORGANISM", 175, 180], ["histone H4 coding sequence", "DNA", 86, 112], ["histone H4 coding sequence", "DNA", 145, 171], ["human", "SPECIES", 116, 121], ["mouse", "SPECIES", 175, 180], ["human", "SPECIES", 116, 121], ["mouse", "SPECIES", 175, 180]]], ["As a result of the difference between the numbers of A bases one can observe in I A i j more positive lines than the negative ones: N A = 73 for the sequence of human and N A = 65 for the sequence of mouse.", [["human", "ORGANISM", 161, 166], ["mouse", "ORGANISM", 200, 205], ["human", "SPECIES", 161, 166], ["mouse", "SPECIES", 200, 205], ["human", "SPECIES", 161, 166], ["mouse", "SPECIES", 200, 205]]], ["The difference in C bases is also clearly seen.", [["The difference in C bases", "PROBLEM", 0, 25], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["C", "OBSERVATION_MODIFIER", 18, 19], ["bases", "ANATOMY_MODIFIER", 20, 25]]], ["There are more negative than positive x Fig. 12 Differences between the spectra for histone H4 coding sequence of human M60749 and histone H4 coding sequence of maize M13377 (i = 9, j = 1, Table 17) lines in I C i j plot: N C = 79 for the sequence of human and N C = 96 for the sequence of mouse.", [["histone H4", "GENE_OR_GENE_PRODUCT", 84, 94], ["human", "ORGANISM", 114, 119], ["M60749", "GENE_OR_GENE_PRODUCT", 120, 126], ["histone H4", "GENE_OR_GENE_PRODUCT", 131, 141], ["human", "ORGANISM", 251, 256], ["mouse", "ORGANISM", 290, 295], ["histone H4 coding sequence", "DNA", 84, 110], ["human M60749 and histone H4 coding sequence", "DNA", 114, 157], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 251, 256], ["mouse", "SPECIES", 290, 295], ["human", "SPECIES", 114, 119], ["maize", "SPECIES", 161, 166], ["human", "SPECIES", 251, 256], ["mouse", "SPECIES", 290, 295], ["histone H4 coding sequence", "TEST", 131, 157], ["j", "TEST", 182, 183], ["lines in I C i j plot", "TEST", 199, 220], ["N C", "TEST", 222, 225], ["the sequence", "TEST", 235, 247], ["human", "TEST", 251, 256], ["N C", "TEST", 261, 264], ["positive x Fig", "OBSERVATION_MODIFIER", 29, 43]]], ["Generally, comparing Fig. 12 and Fig. 13 one can see that the differences human-maize spectra are larger then the differences human-mouse spectra (the number of lines in Fig. 12 is larger then the number of lines in Fig. 13 ). x Fig. 13 Differences between the spectra for histone H4 coding sequence of human M60749 and histone H4 coding sequence of mouse V00753 (i = 9, j = 7, Table 17) As the descriptors of the four-component spectral representation, I have proposed D \u03b3 q .", [["human", "ORGANISM", 74, 79], ["human", "ORGANISM", 126, 131], ["mouse", "ORGANISM", 132, 137], ["lines", "CELL", 161, 166], ["histone H4", "GENE_OR_GENE_PRODUCT", 273, 283], ["human", "ORGANISM", 303, 308], ["M60749", "GENE_OR_GENE_PRODUCT", 309, 315], ["histone H4", "GENE_OR_GENE_PRODUCT", 320, 330], ["mouse", "ORGANISM", 350, 355], ["histone H4 coding sequence", "DNA", 273, 299], ["human M60749", "PROTEIN", 303, 315], ["histone H4 coding sequence", "DNA", 320, 346], ["D \u03b3 q", "PROTEIN", 470, 475], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 126, 131], ["mouse", "SPECIES", 132, 137], ["human", "SPECIES", 303, 308], ["mouse", "SPECIES", 350, 355], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 126, 131], ["mouse", "SPECIES", 132, 137], ["human", "SPECIES", 303, 308], ["mouse", "SPECIES", 350, 355], ["histone H4", "TREATMENT", 273, 283], ["larger", "OBSERVATION_MODIFIER", 98, 104], ["larger", "OBSERVATION_MODIFIER", 181, 187]]], ["Figure 14 shows D G 1 \u2212 D G 4 diagram for ten sequences listed in Table 17 and for one additional sequence (one point in the figure represents descriptors of one sequence).", [["Figure", "TEST", 0, 6], ["D G", "TEST", 16, 19], ["ten sequences", "TEST", 42, 55]]], ["The additional sequence is histone H4 coding sequence of human (M16707).", [["histone H4", "GENE_OR_GENE_PRODUCT", 27, 37], ["human", "ORGANISM", 57, 62], ["histone H4 coding sequence", "DNA", 27, 53], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62]]], ["Obviously, the length of this coding sequence should be 312 and not 311 as it was in the old version of the EMBL database.", [["this coding sequence", "TEST", 25, 45]]], ["The additional base is G, located at the last position of the sequence.", [["G", "GENE_OR_GENE_PRODUCT", 23, 24], ["base", "ANATOMY_MODIFIER", 15, 19], ["G", "OBSERVATION", 23, 24]]], ["The descriptors D \u03b3 q of spectral representation are very sensitive.", [["spectral representation", "TEST", 25, 48]]], ["The difference by only one base can be detected using these descriptors.", [["difference", "OBSERVATION_MODIFIER", 4, 14], ["base", "ANATOMY_MODIFIER", 27, 31]]], ["The descriptors characterizing the same sequence calculated using the old and new version of the EMBL database have been denoted using different symbols in Fig. 14 .", [["the EMBL database", "TEST", 93, 110]]], ["Their locations are different in the diagram.", [["different", "OBSERVATION_MODIFIER", 20, 29]]], ["Panels a in the figures correspond to D Table 17 indicates the location in the sequence of the base that is different for a pair of sequences.", [["Panels", "TEST", 0, 6], ["base", "ANATOMY_MODIFIER", 95, 99]]], ["The additional G base in the new sequence causes the shift to larger values of the mean of the distribution (D G 1 becomes larger, Fig. 14, Fig. 15 , panel a).", [["The additional G base", "TREATMENT", 0, 21], ["the shift", "PROBLEM", 49, 58], ["base", "ANATOMY_MODIFIER", 17, 21], ["new", "OBSERVATION_MODIFIER", 29, 32], ["shift", "OBSERVATION_MODIFIER", 53, 58], ["larger", "OBSERVATION_MODIFIER", 62, 68], ["values", "OBSERVATION_MODIFIER", 69, 75], ["mean", "OBSERVATION_MODIFIER", 83, 87], ["distribution", "OBSERVATION_MODIFIER", 95, 107], ["larger", "OBSERVATION_MODIFIER", 123, 129]]], ["The width of the distribution also increases (D G 2 for the new sequence is larger than for the old one, Fig. 15 Table 17 lows:Four-component spectral representationConsidering the properties of G and A-spectra (G and A-descriptors shown in Figs.", [["the new sequence", "TEST", 56, 72], ["G and A-spectra (G and A-descriptors", "TREATMENT", 195, 231], ["width", "OBSERVATION_MODIFIER", 4, 9], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["increases", "OBSERVATION_MODIFIER", 35, 44], ["larger", "OBSERVATION_MODIFIER", 76, 82]]], ["15, 16, respectively) one can observe clusterization of evolutionary similar organisms: plants and vertebrates that are represented by different symbols in the plots (plants-circles, vertebrates-triangles).", [["plants", "OBSERVATION", 88, 94]]], ["For example in panels a and c where D It is interesting to note that most of the similarity measures (both the standard ones and many alternative ones) indicate larger or equal similarity values between histone H1 coding sequences of chicken (labeled by i = 4, 5 in Table 17 ) and plants (labeled in this Table by j = 1, 2, 3, 6) than between these of chicken and of vertebrates (labeled Table 18 Similarity measures between a pair of sequences labeled by i and j Sim(i, j), where i and j are defined in the first column of Table 17 SimFour-component spectral representationSim (5, 6) Sim ( 100 19 by j = 7, 8, 9) .", [["D", "CHEMICAL", 36, 37], ["histone H1", "GENE_OR_GENE_PRODUCT", 203, 213], ["chicken", "ORGANISM", 234, 241], ["chicken", "ORGANISM", 352, 359], ["histone H1 coding sequences", "DNA", 203, 230], ["SimFour", "PROTEIN", 533, 540], ["chicken", "SPECIES", 234, 241], ["chicken", "SPECIES", 352, 359], ["chicken", "SPECIES", 234, 241], ["chicken", "SPECIES", 352, 359], ["larger or equal similarity values", "PROBLEM", 161, 194], ["histone H1", "TREATMENT", 203, 213], ["larger", "OBSERVATION_MODIFIER", 161, 167]]], ["However, using new similarity approach it is possible to extract such components of the similarity measures that cluster the sequence of chicken with the ones of vertebrates rather than with the ones of plants [147] .", [["chicken", "ORGANISM", 137, 144], ["chicken", "SPECIES", 137, 144], ["chicken", "SPECIES", 137, 144]]], ["Table 18 shows similarity values obtained using different similarity measures \"Sim\".", [["similarity values", "TEST", 15, 32]]], ["Using alignment method (Sim=CL) the similarity value \"chicken-plant\" CL(5,6) is the same as the similarity value \"chicken-vertebrate\" CL (5, 7) .", [["chicken", "ORGANISM", 54, 61], ["chicken", "ORGANISM", 114, 121], ["CL", "MULTI-TISSUE_STRUCTURE", 134, 136], ["chicken", "SPECIES", 54, 61], ["chicken", "SPECIES", 114, 121], ["alignment method", "TEST", 6, 22]]], ["Considering different aspects of similarity, using d \u03b3 3 , one can see that the clusterization of the sequence of chicken with vertebrates is obtained for \u03b3 = G, A, C. However the asymmetry of the gene structure for T bases is identical for the sequence of chicken and of plants (d T 3 (5, 6) = 100) and the similarity value is small in case \"chicken-vertebrate\" (d T 3 (5, 7) = 19).", [["d \u03b3 3", "GENE_OR_GENE_PRODUCT", 51, 56], ["chicken", "ORGANISM", 114, 121], ["\u03b3 = G", "GENE_OR_GENE_PRODUCT", 155, 160], ["chicken", "ORGANISM", 257, 264], ["chicken", "ORGANISM", 343, 350], ["chicken", "SPECIES", 114, 121], ["chicken", "SPECIES", 257, 264], ["chicken", "SPECIES", 343, 350], ["chicken", "SPECIES", 114, 121], ["chicken", "SPECIES", 257, 264], ["chicken", "SPECIES", 343, 350], ["the similarity value", "TEST", 304, 324], ["asymmetry", "OBSERVATION", 180, 189], ["bases", "ANATOMY_MODIFIER", 218, 223], ["small", "OBSERVATION_MODIFIER", 328, 333]]], ["Figures 19 and 20 show the diagrams for the sequences listed in Table 16 (histone H1 coding sequences of different species).", [["histone H1", "GENE_OR_GENE_PRODUCT", 74, 84], ["histone H1 coding sequences", "DNA", 74, 101], ["Figures", "TEST", 0, 7], ["the diagrams", "TEST", 23, 35], ["the sequences", "TEST", 40, 53]]], ["In particular, Fig. 19 shows D and D \u03b3 2 is linear.", [["D", "SIMPLE_CHEMICAL", 29, 30], ["D \u03b3 2", "GENE_OR_GENE_PRODUCT", 35, 40], ["Fig.", "TEST", 15, 19], ["linear", "OBSERVATION_MODIFIER", 44, 50]]], ["The most regular linear dependence is for G-descriptors (Fig. 20, panel d) .", [["linear", "OBSERVATION_MODIFIER", 17, 23], ["dependence", "OBSERVATION", 24, 34]]], ["However, using the diagrams for the descriptors independent of the lengths of sequences (Fig. 19) , for A and G-descriptors (panels a, d respectively) the clusterization of plants and vertebrates is observed.", [["the diagrams", "TEST", 15, 27], ["plants", "OBSERVATION", 173, 179]]], ["For C-descriptors, the effect of clusterization is smaller.", [["C-descriptors", "PROBLEM", 4, 17], ["clusterization", "PROBLEM", 33, 47], ["smaller", "OBSERVATION_MODIFIER", 51, 58]]], ["The effect of clusterization is not observed for T-descriptors.", [["clusterization", "PROBLEM", 14, 28]]], ["These observations are the same as in the case of histone H4 coding sequences.", [["histone H4", "GENE_OR_GENE_PRODUCT", 50, 60], ["histone H4 coding sequences", "DNA", 50, 77], ["histone H4 coding sequences", "TREATMENT", 50, 77]]], ["Figures 21, 22, 23, 24, 25 show the relations between the standard calculations Clustal W (C L) and the new measures (Eqs.", [["Figures", "TEST", 0, 7], ["the standard calculations Clustal W (C L)", "TREATMENT", 54, 95]]], ["24, 25, 27) for the sequences listed in Table 17 (histone H4 coding sequences).", [["histone H4", "GENE_OR_GENE_PRODUCT", 50, 60], ["histone H4 coding sequences", "DNA", 50, 77], ["the sequences", "TEST", 16, 29], ["histone H4 coding sequences", "TREATMENT", 50, 77]]], ["For example, the horizontal axis in Fig. 21 corresponds to the similarity matrix between sequences of different species using Clustal W method (C L) and the vertical axes correspond to the similarity matrix between the same sequences using different components of alternative similarity measures d \u03b3 q .", [["\u03b3 q", "PROTEIN", 298, 301], ["different species", "PROBLEM", 102, 119], ["Clustal W method (C L)", "TREATMENT", 126, 148], ["horizontal", "OBSERVATION_MODIFIER", 17, 27], ["axis", "OBSERVATION_MODIFIER", 28, 32]]], ["As a consequence each plot represents two similarity matrices, which gives a better visualization of the relations between two different similarity measures.", [["similarity matrices", "OBSERVATION", 42, 61]]], ["In the figures, the functions x = y, where x and y represent, respectively, the horizontal and vertical axes, are plotted Table 16 (dashed lines).", [["lines", "CELL", 139, 144]]], ["Comparing the distributions of the points around the dashed lines it is easy to recognize these aspects of similarity for which the relations are the same.", [["lines", "CELL", 60, 65], ["dashed lines", "CELL_LINE", 53, 65], ["the dashed lines", "TREATMENT", 49, 65], ["distributions", "OBSERVATION_MODIFIER", 14, 27], ["dashed lines", "OBSERVATION", 53, 65]]], ["The similarity matrix C L based on Clustal W approach for the considered sequences is given in [146] .", [["C L", "DNA", 22, 25], ["Clustal W approach", "TREATMENT", 35, 53]]], ["Small range of similarity measures indicates small differences Table 17 between the sequences of different species.", [["small differences Table", "PROBLEM", 45, 68], ["range", "OBSERVATION_MODIFIER", 6, 11], ["small", "OBSERVATION_MODIFIER", 45, 50], ["differences", "OBSERVATION_MODIFIER", 51, 62]]], ["The range of values of C L is from 78% to 100%.", [["C L", "GENE_OR_GENE_PRODUCT", 23, 26], ["range", "OBSERVATION_MODIFIER", 4, 9]]], ["The ranges of values of d \u03b3 q for q = 1, q = 2, and q = 4 are smaller than for q = 3 for all \u03b3 . d \u03b3 3 changes from about 15% to 100% for all \u03b3 .", [["d \u03b3 3", "GENE_OR_GENE_PRODUCT", 97, 102], ["\u03b3", "PROTEIN", 93, 94], ["\u03b3 3", "PROTEIN", 99, 102], ["ranges", "OBSERVATION_MODIFIER", 4, 10]]], ["The differences between sequences across species using d \u03b3 4 are smaller than using d Since each \u03b3 -component is related in a different way to the standard measure, one may expect that it carries independent similarity information.", [["d \u03b3 4", "DNA", 55, 60], ["\u03b3", "DNA", 97, 98], ["smaller", "OBSERVATION_MODIFIER", 65, 72]]], ["The convergence of d n measures to the standard measure CL we have discussed in [147] .", [["CL", "MULTI-TISSUE_STRUCTURE", 56, 58], ["d n measures", "TREATMENT", 19, 31]]], ["In the present paper this effect is shown in detail adding d 1 Table 17 term. d 1 is very different from CL (the points are located far away from the dashed line, panel a, Fig. 25 ).", [["CL", "MULTI-TISSUE_STRUCTURE", 105, 107], ["very", "OBSERVATION_MODIFIER", 85, 89], ["different", "OBSERVATION_MODIFIER", 90, 99]]], ["Adding higher-order terms, the points are pushed towards the dashed lines (panels b, c, d Fig. 25 ).", [["lines", "CELL", 68, 73], ["dashed lines", "CELL_LINE", 61, 73], ["higher-order terms", "TREATMENT", 7, 25]]], ["Figures 26, 27, 28, 29, 30 show similarity relations for \u03b2-globin gene across species using similarity measures defined in Eqs.", [["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 57, 65], ["\u03b2-globin gene", "DNA", 57, 70], ["Figures", "TEST", 0, 7], ["\u03b2-globin gene across species", "PROBLEM", 57, 85], ["similarity measures", "TREATMENT", 92, 111]]], ["These data are the standard ones for alternative methods.", [["alternative methods", "TREATMENT", 37, 56]]], ["Since the sequences in the database are not complete for some species, they are unified in this work and the appropriate locations in the gene are listed in the tables.", [["the sequences", "TEST", 6, 19], ["some species", "PROBLEM", 57, 69]]], ["In particular, the sequences of mouse and of chicken belong to the standard set of data used by many authors.", [["mouse", "ORGANISM", 32, 37], ["chicken", "ORGANISM", 45, 52], ["mouse", "SPECIES", 32, 37], ["chicken", "SPECIES", 45, 52], ["mouse", "SPECIES", 32, 37], ["chicken", "SPECIES", 45, 52]]], ["However, several bases are ambiguous for the third exons for the sequences of the two species.", [["exons", "DNA", 51, 56], ["the third exons", "PROBLEM", 41, 56], ["bases", "ANATOMY_MODIFIER", 17, 22], ["ambiguous", "OBSERVATION", 27, 36]]], ["Therefore the sequences of mouse and of chicken are omitted from this consideration.", [["mouse", "ORGANISM", 27, 32], ["chicken", "ORGANISM", 40, 47], ["mouse", "SPECIES", 27, 32], ["chicken", "SPECIES", 40, 47], ["mouse", "SPECIES", 27, 32], ["chicken", "SPECIES", 40, 47]]], ["Moreover, in gorilla and chimpanzee sequences the stop codons are not available in the database.", [["gorilla", "ORGANISM", 13, 20], ["chimpanzee", "ORGANISM", 25, 35], ["gorilla and chimpanzee sequences", "DNA", 13, 45]]], ["Therefore for all the species the stop codons are excluded from the calculations.", [["the stop codons", "TREATMENT", 30, 45], ["the calculations", "TEST", 64, 80]]], ["This means that the length of the coding sequence N CDS is three times larger than the corresponding length of the protein sequence for all the species.", [["coding sequence N CDS", "DNA", 34, 55]]], ["In this way (excluding the stop codons) all the data used in the calculations are consistent.", [["the stop codons", "TREATMENT", 23, 38]]], ["Table 17 The locations in the gene, the numbers of \u03b3 bases, N \u03b3 k , for each k-th exon according to the latest version of the EMBL database are specified in Tables 19, 20 Table 17.", [["N \u03b3 k", "GENE_OR_GENE_PRODUCT", 60, 65], ["\u03b3 bases", "DNA", 51, 58], ["N \u03b3 k", "DNA", 60, 65], ["k-th exon", "DNA", 77, 86], ["EMBL database", "DNA", 126, 139], ["bases", "ANATOMY_MODIFIER", 53, 58]]], ["The whole first exons which are given in the EMBL database only for three species with the length N W 1 , denoted Exon 1, 6.", [["exons", "DNA", 16, 21], ["length N W 1", "DNA", 91, 103], ["Exon 1", "DNA", 114, 120]]], ["The coding sequences with the lengths N CDS = 3 k=1 N k , denoted CDS. \u03b3 are also shown in Fig. 28 .", [["\u03b3", "GENE_OR_GENE_PRODUCT", 71, 72], ["coding sequences", "DNA", 4, 20], ["N CDS", "DNA", 38, 43], ["CDS", "DNA", 66, 69], ["\u03b3", "PROTEIN", 71, 72], ["The coding sequences", "TEST", 0, 20], ["the lengths", "TEST", 26, 37], ["CDS", "TEST", 40, 43], ["k", "TEST", 48, 49], ["Fig", "OBSERVATION", 91, 94]]], ["In this figure the measures are compared for different parts of the \u03b2-globin gene.", [["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 68, 76], ["\u03b2-globin gene", "DNA", 68, 81]]], ["The horizontal axes correspond to the sequences with introns, PlusI.", [["introns", "DNA", 53, 60], ["PlusI", "DNA", 62, 67], ["horizontal", "OBSERVATION_MODIFIER", 4, 14]]], ["The vertical axes correspond to the coding sequences of particular exons: column 1 to Exon 1 C DS , column 2 to Exon 2 C DS and column 3 to Exon 3 C DS .", [["exons", "DNA", 67, 72], ["Exon 1 C DS", "DNA", 86, 97], ["column 2", "DNA", 100, 108], ["Exon 2 C DS", "DNA", 112, 123], ["column 3", "DNA", 128, 136], ["Exon 3 C DS", "DNA", 140, 151], ["Exon", "TEST", 86, 90], ["DS", "TEST", 95, 97], ["column", "TEST", 100, 106], ["Exon 2 C DS and column", "TREATMENT", 112, 134], ["vertical axes", "OBSERVATION", 4, 17]]], ["The first row of subfigures correspond to A bases, the second row to C bases, the third row to T bases and the fourth row to G bases.Four-component spectral representationWe observe that the points are concentrated around the dashed lines in the middle column (Exon 2 C DS ) comparing to the first and to the third columns.", [["C", "CHEMICAL", 69, 70], ["lines", "CELL", 233, 238], ["C bases", "DNA", 69, 76], ["third row to T bases", "DNA", 82, 102], ["dashed lines", "CELL_LINE", 226, 238], ["Exon 2 C DS )", "TREATMENT", 261, 274], ["bases", "ANATOMY_MODIFIER", 44, 49], ["bases", "ANATOMY_MODIFIER", 71, 76], ["third", "OBSERVATION_MODIFIER", 82, 87], ["row", "OBSERVATION_MODIFIER", 88, 91], ["bases", "ANATOMY_MODIFIER", 97, 102], ["fourth row", "ANATOMY_MODIFIER", 111, 121], ["bases", "ANATOMY_MODIFIER", 127, 132], ["concentrated", "OBSERVATION_MODIFIER", 202, 214], ["dashed lines", "OBSERVATION", 226, 238], ["middle", "ANATOMY_MODIFIER", 246, 252], ["column", "ANATOMY_MODIFIER", 253, 259], ["third", "ANATOMY_MODIFIER", 309, 314], ["columns", "ANATOMY_MODIFIER", 315, 322]]], ["Small deviations from the dashed lines mean that the second exon is most representative in the whole sequence, PlusI (the similarity relations across species fulfilled by PlusI and and by Exon 2 C DS are closer to each other than the relations fulfilled by PlusI and by the other exons).", [["lines", "CELL", 33, 38], ["PlusI", "GENE_OR_GENE_PRODUCT", 257, 262], ["exon", "DNA", 60, 64], ["PlusI", "DNA", 111, 116], ["PlusI", "DNA", 171, 176], ["Exon 2 C DS", "DNA", 188, 199], ["PlusI", "DNA", 257, 262], ["exons", "DNA", 280, 285], ["Small deviations", "PROBLEM", 0, 16], ["the dashed lines", "TREATMENT", 22, 38], ["Exon 2 C DS", "TREATMENT", 188, 199], ["deviations", "OBSERVATION", 6, 16], ["dashed lines", "OBSERVATION", 26, 38]]], ["We have also shown that the similarity relations across species fulfilled by CDS and and by Exon 2 C DS are closer to each other than the relations fulfilled by CDS and by the other exons [71] .Four-component spectral representationIf we compare the distributions of the points between different bases (rows) one can extract some properties common for particular bases and for some parts of the genes.", [["CDS", "DNA", 77, 80], ["Exon 2 C DS", "DNA", 92, 103], ["CDS", "DNA", 161, 164], ["exons", "DNA", 182, 187], ["Exon 2 C DS", "TREATMENT", 92, 103], ["spectral representation", "OBSERVATION", 209, 232], ["bases", "ANATOMY_MODIFIER", 296, 301], ["genes", "ANATOMY", 395, 400]]], ["By a common property we understand close to zero S 3,4 \u03b3 (small values correspond to large similarities).", [["small values", "PROBLEM", 58, 70]]], ["In particular small differences between sequences across species are revealed for G bases for the first and for the second exons (panels j, k) and also for C and for T bases for the second exon (panels e, h).", [["exons", "DNA", 123, 128], ["exon", "DNA", 189, 193], ["small differences between sequences across species", "PROBLEM", 14, 64], ["G bases", "TREATMENT", 82, 89], ["small", "OBSERVATION_MODIFIER", 14, 19]]], ["Generally, larger differences are seen for longer sequences.", [["larger", "OBSERVATION_MODIFIER", 11, 17]]], ["However also for PlusI one can extract properties more common for the species (small ranges of S 3,4 A [PlusI] and S 3,4 T [PlusI]-first and third rows).", [["PlusI", "CHEMICAL", 17, 22], ["PlusI", "TREATMENT", 17, 22], ["the species", "TEST", 66, 77], ["PlusI", "TEST", 104, 109], ["PlusI]-first and third rows", "TREATMENT", 124, 151], ["small", "OBSERVATION_MODIFIER", 79, 84]]], ["Figure 29 shows similarity relations for different exons using standard alignment method Clustal W version 2.0 [148] .", [["exons", "DNA", 51, 56], ["different exons", "TREATMENT", 41, 56], ["standard alignment method Clustal W version", "TREATMENT", 63, 106]]], ["As it was mentioned before, the alignment methods do not take into account which bases are aligned.", [["the alignment methods", "TEST", 28, 49], ["bases", "ANATOMY_MODIFIER", 81, 86]]], ["The alignment of all the bases gives the contribution to the final result and, as a consequence, the similarity is large for all the parts.", [["alignment", "OBSERVATION_MODIFIER", 4, 13], ["bases", "ANATOMY_MODIFIER", 25, 30], ["large", "OBSERVATION", 115, 120]]], ["It is not possible to extract detailed properties of similarities.", [["not possible", "UNCERTAINTY", 6, 18]]], ["The information coming from these calculations is averaged.", [["these calculations", "TEST", 28, 46]]], ["Finally, the similarity Table 23 values for different exons are the same for all the species since most of the points are concentrated close to the dashed lines.", [["lines", "CELL", 155, 160], ["exons", "DNA", 54, 59], ["dashed lines", "CELL_LINE", 148, 160], ["the similarity Table 23 values", "TEST", 9, 39], ["different exons", "PROBLEM", 44, 59], ["dashed lines", "OBSERVATION", 148, 160]]], ["Complete sequences for the first exons are given only for three species (Table 23 ).", [["exons", "DNA", 33, 38], ["the first exons", "TREATMENT", 23, 38]]], ["The whole sequences of the first exons for human and gorilla differ by only one base.", [["human", "ORGANISM", 43, 48], ["gorilla", "ORGANISM", 53, 60], ["exons", "DNA", 33, 38], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["The whole sequences", "TEST", 0, 19], ["base", "ANATOMY_MODIFIER", 80, 84]]], ["As we see in Fig. 30 this is G base.", [["base", "ANATOMY_MODIFIER", 31, 35]]], ["The descriptors D A 1 , D C 1 , D T 1 are exactly the same for human and gorilla sequences.", [["D C 1", "GENE_OR_GENE_PRODUCT", 24, 29], ["D T 1", "GENE_OR_GENE_PRODUCT", 32, 37], ["human", "ORGANISM", 63, 68], ["gorilla", "ORGANISM", 73, 80], ["human and gorilla sequences", "DNA", 63, 90], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["The descriptors D A 1 , D C 1 , D T 1", "TEST", 0, 37], ["human and gorilla sequences", "TEST", 63, 90]]], ["The difference caused by this single base is recognized by D G 1 (panel d).ConclusionsSummarizing, four-component spectral representation has been used for similarity/dissimilarity analysis of histone H4 coding sequences across species (Figs.", [["D G 1", "GENE_OR_GENE_PRODUCT", 59, 64], ["histone H4", "GENE_OR_GENE_PRODUCT", 193, 203], ["histone H4 coding sequences", "DNA", 193, 220], ["similarity/dissimilarity analysis", "TEST", 156, 189], ["histone H4 coding sequences across species", "PROBLEM", 193, 235]]], ["12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25) , of histone H1 coding sequences across species (Figs.", [["histone H1", "GENE_OR_GENE_PRODUCT", 53, 63], ["12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25", "DNA", 0, 46], ["histone H1 coding sequences", "DNA", 53, 80], ["histone H1 coding sequences across species", "PROBLEM", 53, 95]]], ["19, 20) , and of different parts of \u03b2-globin gene across species (Figs.", [["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 36, 44], ["\u03b2-globin gene", "DNA", 36, 49]]], ["Since many authors use slightly different data for \u03b2-globin gene, the locations of different subsequences in this gene and their full description listed in the tables may be helpful for some alternative similarity studies.", [["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 51, 59], ["\u03b2-globin gene", "DNA", 51, 64], ["\u03b2-globin gene", "TREATMENT", 51, 64], ["some alternative similarity studies", "TEST", 186, 221]]], ["The numbers of particular bases in all the sequences are also given.", [["numbers", "OBSERVATION_MODIFIER", 4, 11], ["bases", "ANATOMY_MODIFIER", 26, 31]]], ["It has been shown that the four-component spectral representation can be used for the classification studies (clusterization of the descriptors representing histones H4 and H1 coding sequences of plants and of vertebrates).", [["histones H4", "GENE_OR_GENE_PRODUCT", 157, 168], ["histones H4 and H1 coding sequences", "DNA", 157, 192], ["the classification studies", "TEST", 82, 108], ["histones H4", "TREATMENT", 157, 168], ["H1 coding sequences", "TREATMENT", 173, 192]]], ["Analogous clusterization is also obtained using some descriptors related to 2D-dynamic graphs (Sect.", [["Analogous clusterization", "PROBLEM", 0, 24]]], ["In particular, a difference between a pair of sequences by only one base can be recognized.", [["a pair of sequences", "TEST", 36, 55]]], ["Also the approximate location of the difference and the base which is different in the compared sequences can be also determined.ConclusionsIt has been shown that if higher-order terms of similarity measure based on the descriptors of the four-component spectral representation are added and normalized in the same way as in the alignment methods then a convergence to Clustal W results may be obtained.", [["difference", "OBSERVATION_MODIFIER", 37, 47], ["base", "ANATOMY_MODIFIER", 56, 60], ["different", "OBSERVATION_MODIFIER", 70, 79]]], ["This means that the results obtained with the alignment method may be interpreted as an average of the considered components of the alternative similarity measures.", [["the alignment method", "TEST", 42, 62]]], ["Calculating an average is always related to some loss of information, i.e. large degree of degeneracy may appear.", [["some loss of information", "PROBLEM", 44, 68], ["large degree of degeneracy", "PROBLEM", 75, 101], ["average", "OBSERVATION_MODIFIER", 15, 22], ["always related to", "UNCERTAINTY", 26, 43], ["some", "OBSERVATION_MODIFIER", 44, 48], ["loss", "OBSERVATION", 49, 53], ["large", "OBSERVATION_MODIFIER", 75, 80], ["degree", "OBSERVATION_MODIFIER", 81, 87], ["degeneracy", "OBSERVATION", 91, 101]]], ["As we know, this is an inconvenient feature of similarity/dissimilarity analysis.", [["similarity/dissimilarity analysis", "TEST", 47, 80]]], ["TTTT TTTT cannot be distinguished.", [["TTTT", "PROTEIN", 5, 9], ["cannot be distinguished", "UNCERTAINTY", 10, 33]]], ["Therefore, using the four-component spectral representations one has a chance to decompose the similarity information and remove the degeneracy.ConclusionsReducing the degeneracy can also be obtained by adding the corrections to the alignment methods related to different aspects of similarity, as it is proposed in Sect.", [["the alignment methods", "TEST", 229, 250]]], ["It has been shown that each part of \u03b2-globin gene demonstrates different similarity relations across species.", [["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 36, 44], ["\u03b2-globin gene", "DNA", 36, 49], ["different similarity", "OBSERVATION", 63, 83], ["species", "OBSERVATION_MODIFIER", 101, 108]]], ["Different alternative methods describe different aspects of similarity.", [["Different alternative methods", "TREATMENT", 0, 29]]], ["In particular, most of alternative studies that have been performed for Exon 1 CDS of \u03b2-globin gene often give contradictory results.", [["Exon 1", "GENE_OR_GENE_PRODUCT", 72, 78], ["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 86, 94], ["Exon 1 CDS", "DNA", 72, 82], ["\u03b2-globin gene", "DNA", 86, 99], ["alternative studies", "TEST", 23, 42]]], ["For example the similarity value of Exon 1 CDS human-goat is larger than human-mouse if the methods described in the works [106, 112, 126, 137, 149] are used.", [["human", "ORGANISM", 47, 52], ["goat", "ORGANISM", 53, 57], ["human", "ORGANISM", 73, 78], ["mouse", "ORGANISM", 79, 84], ["Exon 1 CDS human-goat", "DNA", 36, 57], ["human", "SPECIES", 47, 52], ["goat", "SPECIES", 53, 57], ["human", "SPECIES", 73, 78], ["mouse", "SPECIES", 79, 84], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 73, 78], ["mouse", "SPECIES", 79, 84], ["Exon 1 CDS human", "TEST", 36, 52], ["larger", "OBSERVATION_MODIFIER", 61, 67]]], ["The reverse situation i.e. similarity value between the sequences of Exon 1 CDS human-goat is smaller than human-mouse if methods taken from [32, 33, 36, 108, 110, 122, [150] [151] [152] are applied.ConclusionsMany authors introducing new graphical representations for beta-globin gene try to avoid considering chimpanzee and gorilla sequences not only because the data are not complete but also because the results are often different than our expectations.", [["Exon 1", "GENE_OR_GENE_PRODUCT", 69, 75], ["human", "ORGANISM", 80, 85], ["goat", "ORGANISM", 86, 90], ["human", "ORGANISM", 107, 112], ["mouse", "ORGANISM", 113, 118], ["beta-globin", "GENE_OR_GENE_PRODUCT", 269, 280], ["chimpanzee", "ORGANISM", 311, 321], ["gorilla", "ORGANISM", 326, 333], ["Exon 1 CDS human-goat", "DNA", 69, 90], ["beta-globin gene", "DNA", 269, 285], ["chimpanzee and gorilla sequences", "DNA", 311, 343], ["human", "SPECIES", 80, 85], ["goat", "SPECIES", 86, 90], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 113, 118], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 113, 118], ["Exon 1 CDS human", "TEST", 69, 85], ["beta-globin gene", "TREATMENT", 269, 285], ["chimpanzee and gorilla sequences", "TEST", 311, 343], ["the data", "TEST", 361, 369]]], ["We expect the largest similarity for human-chimpanzee sequences.", [["human", "ORGANISM", 37, 42], ["chimpanzee", "ORGANISM", 43, 53], ["human-chimpanzee sequences", "DNA", 37, 63], ["human", "SPECIES", 37, 42], ["human-chimpanzee", "SPECIES", 37, 53], ["human-chimpanzee sequences", "TREATMENT", 37, 63], ["largest", "OBSERVATION_MODIFIER", 14, 21]]], ["However detailed similarity/dissimilarity analysis of beta-globin gene using four-component spectral representation indicates that this is not true for all parts of the beta-globin gene and for all \u03b3 -components of similarity measures.", [["beta-globin", "GENE_OR_GENE_PRODUCT", 54, 65], ["beta-globin", "GENE_OR_GENE_PRODUCT", 169, 180], ["beta-globin gene", "DNA", 54, 70], ["beta-globin gene", "DNA", 169, 185], ["beta-globin gene", "TREATMENT", 54, 70], ["similarity measures", "TREATMENT", 215, 234]]], ["According to the definition of the new measures, S 3,4 \u03b3 becomes smaller if the sequences are more similar.", [["S 3,4 \u03b3", "SIMPLE_CHEMICAL", 49, 56], ["smaller", "OBSERVATION_MODIFIER", 65, 72], ["more similar", "OBSERVATION_MODIFIER", 94, 106]]], ["Considering the second exon, I obtain the largest similarity in the case of human-chimpanzee sequences.", [["human", "ORGANISM", 76, 81], ["chimpanzee", "ORGANISM", 82, 92], ["exon", "DNA", 23, 27], ["human-chimpanzee sequences", "DNA", 76, 102], ["human", "SPECIES", 76, 81], ["human-chimpanzee", "SPECIES", 76, 92], ["human-chimpanzee sequences", "TREATMENT", 76, 102]]], ["This means that S 3,4 \u03b3 is the smallest for the two sequences for all \u03b3 , and in particular S 3,4 \u03b3 =0 for \u03b3 = A, C, T .", [["S 3,4 \u03b3", "SIMPLE_CHEMICAL", 16, 23], ["\u03b3 = A", "SIMPLE_CHEMICAL", 107, 112], ["C", "SIMPLE_CHEMICAL", 114, 115]]], ["The difference between the two sequences is only in the distribution of G bases.", [["the two sequences", "TEST", 23, 40], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["bases", "ANATOMY_MODIFIER", 74, 79]]], ["It is interesting to note that S 3,4 \u03b3 = 0 for the second exon, both for C and for T bases, in three cases: human-chimpanzee, human-gorilla and gorilla-chimpanzee sequences.", [["human", "ORGANISM", 108, 113], ["chimpanzee", "ORGANISM", 114, 124], ["human", "ORGANISM", 126, 131], ["gorilla", "ORGANISM", 132, 139], ["gorilla", "ORGANISM", 144, 151], ["chimpanzee", "ORGANISM", 152, 162], ["human-chimpanzee, human-gorilla and gorilla-chimpanzee sequences", "DNA", 108, 172], ["human", "SPECIES", 108, 113], ["chimpanzee", "SPECIES", 114, 124], ["human", "SPECIES", 126, 131], ["-gorilla", "SPECIES", 131, 139], ["gorilla-chimpanzee", "SPECIES", 144, 162], ["human-chimpanzee", "SPECIES", 108, 124], ["human-gorilla", "SPECIES", 126, 139], ["gorilla-chimpanzee", "SPECIES", 144, 162]]], ["However for other exons, S 3,4 \u03b3 is not always the smallest in the case of human-chimpanzee sequences comparing to human-other species sequences.", [["S 3,4 \u03b3", "GENE_OR_GENE_PRODUCT", 25, 32], ["human", "ORGANISM", 75, 80], ["chimpanzee", "ORGANISM", 81, 91], ["human", "ORGANISM", 115, 120], ["exons", "DNA", 18, 23], ["S 3,4 \u03b3", "DNA", 25, 32], ["human-chimpanzee sequences", "DNA", 75, 101], ["human-other species sequences", "DNA", 115, 144], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 115, 120], ["human-chimpanzee", "SPECIES", 75, 91], ["human", "SPECIES", 115, 120], ["human-chimpanzee sequences", "TREATMENT", 75, 101]]], ["If the sequence with introns, PlusI, is considered then S 3,4 C is the smallest for humanchimpanzee sequences and for \u03b3 = A, T, G, S 3, 4 \u03b3 are the smallest for human-gorilla sequences.ConclusionsEach descriptor may be related to different biological function.", [["C", "GENE_OR_GENE_PRODUCT", 62, 63], ["\u03b3 = A", "GENE_OR_GENE_PRODUCT", 118, 123], ["S 3", "GENE_OR_GENE_PRODUCT", 131, 134], ["\u03b3", "GENE_OR_GENE_PRODUCT", 138, 139], ["human", "ORGANISM", 161, 166], ["gorilla", "ORGANISM", 167, 174], ["introns", "DNA", 21, 28], ["PlusI", "DNA", 30, 35], ["humanchimpanzee sequences", "DNA", 84, 109], ["human-gorilla sequences", "DNA", 161, 184], ["human", "SPECIES", 161, 166], ["human-gorilla", "SPECIES", 161, 174], ["humanchimpanzee sequences", "TEST", 84, 109], ["may be related to", "UNCERTAINTY", 212, 229]]], ["Since we are at the beginning of the way of understanding in which contexts particular descriptors may play the key role, the creation of new alternative methods aiming at similarity/dissimilarity analysis of biological sequences is of particular importance.ConclusionsOpen Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.", [["new alternative methods", "TREATMENT", 138, 161]]]], "28f7285863477f362bf3d4adacbbed19faef484f": [["Plotted as the y-axes are log intensities for the single-color-channel arrays (HuEx1.0 and Affymetrix) and log ratios for the two-color-channel array (Agilent); and the x-axes indicate beta values for DNA methylation from 0 (unmethylated) to 1 (methylated).", [["beta", "GENE_OR_GENE_PRODUCT", 185, 189], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["y-axes", "DNA", 15, 21], ["the single-color-channel arrays", "TREATMENT", 46, 77], ["HuE", "TEST", 79, 82], ["Affymetrix", "TEST", 91, 101], ["log ratios", "TEST", 107, 117], ["the x-axes", "TEST", 165, 175], ["beta values", "TEST", 185, 196], ["DNA methylation", "PROBLEM", 201, 216]]], ["We observe with each of the individual platform the same pattern that we observed with the median integrated data, i.e., HNF1B is generally silenced in the tumors, half of them possibly by an epigenetic mechanism.", [["tumors", "ANATOMY", 156, 162], ["tumors", "DISEASE", 156, 162], ["HNF1B", "GENE_OR_GENE_PRODUCT", 121, 126], ["tumors", "CANCER", 156, 162], ["HNF1B", "PROTEIN", 121, 126], ["tumors", "OBSERVATION", 156, 162], ["epigenetic mechanism", "OBSERVATION", 192, 212]]]], "PMC7434304": [["A five-point range scale was applied to allow the respondents to indicate how much they disagree or agree with a certain statement, so a numerical value in the dataset file means the respondent level of agreement, with 1 being \"strongly disagree\" and 5 being \"strongly agree\".", [["A five-point range scale", "TREATMENT", 0, 24], ["a numerical value", "TEST", 135, 152]]], ["Of the 587 students that participated in the study, 111 are from the Faculty of Business, 172 from the Faculty of Languages and Arts, 39 from the Faculty of Engineering, 116 from the Faculty of Pharmacy, 125 from the Faculty of Educational Sciences, and 24 from the Faculty of Law.", [["the study", "TEST", 41, 50]]], ["Of the 587 students that participated in the study, 172 from the Faculty of Languages and Arts, 116 from the Faculty of Pharmacy, 111 are from the Faculty of Business, 77 from Faculty of Science and Information Technology, 48 from Faculty of Educational Sciences, 39 from the Faculty of Engineering, and 24 from the Faculty of Law.Data Description", [["the study", "TEST", 41, 50]]]], "PMC7315906": [["In Freiburg waren es zum Vergleich 200 (Intensivstation: 70, verstorben: 50); 82.246 verstorbene Menschen bedeuten laut dem Statistischen Bundesamt eine Erh\u00f6hung um 8 % (+5942 F\u00e4lle) gegen\u00fcber dem Durchschnitt der 4 Vorjahre.", [["verstorbene", "TREATMENT", 85, 96]]], ["Obwohl diese sog.", [["diese sog", "OBSERVATION", 7, 16]]], ["\u00dcbersterblichkeit in Deutschland also geringer war als in den europ\u00e4ischen Nachbarl\u00e4ndern (Frankreich: +27 % 01.03.\u201320.04.2020; Italien: +49 % 03.2020), trugen ma\u00dfgeblich 3 Bundesl\u00e4nder zu erh\u00f6hten Sterbefallzahlen bei (Bayern: +18 %, Baden-W\u00fcrttemberg: 16 %, Nordrhein-Westfalen: +5 %).", [["Italien", "TEST", 128, 135], ["ma\u00dfgeblich", "TEST", 160, 170], ["Baden", "TEST", 235, 240]]], ["Das eindr\u00fcckliche Beispiel verdeutlicht gut, dass die Ausbreitung \u00fcber Pflegepersonal und \u00c4rzte eine relevante Gefahr darstellt.Immunantwort und unterschiedliche TestverfahrenRelativ zeitgleich, 10 bis 14 Tage nach Beginn der Infektion, wurde die Bildung von IgM- und IgG-Antik\u00f6rpern beschrieben [17\u201319].", [["IgM", "PROTEIN", 259, 262], ["IgG", "PROTEIN", 268, 271], ["Immunantwort und unterschiedliche TestverfahrenRelativ zeitgleich, 10 bis 14 Tage nach Beginn der Infektion, wurde die Bildung von IgM- und IgG-Antik\u00f6rpern beschrieben", "SPECIES", 128, 295], ["Immunantwort", "TEST", 128, 140], ["TestverfahrenRelativ zeitgleich", "TREATMENT", 162, 193], ["von IgM", "TEST", 255, 262], ["Antik\u00f6rpern beschrieben", "TREATMENT", 272, 295], ["gut", "ANATOMY", 40, 43]]], ["Dar\u00fcber hinaus wurde beschrieben, dass Alter und Geschlecht Einfluss auf Zeitpunkt und St\u00e4rke der Antik\u00f6rperformation haben k\u00f6nnen [20].", [["Dar\u00fcber hinaus wurde beschrieben, dass Alter und Geschlecht Einfluss auf Zeitpunkt und St\u00e4rke der Antik\u00f6rperformation haben k\u00f6nnen", "SPECIES", 0, 130]]], ["Erste Berichte von keinen (6 %) oder geringen Antik\u00f6rperspiegeln (30 %) best\u00e4tigten sich nicht [22].", [["Erste Berichte von keinen", "TREATMENT", 0, 25], ["Antik\u00f6rperspiegeln", "TREATMENT", 46, 64]]], ["Trotz enormer und andauernder Bem\u00fchungen, Immunreaktionen auf SARS-CoV\u20112 in verschiedenen klinischen Umgebungen zu untersuchen, gibt es bisher unzureichende Daten und ein schlechtes Verst\u00e4ndnis des Ausma\u00dfes und der Dauer von Antik\u00f6rperreaktionen (IgM, IgG und IgA) nach asymptomatischen, leichten und schweren Infektionen.", [["SARS-CoV\u20112", "DISEASE", 62, 72], ["IgM", "PROTEIN", 247, 250], ["Trotz enormer und andauernder Bem\u00fchungen, Immunreaktionen auf SARS-CoV\u20112 in verschiedenen klinischen Umgebungen zu untersuchen, gibt es bisher unzureichende Daten und ein schlechtes Verst\u00e4ndnis des Ausma\u00dfes und der Dauer von Antik\u00f6rperreaktionen", "SPECIES", 0, 245], ["Antik\u00f6rperreaktionen", "TEST", 225, 245], ["IgM", "TEST", 247, 250], ["IgG", "TEST", 252, 255]]], ["Die M\u00f6glichkeit einer T\u2011Zell-vermittelten Immunit\u00e4t bedeutet, dass doch einige der Infizierten \u00fcberhaupt keine Antik\u00f6rper ausbilden [18].Immunantwort und unterschiedliche TestverfahrenAussagekraft und Informationsgehalt der Testverfahren k\u00f6nnen sich erheblich unterscheiden [23, 24].", [["Immunantwort", "TEST", 137, 149]]], ["Obwohl die Pr\u00e4analytik, also die Gewinnung einer Serum- oder Plasmaprobe relativ unempfindlich gegen\u00fcber m\u00f6glichen Fehlern ist, hat ein fehlendes schnelles oder erleichtertes Zulassungsverfahren der Beh\u00f6rden anfangs dazu gef\u00fchrt, dass Tests mit einer Genauigkeit unter 30 % verwendet wurden [25].Immunantwort und unterschiedliche TestverfahrenSchnelltests (POC: \u201epoint of care\u201c) auf Antik\u00f6rper boten anfangs eine einfache Anwendung mit wenig logistischem Aufwand (Abb.", [["Serum", "TEST", 49, 54], ["Plasmaprobe", "TREATMENT", 61, 72], ["hat ein fehlendes schnelles", "TREATMENT", 128, 155]]], ["Quantitative ELISA-Assays liefern dagegen einen Titer; sie erfordern eine sorgf\u00e4ltige Kalibrierung (Abb.", [["Quantitative ELISA", "TEST", 0, 18], ["Assays", "TEST", 19, 25]]], ["Nachdem gerade anfangs zahlreiche unseri\u00f6se und unzuverl\u00e4ssige Schnelltests angeboten wurden, hat die Bedeutung der POC-Tests abgenommen.", [["Nachdem gerade anfangs", "TREATMENT", 0, 22]]], ["Angesichts ausgezeichneter Plattformen und schnell verf\u00fcgbarer Tests mit stark verbesserter Spezifit\u00e4t (ATELICA\u00ae [Siemens Healthcare GmbH, Erlangen, Deutschland], ELECYS\u00ae [Roche Diagnostics Deutschland GmbH, Mannheim, Deutschland], ARCHITECT\u00ae [Abbott GmbH, Wiesbaden, Deutschland], VITROS\u00ae [Ortho, Ortho-Clinical Diagnostics GmbH, Neckargm\u00fcnd, Deutschland]; LIAISON\u00ae [Diasorrin, Saluggia Italien]) ist eine fl\u00e4chendeckende und schnelle Testung mit hohem Durchsatz m\u00f6glich.Immunantwort und unterschiedliche TestverfahrenNeutralisationstests, bei denen Antik\u00f6rper einer Serumprobe verhindern sollen, dass anf\u00e4llige Zellen infiziert werden, stellen als Goldstandard die Referenzmethode dar.", [["Angesichts ausgezeichneter Plattformen und schnell verf\u00fcgbarer Tests mit stark verbesserter Spezifit\u00e4t", "SPECIES", 0, 102], ["Angesichts", "TEST", 0, 10], ["Plattformen", "TEST", 27, 38], ["Diasorrin", "TREATMENT", 368, 377], ["Saluggia Italien]", "TREATMENT", 379, 396], ["ist eine fl\u00e4chendeckende", "TREATMENT", 398, 422], ["Immunantwort", "TREATMENT", 472, 484]]], ["Eine Alternative ist das Ausweichen auf pseudotypisierte Viren (PV).Information schafft Sicherheit: Seropr\u00e4valenz in GesundheitsberufenAugen\u00e4rzte und Mitarbeiter entsprechender Einrichtungen sind aufgrund der k\u00f6rperlichen N\u00e4he einem erh\u00f6hten Risiko ausgesetzt [28].", [["Eine Alternative ist das Ausweichen auf pseudotypisierte Viren (PV)", "SPECIES", 0, 67], ["Seropr\u00e4valenz in GesundheitsberufenAugen\u00e4rzte und Mitarbeiter entsprechender", "TREATMENT", 100, 176]]], ["Seroepidemiologie kann das Verst\u00e4ndnis der \u00dcbertragungsintensit\u00e4t und der Anf\u00e4lligkeit in der Bev\u00f6lkerung verbessern.", [["kann das Verst\u00e4ndnis der \u00dcbertragungsintensit\u00e4t und der Anf\u00e4lligkeit in der Bev\u00f6lkerung verbessern", "SPECIES", 18, 116]]], ["Trotz Restunsicherheiten auf individueller Ebene sind serologische Tests in definierten Stichproben (Sero-Surveillance) sinnvoll.", [["Trotz", "TEST", 0, 5], ["serologische", "TEST", 54, 66], ["Tests", "TEST", 67, 72], ["Stichproben", "TEST", 88, 99]]], ["Nach den amerikanischen Centers for Disease Control and Prevention (CDC) sind 3 Strategien empfohlen [29]:Die initiale Verwendung eines Tests mit einer hohen Spezifit\u00e4t erm\u00f6glicht eine hohe Zuverl\u00e4ssigkeit ab einer Pr\u00e4valenz von \u22655 %.Eine sequenzielle Testung erh\u00f6ht die Zuverl\u00e4ssigkeit, falls der zweite Test ein anderes Design (z.", [["Disease Control", "TREATMENT", 36, 51], ["Die", "PROBLEM", 106, 109], ["ab einer Pr\u00e4valenz von \u2265", "TREATMENT", 206, 230]]], ["B. Antigenepitop oder Format) aufweisen.Eine Konzentration der Testung auf Personen mit hoher Erkrankungswahrscheinlichkeit (Symptomatik und zeitlicher Bezug von infizierten Kontaktpersonen) ist eine m\u00f6gliche Strategie.Information schafft Sicherheit: Seropr\u00e4valenz in GesundheitsberufenIm Hinblick auf die letzten beiden Punkte wurde allen Mitarbeitern der T\u00fcbinger Augenklinik und des Forschungsinstituts die Testung mittels validierter Assays (hohe Schwellenwerte und geringe Kreuzreaktivit\u00e4t der Coronaviren Untergruppe B) angeboten (Abb.", [["Eine Konzentration der Testung auf Personen mit hoher Erkrankungswahrscheinlichkeit (Symptomatik und zeitlicher Bezug von infizierten Kontaktpersonen) ist eine m\u00f6gliche", "SPECIES", 40, 208], ["GesundheitsberufenIm Hinblick auf die letzten beiden Punkte wurde allen Mitarbeitern der T\u00fcbinger Augenklinik und des Forschungsinstituts die Testung mittels validierter Assays (hohe Schwellenwerte und geringe Kreuzreaktivit\u00e4t der Coronaviren Untergruppe B) angeboten", "SPECIES", 268, 535], ["Symptomatik und zeitlicher Bezug von infizierten Kontaktpersonen", "TREATMENT", 125, 189], ["Seropr\u00e4valenz", "TREATMENT", 251, 264], ["Assays", "TEST", 438, 444]]], ["Antik\u00f6rper gegen die S1-Dom\u00e4ne des Spike-Proteins von SARS-CoV\u20112 (ELISA, Euroimmun AG, L\u00fcbeck, Deutschland [EI 2606\u20139601 G], Sensitivit\u00e4t >10 Tage: 75 %, \u226521 Tage: 93,8 %; Spezifit\u00e4t: 99,0 %) werden bestimmt.", [["Antik\u00f6rper gegen die S1-Dom\u00e4ne des Spike-Proteins von SARS-CoV\u20112", "SPECIES", 0, 64], ["Antik\u00f6rper", "TEST", 0, 10], ["von SARS", "TEST", 50, 58], ["CoV\u20112", "TEST", 59, 64], ["ELISA", "TEST", 66, 71], ["Euroimmun", "TEST", 73, 82], ["AG", "TEST", 83, 85], ["L\u00fcbeck", "TEST", 87, 93], ["Deutschland", "TEST", 95, 106], ["Sensitivit\u00e4t", "TEST", 125, 137], ["Tage", "TEST", 158, 162], ["Spezifit\u00e4t", "TEST", 172, 182]]], ["In weiteren Tests wird ein rekombinantes Antigen des Nukleocapsid(N-)Proteins zur Bestimmung der SARS-CoV-2-Antik\u00f6rper mittels Elektrochemilumineszenz-Immunoassay (ECLIA, Roche Deutschland GmbH, Grenzach-Wyhlen, Deutschland [Elecys\u00ae], Sensitivit\u00e4t >14 Tage: 100 %, Spezifit\u00e4t: 99,8 %) verwendet.", [["Nukleocapsid", "TEST", 53, 65], ["der SARS", "TEST", 93, 101], ["CoV", "TEST", 102, 105], ["Antik\u00f6rper", "TEST", 108, 118], ["Elektrochemilumineszenz", "TEST", 127, 150], ["ECLIA", "TEST", 164, 169], ["Grenzach", "TEST", 195, 203], ["Sensitivit\u00e4t", "TEST", 235, 247]]], ["Chemilumineszenz-markiertes rekombinantes SARS-CoV-2 Antigen (S1 RBD-Antigen-Sandwich-Immuntest, Siemens Healthcare Diagnostics GmbH, Erlangen, Deutschland [ADVIA Centaur\u00ae] dient zur Bestimmung der Gesamtantik\u00f6rper (IgM und IgG).Kritische Diskussion der Aussagekraft und Validit\u00e4tEs darf nicht vergessen werden, dass die Pr\u00e4valenz einer Erkrankung entscheidenden Einfluss auf die Eignung eines diagnostischen Tests hat (Tab.", [["Chemilumineszenz", "SIMPLE_CHEMICAL", 0, 16], ["IgM und IgG", "GENE_OR_GENE_PRODUCT", 216, 227], ["RBD", "PROTEIN", 65, 68], ["IgM", "PROTEIN", 216, 219], ["IgG", "PROTEIN", 224, 227], ["Chemilumineszenz", "TEST", 0, 16], ["markiertes", "TEST", 17, 27], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["Antigen", "TEST", 53, 60], ["S1 RBD", "TEST", 62, 68], ["Antigen", "TEST", 69, 76], ["Sandwich", "TEST", 77, 85], ["Deutschland", "TEST", 144, 155], ["Centaur\u00ae", "TEST", 163, 171]]], ["Augen\u00e4rzten sind die Probleme vom Thema Fr\u00fcherkennung vor dem Hintergrund einer niedrigen Glaukompr\u00e4valenz gut bekannt [30].", [["Augen\u00e4rzten sind die", "PROBLEM", 0, 20], ["Probleme", "PROBLEM", 21, 29]]], ["M\u00f6gliche Limitationen und die Relevanz falsch positiver Befunde sind erst recht dann von Bedeutung, wenn die Hoffnungen auf eine unklare Immunit\u00e4t oder die R\u00fcckkehr an den Arbeitsplatz damit verbunden werden.", [["M\u00f6gliche Limitationen und die Relevanz falsch positiver Befunde sind erst recht dann von Bedeutung, wenn die Hoffnungen auf eine unklare Immunit\u00e4t oder die R\u00fcckkehr an den Arbeitsplatz damit verbunden werden", "SPECIES", 0, 207], ["M\u00f6gliche", "TREATMENT", 0, 8]]], ["Ob das Vorhandensein von Antik\u00f6rpern eine ausreichende Immunit\u00e4t gegen weitere Infektionen und ggf. \u00fcber welchen Zeitraum bietet, ist dar\u00fcber hinaus eine Pr\u00e4misse, die erst noch durch Studien belegt werden muss.Kritische Diskussion der Aussagekraft und Validit\u00e4tDie Zuverl\u00e4ssigkeit eines positiven Testergebnisses wird durch den \u201epr\u00e4diktiven Wert\u201c angegeben, dessen Bedeutung f\u00fcr die SARS-CoV-2-Infektion au\u00dferhalb von Hotspots bereits hervorgehoben wurde [31]: Angesichts einer mittleren Sensitivit\u00e4t bzw.", [["Kritische Diskussion der Aussagekraft und Validit\u00e4tDie Zuverl\u00e4ssigkeit eines positiven Testergebnisses wird durch den \u201epr\u00e4diktiven Wert\u201c angegeben, dessen Bedeutung f\u00fcr die SARS-CoV-2-Infektion au\u00dferhalb von Hotspots bereits hervorgehoben wurde", "SPECIES", 211, 455], ["Vorhandensein von Antik\u00f6rpern eine ausreichende", "TREATMENT", 7, 54], ["Kritische Diskussion der Aussagekraft und Validit\u00e4tDie Zuverl\u00e4ssigkeit eines", "TREATMENT", 211, 287], ["CoV", "TEST", 389, 392], ["Angesichts", "TREATMENT", 462, 472]]], ["Spezifit\u00e4t zugelassener Antik\u00f6rpertests zwischen 84,90 % bzw.", [["Spezifit\u00e4t zugelassener Antik\u00f6rpertests zwischen", "TREATMENT", 0, 48]]], ["98,63 % kann der positive Vorhersagewert (a / (a + b) mit a: Anzahl der richtig positiv getesteten Personen und a + b: Anzahl aller positiv getesteten Personen) in Gebieten mit geringer Pr\u00e4valenz nur 30\u201350 % betragen.", [["Anzahl der richtig positiv getesteten Personen und a + b: Anzahl aller positiv getesteten Personen", "SPECIES", 61, 159], ["Anzahl", "TREATMENT", 119, 125], ["Gebieten mit geringer Pr\u00e4valenz nur", "TREATMENT", 164, 199]]]], "629a1c20d3907f5af3cb4a491645e14daca86a1e": [["Les gastroent6rites virales (GEV) sont r6pandues dans le monde entier.", [["Les gastroent6rites virales", "TEST", 0, 27]]], ["I1 n'en est pas de m6me dans les pays en d6veloppement off ces GEV, essentiellement par la d6shydratation qu'elles entrainent, constituent une cause tr~s importante de mortalit6 infantile.", [["infantile", "DISEASE", 178, 187], ["essentiellement par la d6shydratation", "TREATMENT", 68, 105]]]], "45b1241135916091afe73323f03b0f62619ffb70": [["IntroductionThe coronavirus disease 2019 (COVID-19) originated from Wuhan, Hubei state, China carrying similar DNA structure to SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) has spread throughout the world and creating massive panic to the human life 1, 2 .", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["SARS", "DISEASE", 128, 132], ["Acute Respiratory Syndrome", "DISEASE", 141, 167], ["MERS", "DISEASE", 173, 177], ["Middle East Respiratory Syndrome", "DISEASE", 179, 211], ["panic", "DISEASE", 266, 271], ["coronavirus", "ORGANISM", 16, 27], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["human", "ORGANISM", 279, 284], ["human", "SPECIES", 279, 284], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["human", "SPECIES", 279, 284], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["SARS (Severe Acute Respiratory Syndrome)", "PROBLEM", 128, 168], ["MERS (Middle East Respiratory Syndrome", "PROBLEM", 173, 211], ["coronavirus disease", "OBSERVATION", 16, 35], ["Severe", "OBSERVATION_MODIFIER", 134, 140], ["Acute", "OBSERVATION_MODIFIER", 141, 146], ["Respiratory Syndrome", "OBSERVATION", 147, 167], ["Middle", "ANATOMY_MODIFIER", 179, 185], ["Respiratory Syndrome", "OBSERVATION", 191, 211], ["massive", "OBSERVATION_MODIFIER", 258, 265], ["panic", "OBSERVATION", 266, 271]]], ["The disease has the worst feature to transmit from person to person 3 considering this feature and its lofty infection rate on January 30, 2020, the World Health Organization (WHO) declared COVID-19 as a global emergency.IntroductionTo date, it has infected more than 3 million people and over 2 lakh have died.", [["infection", "DISEASE", 109, 118], ["people", "ORGANISM", 278, 284], ["person", "SPECIES", 51, 57], ["person", "SPECIES", 61, 67], ["people", "SPECIES", 278, 284], ["The disease", "PROBLEM", 0, 11], ["its lofty infection rate", "PROBLEM", 99, 123], ["disease", "OBSERVATION", 4, 11]]], ["This three-country together holds over 1.3 million total identified cases and over 50% of the total death because of COVID-19 4 .", [["death", "DISEASE", 100, 105], ["COVID", "TEST", 117, 122]]], ["As no proven treatment/medicine or vaccine is available to date 5 the harm of COVID-19 has already overtaken SARS and MARS 6 .IntroductionAlthough the infection rate is very high, all the patients getting infected by this disease don't always die.", [["COVID-19", "CHEMICAL", 78, 86], ["SARS", "DISEASE", 109, 113], ["infection", "DISEASE", 151, 160], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["medicine", "TREATMENT", 23, 31], ["vaccine", "TREATMENT", 35, 42], ["COVID", "TEST", 78, 83], ["the infection rate", "TEST", 147, 165], ["infection", "OBSERVATION", 151, 160]]], ["The global recovery rate is about 28.6% and the death rate is about 7% until April 28, 2020 4 .", [["death", "DISEASE", 48, 53], ["The global recovery rate", "TEST", 0, 24], ["the death rate", "TEST", 44, 58], ["global", "OBSERVATION_MODIFIER", 4, 10], ["recovery", "OBSERVATION_MODIFIER", 11, 19], ["rate", "OBSERVATION_MODIFIER", 20, 24]]], ["This information suggests that there may be some factors that influence the risk of death or critical medical states of the patients.", [["death", "DISEASE", 84, 89], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["death", "PROBLEM", 84, 89]]], ["That's why it is important to identify and estimate such risk factors to predict the severe complication of the patients for avoiding or to minimize the severity 7 .IntroductionResearchers are trying to identify risk factors that deteriorate the health state of the COVID-19 patients mostly by using meta-analysis and systematic review.", [["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 275, 283], ["the severity", "PROBLEM", 149, 161], ["systematic review", "TEST", 318, 335]]], ["Some earlier investigations reported males are more likely to die or to go through the critical states of COVID-19 8,9 .", [["COVID", "TEST", 106, 111]]], ["There is an ongoing debate on whether smoking is a risk factor for COVID-19 severity.", [["smoking", "CHEMICAL", 38, 45], ["COVID", "TEST", 67, 72]]], ["Although some regard it as a risk factor 9 , others found no significant alliance between smoking and the .", [["no", "UNCERTAINTY", 58, 60], ["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted May 5, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In this study, we endeavor to identify some demographic and clinical characteristics which can be appraised as risk factors for the severity of COVID-19 by summarizing findings of the published literature.Literature SearchThe literature search lasted from April 2, 2020, to April 18, 2020.", [["this study", "TEST", 3, 13], ["COVID", "TEST", 144, 149]]], ["Both of the authors searched through PubMed, Google Scholar, EMBASE, and Cochrane Library using keywords:Literature Search\"COVID-19\", \"Novel Coronavirus\", \"COVID-19 characteristics\", \"COVID-19 patient\", and \"China coronavirus\".", [["patient", "ORGANISM", 193, 200], ["patient", "SPECIES", 193, 200], ["China coronavirus", "SPECIES", 208, 225]]], ["We initially identified all the studies conformed to the keywords without any further investigations.Inclusion CriteriaBased on the following criteria, we have included literature in the current study: a) bivariate data available for the severity (death/ICU (Intensive Care Unit)/severe state/others) of COVID-19 patients, b) multiple factors available for the severity of the disease, c) full-text access to the article, d) information presented in English language, e) peer-reviewed accepted/published articles, and f) literature published in and after December 2019 (after the first patient identified).Inclusion CriteriaWe illustrate the systematic selection procedure of literature in Figure 1 .Outcomes and CovariatesThe authors extracted the number of patients that have undergone the severity of COVID-19 and are stable/recovered under various factors like sex, smoking history, fatigue or myalgia, cough, fever, diarrhea, hypertension, and diabetes.", [["death", "DISEASE", 248, 253], ["fatigue", "DISEASE", 887, 894], ["myalgia", "DISEASE", 898, 905], ["cough", "DISEASE", 907, 912], ["fever", "DISEASE", 914, 919], ["diarrhea", "DISEASE", 921, 929], ["hypertension", "DISEASE", 931, 943], ["diabetes", "DISEASE", 949, 957], ["patients", "ORGANISM", 313, 321], ["patient", "ORGANISM", 586, 593], ["patients", "ORGANISM", 759, 767], ["patients", "SPECIES", 313, 321], ["patient", "SPECIES", 586, 593], ["patients", "SPECIES", 759, 767], ["the studies", "TEST", 28, 39], ["any further investigations", "TEST", 74, 100], ["severe state/others", "PROBLEM", 280, 299], ["COVID", "TEST", 304, 309], ["multiple factors", "PROBLEM", 326, 342], ["the disease", "PROBLEM", 373, 384], ["the systematic selection procedure", "TREATMENT", 638, 672], ["COVID", "TEST", 804, 809], ["fatigue", "PROBLEM", 887, 894], ["myalgia", "PROBLEM", 898, 905], ["cough", "PROBLEM", 907, 912], ["fever", "PROBLEM", 914, 919], ["diarrhea", "PROBLEM", 921, 929], ["hypertension", "PROBLEM", 931, 943], ["diabetes", "PROBLEM", 949, 957], ["stable", "OBSERVATION_MODIFIER", 821, 827], ["diarrhea", "OBSERVATION", 921, 929], ["hypertension", "OBSERVATION", 931, 943], ["diabetes", "OBSERVATION", 949, 957]]], ["The term severity in this study represents death/ICU/severe state or any other critical medical state.", [["death", "DISEASE", 43, 48], ["The term severity", "PROBLEM", 0, 17], ["this study", "TEST", 21, 31], ["term severity", "OBSERVATION_MODIFIER", 4, 17]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Outcomes and CovariatesThe copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20086744 doi: medRxiv preprint publication year, study design, sample size, country, and other related information from the finally selected studies.Statistical AnalysisConsidering the primary goal of the study we performed random effect meta-analysis where the effect sizes were computed from the raw information dragged from individual studies.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 225, 245], ["the finally selected studies", "TEST", 454, 482], ["Statistical Analysis", "TEST", 483, 503], ["the study", "TEST", 535, 544], ["the effect sizes", "PROBLEM", 592, 608], ["individual studies", "TEST", 661, 679], ["med", "ANATOMY", 105, 108], ["size", "OBSERVATION_MODIFIER", 404, 408]]], ["We considered the effect size for the study to be a Risk Ratio [RR] and reported with a 95% confidence interval.", [["the study", "TEST", 34, 43], ["a Risk Ratio", "TEST", 50, 62], ["RR", "TEST", 64, 66], ["size", "OBSERVATION_MODIFIER", 25, 29]]], ["I 2 statistic reported in the forest plot reflects relative between studies heterogeneity and P value (two tail with level 0.05) determines the significance of the heterogeneity test.", [["the forest plot", "TEST", 26, 41], ["P value", "TEST", 94, 101], ["the heterogeneity test", "TEST", 160, 182]]], ["Microsoft Excel 2013 was used to create metadata, get their univariate characteristics, and export to other software for further analysis.", [["further analysis", "TEST", 121, 137]]], ["Random effect meta-analysis and relevant forest plots were generated using statistical software R version 3.5.1.ResultsWe have extracted 2272 patients' information from 10 autonomous studies 14-23 and incorporated them into this research.", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["Random effect meta-analysis", "PROBLEM", 0, 27], ["relevant forest plots", "PROBLEM", 32, 53], ["statistical software R version", "TEST", 75, 105], ["autonomous studies", "TEST", 172, 190]]], ["The highest sample size for the isolated study was 1099, and 34 was the smallest sample size, other study characteristics are summarized in Table 1 .", [["sample", "ANATOMY", 12, 18], ["the isolated study", "TEST", 28, 46], ["other study", "TEST", 94, 105], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 19, 23], ["size", "OBSERVATION_MODIFIER", 88, 92]]], ["Table 2 demonstrates that the bulk of the COVID-19 patients included in the study through a methodical scheme are male (60%).", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["the study", "TEST", 72, 81]]], ["The clinical characteristics of the patients comprise diabetes (11.2%), hypertension (21.3%), fever (90.2%), cough (65%), fatigue or myalgia (41.0%), and diarrhea (9.2%).", [["diabetes", "DISEASE", 54, 62], ["hypertension", "DISEASE", 72, 84], ["fever", "DISEASE", 94, 99], ["cough", "DISEASE", 109, 114], ["fatigue", "DISEASE", 122, 129], ["myalgia", "DISEASE", 133, 140], ["diarrhea", "DISEASE", 154, 162], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["diabetes", "TEST", 54, 62], ["hypertension", "PROBLEM", 72, 84], ["fever", "PROBLEM", 94, 99], ["cough", "PROBLEM", 109, 114], ["fatigue", "PROBLEM", 122, 129], ["myalgia", "PROBLEM", 133, 140], ["diarrhea", "PROBLEM", 154, 162], ["hypertension", "OBSERVATION", 72, 84]]], ["Only 11.3% of the patients smoke cigarettes (current or past smoker).ResultsForest plot in (Figure 2) illustrates that only six studies were entailed for the meta-analysis for characteristic smoking history where all ten studies availed information about the sex of the patients.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 270, 278], ["Forest plot", "TEST", 76, 87], ["six studies", "TEST", 124, 135]]], ["From the random-effect meta-analysis, we see that patients with smoking history have a higher risk to experience a severe state of COVID-19 (RR =1.71; 95% CI, 1.25 to 2.35) or .", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["COVID", "TEST", 131, 136], ["RR", "TEST", 141, 143], ["CI", "TEST", 155, 157]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20086744 doi: medRxiv preprint 71% higher risk pertained to a non-smoker patient.", [["CC", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 383, 390], ["patient", "SPECIES", 383, 390], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 324, 331], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The pooled risk ratio for the male suggests higher risk compared to female patients (RR=1.29; 95% CI, 1.07 to 1.54).", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["The pooled risk ratio", "TEST", 0, 21], ["RR", "TEST", 85, 87], ["CI", "TEST", 98, 100]]], ["In both cases between-study heterogeneity is low and the test of heterogeneity is insignificant (I 2 =38%, P=0.15; and I 2 =33%, P=0.15, respectively).", [["study heterogeneity", "TEST", 22, 41], ["P", "TEST", 107, 108], ["I", "TEST", 119, 120], ["P", "TEST", 129, 130], ["low", "OBSERVATION_MODIFIER", 45, 48], ["insignificant", "OBSERVATION_MODIFIER", 82, 95]]], ["Although six isolated studies data implies that diabetes is an insignificant risk factor but the overall effect is significant and indicates a higher risk to undergo brutal state for a patient with diabetes (RR =1.57; 95% CI, 1.25 to 1.98).", [["diabetes", "DISEASE", 48, 56], ["diabetes", "DISEASE", 198, 206], ["patient", "ORGANISM", 185, 192], ["patient", "SPECIES", 185, 192], ["six isolated studies data", "TEST", 9, 34], ["diabetes", "PROBLEM", 48, 56], ["an insignificant risk factor", "PROBLEM", 60, 88], ["diabetes", "PROBLEM", 198, 206], ["RR", "TEST", 208, 210], ["CI", "TEST", 222, 224], ["diabetes", "OBSERVATION", 48, 56]]], ["The heterogeneity is moderate (I 2 =54%) and the test for heterogeneity is significant ( 2 =19.59, P=0.02).", [["the test", "TEST", 45, 53], ["P", "TEST", 99, 100], ["heterogeneity", "OBSERVATION", 4, 17], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["significant", "OBSERVATION_MODIFIER", 75, 86]]], ["Also, patients with hypertension have a higher risk (RR=1.79; 95% CI, 1.57 to 2.04) compared to patient those are not suffering from hypertension with insignificant heterogeneity, I 2 =0% (P=0.50).(which was not certified by peer review)Respectively eight and nine studies were involved in the analysis for factors diarrhea and fatigue or myalgia of patients ( Figure 4 ).", [["hypertension", "DISEASE", 20, 32], ["hypertension", "DISEASE", 133, 145], ["diarrhea", "DISEASE", 315, 323], ["fatigue", "DISEASE", 328, 335], ["myalgia", "DISEASE", 339, 346], ["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 96, 103], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 96, 103], ["patients", "SPECIES", 350, 358], ["hypertension", "PROBLEM", 20, 32], ["RR", "TEST", 53, 55], ["CI", "TEST", 66, 68], ["hypertension", "PROBLEM", 133, 145], ["insignificant heterogeneity", "PROBLEM", 151, 178], ["P", "TEST", 189, 190], ["nine studies", "TEST", 260, 272], ["the analysis", "TEST", 290, 302], ["diarrhea", "PROBLEM", 315, 323], ["fatigue", "PROBLEM", 328, 335], ["myalgia", "PROBLEM", 339, 346], ["hypertension", "OBSERVATION", 20, 32], ["hypertension", "OBSERVATION", 133, 145], ["insignificant", "OBSERVATION_MODIFIER", 151, 164], ["heterogeneity", "OBSERVATION", 165, 178]]], ["In both cases the heterogeneity is very low and is insignificant (I 2 =8%, P=0.37) and (I 2 =0%, P=0.86), respectively).", [["P", "TEST", 75, 76], ["P", "TEST", 97, 98], ["heterogeneity", "OBSERVATION", 18, 31], ["very", "OBSERVATION_MODIFIER", 35, 39], ["low", "OBSERVATION_MODIFIER", 40, 43], ["insignificant", "OBSERVATION_MODIFIER", 51, 64]]], ["The pooled random effect infers diarrhea have an insignificant impact on the severity of COVID-19 (RR=1.14; 95% CI, 0.93 to 1.40).", [["diarrhea", "DISEASE", 32, 40], ["The pooled random effect infers diarrhea", "PROBLEM", 0, 40], ["COVID", "TEST", 89, 94], ["RR", "TEST", 99, 101], ["CI", "TEST", 112, 114], ["insignificant", "OBSERVATION_MODIFIER", 49, 62], ["impact", "OBSERVATION_MODIFIER", 63, 69]]], ["But the overall RR=1.17 (95% CI, 1.02 to 1.35) suggests that patients with fatigue or myalgia have a 17% higher risk to go through a severe state of COVID-19.(which was not certified by peer review)From ( Figure 5 ), we glimpse that cough and fever have no considerable relation with the severity of COVID-19.", [["fatigue", "DISEASE", 75, 82], ["myalgia", "DISEASE", 86, 93], ["cough", "DISEASE", 233, 238], ["fever", "DISEASE", 243, 248], ["COVID-19", "CHEMICAL", 300, 308], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["the overall RR", "TEST", 4, 18], ["CI", "TEST", 29, 31], ["fatigue", "PROBLEM", 75, 82], ["myalgia", "PROBLEM", 86, 93], ["a severe state of COVID", "PROBLEM", 131, 154], ["cough", "PROBLEM", 233, 238], ["fever", "PROBLEM", 243, 248], ["COVID", "TEST", 300, 305]]], ["The pooled effect reflects patient with cough symptom has RR=1.13 (95% CI, 0.98 to 1.30) and patient with fever has RR=1.21 (95% CI, 0.66 to 2.22).", [["cough", "DISEASE", 40, 45], ["fever", "DISEASE", 106, 111], ["patient", "ORGANISM", 27, 34], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 27, 34], ["patient", "SPECIES", 93, 100], ["cough symptom", "PROBLEM", 40, 53], ["RR", "TEST", 58, 60], ["CI", "TEST", 71, 73], ["fever", "PROBLEM", 106, 111], ["RR", "TEST", 116, 118], ["CI", "TEST", 129, 131]]], ["Although for cough symptom the between-study heterogeneity is nil and insignificant (I 2 =0%, P=0.48), it is very big and also significant for fever (I 2 =85%, P<0.01).(which was not certified by peer review).", [["cough", "DISEASE", 13, 18], ["fever", "DISEASE", 143, 148], ["cough symptom", "PROBLEM", 13, 26], ["P", "TEST", 94, 95], ["fever", "PROBLEM", 143, 148], ["I", "TEST", 150, 151], ["P", "TEST", 160, 161], ["insignificant", "OBSERVATION_MODIFIER", 70, 83]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020.DiscussionThis study through an organized way incorporated 10 publications and performed a randomeffect meta-analysis to identify some risk factors that are probably accountable for the severity of COVID-19.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["This study", "TEST", 282, 292], ["a randomeffect meta-analysis", "TEST", 361, 389], ["some risk factors", "PROBLEM", 402, 419], ["COVID", "TEST", 470, 475], ["med", "ANATOMY", 105, 108]]], ["Although none of the articles incorporated in the current research reports any effect size, we computed the effect size (risk ratio) from the published data.", [["the published data", "TEST", 138, 156], ["size", "OBSERVATION_MODIFIER", 86, 90], ["size", "OBSERVATION_MODIFIER", 115, 119]]], ["The pooled effect size with confidence interval deemed to avouch a factor as a significant risk factor.DiscussionWe found male patients have a reasonably higher risk to undergo the severity of COVID-19 compared to female patients echoing with some previous studies 8, 9 .", [["COVID", "DISEASE", 193, 198], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 221, 229], ["a factor", "PROBLEM", 65, 73], ["a significant risk factor", "PROBLEM", 77, 102], ["COVID", "TEST", 193, 198], ["some previous studies", "TEST", 243, 264], ["effect", "OBSERVATION_MODIFIER", 11, 17], ["size", "OBSERVATION_MODIFIER", 18, 22]]], ["An explanation of this can be, the male has weaker immunity because of genetic and hormonal factors and has shown higher mortality in several infectious diseases 24,25 .DiscussionAlthough some aforementioned studies 8,10 found smoking as an insignificant factor to worsen the state of COVID-19 patients, we have found smoking as a significant factor.", [["infectious diseases", "DISEASE", 142, 161], ["smoking", "CHEMICAL", 227, 234], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["genetic and hormonal factors", "PROBLEM", 71, 99], ["several infectious diseases", "PROBLEM", 134, 161], ["some aforementioned studies", "TEST", 188, 215], ["an insignificant factor", "PROBLEM", 238, 261], ["higher", "OBSERVATION_MODIFIER", 114, 120], ["mortality", "OBSERVATION_MODIFIER", 121, 130], ["several", "OBSERVATION_MODIFIER", 134, 141], ["infectious", "OBSERVATION", 142, 152]]], ["Smoking is associated with lower or impoverished immunity of smokers 26 , which can explain why smokers might have elevated risks.", [["Smoking", "DISEASE", 0, 7], ["smokers", "ORGANISM", 96, 103], ["elevated risks", "PROBLEM", 115, 129]]], ["A meta-analysis 9 supports our finding, which documented smoking as a significant risk factor, and smokers have a higher risk to undergo a severe state of COVID-19.", [["smoking", "CHEMICAL", 57, 64], ["COVID-19", "CHEMICAL", 155, 163], ["A meta-analysis", "TEST", 0, 15], ["COVID", "TEST", 155, 160]]], ["In a previous study 27 , smoking was also reported as a risk factor for the critical illness of MERS (Middle East Respiratory Syndrome) too.DiscussionWe incorporated some clinical traits of the patients like cough, fever, fatigue or myalgia, diarrhea, diabetes, and hypertension in this study.", [["MERS", "DISEASE", 96, 100], ["Middle East Respiratory Syndrome", "DISEASE", 102, 134], ["cough", "DISEASE", 208, 213], ["fever", "DISEASE", 215, 220], ["fatigue", "DISEASE", 222, 229], ["myalgia", "DISEASE", 233, 240], ["diarrhea", "DISEASE", 242, 250], ["diabetes", "DISEASE", 252, 260], ["hypertension", "DISEASE", 266, 278], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["a previous study", "TEST", 3, 19], ["Middle East Respiratory Syndrome", "PROBLEM", 102, 134], ["cough", "PROBLEM", 208, 213], ["fever", "PROBLEM", 215, 220], ["fatigue", "PROBLEM", 222, 229], ["myalgia", "PROBLEM", 233, 240], ["diarrhea", "PROBLEM", 242, 250], ["diabetes", "PROBLEM", 252, 260], ["hypertension", "PROBLEM", 266, 278], ["this study", "TEST", 282, 292], ["Respiratory Syndrome", "OBSERVATION", 114, 134], ["myalgia", "OBSERVATION", 233, 240], ["diarrhea", "OBSERVATION", 242, 250], ["diabetes", "OBSERVATION", 252, 260], ["hypertension", "OBSERVATION", 266, 278]]], ["Among those, we have found fatigue or myalgia, hypertension, and diabetes are significant risk factors that might lead to a critical state of COVID-19 patients.", [["fatigue", "DISEASE", 27, 34], ["myalgia", "DISEASE", 38, 45], ["hypertension", "DISEASE", 47, 59], ["diabetes", "DISEASE", 65, 73], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["fatigue", "PROBLEM", 27, 34], ["myalgia", "PROBLEM", 38, 45], ["hypertension", "PROBLEM", 47, 59], ["diabetes", "PROBLEM", 65, 73], ["significant risk factors", "PROBLEM", 78, 102], ["fatigue", "OBSERVATION", 27, 34], ["myalgia", "OBSERVATION", 38, 45], ["hypertension", "OBSERVATION", 47, 59]]], ["Some previous studies 8,12,13 also reported both diabetes and hypertension are significant risk factors of COVID-19 progression.", [["diabetes", "DISEASE", 49, 57], ["hypertension", "DISEASE", 62, 74], ["Some previous studies", "TEST", 0, 21], ["both diabetes", "PROBLEM", 44, 57], ["hypertension", "PROBLEM", 62, 74], ["COVID", "TEST", 107, 112], ["diabetes", "OBSERVATION", 49, 57], ["hypertension", "OBSERVATION", 62, 74]]], ["These two comorbidities negatively affected MERS-CoV patients' too 28 .Discussion.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["MERS-CoV", "SPECIES", 44, 52], ["These two comorbidities", "PROBLEM", 0, 23], ["comorbidities", "OBSERVATION", 10, 23]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["From the random-effect meta-analysis, we conclude fever, cough, and diarrhea are insignificant risk factors for the severity of COVID-19.", [["fever", "DISEASE", 50, 55], ["cough", "DISEASE", 57, 62], ["diarrhea", "DISEASE", 68, 76], ["COVID-19", "CHEMICAL", 128, 136], ["fever", "PROBLEM", 50, 55], ["cough", "PROBLEM", 57, 62], ["diarrhea", "PROBLEM", 68, 76], ["insignificant risk factors", "PROBLEM", 81, 107], ["COVID", "TEST", 128, 133], ["fever", "OBSERVATION", 50, 55]]], ["But a previous meta-analysis 8 published fever as a significant risk factor for the severity of COVID-19.(which was not certified by peer review)In conclusion, sex (male), smoking history, diabetes, hypertension, and fatigue or myalgia can be considered as significant risk factors for the severity of COVID-19.", [["fever", "DISEASE", 41, 46], ["diabetes", "DISEASE", 189, 197], ["hypertension", "DISEASE", 199, 211], ["fatigue", "DISEASE", 217, 224], ["myalgia", "DISEASE", 228, 235], ["COVID-19", "CHEMICAL", 96, 104], ["COVID-19", "CHEMICAL", 302, 310], ["a previous meta-analysis", "TEST", 4, 28], ["fever", "PROBLEM", 41, 46], ["COVID", "TEST", 96, 101], ["diabetes", "PROBLEM", 189, 197], ["hypertension", "PROBLEM", 199, 211], ["fatigue", "PROBLEM", 217, 224], ["myalgia", "PROBLEM", 228, 235], ["significant risk factors", "PROBLEM", 257, 281], ["COVID", "TEST", 302, 307], ["diabetes", "OBSERVATION", 189, 197], ["hypertension", "OBSERVATION", 199, 211]]], ["It may require additional medical attention for patients with higher risk from the very beginning of the treatment.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["additional medical attention", "TREATMENT", 15, 43], ["the treatment", "TREATMENT", 101, 114]]], ["We also hope the findings of this study may assist experts in vaccine development programs. .", [["this study", "TEST", 29, 39], ["vaccine development programs", "TREATMENT", 62, 90]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Note: Data are presented as n, and (n/N *100%); where n is the number of patients with certain characteristics and N is the total number of available patients observed in the study under that certain characteristics.(which was not certified by peer review).", [["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 150, 158], ["the study", "TEST", 171, 180]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20086744 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["The copyright holder", "TREATMENT", 489, 509], ["medRxiv", "TREATMENT", 612, 619], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 352, 355]]]], "PMC7334736": [["IntroductionIntroductory programming courses are difficult [10], frustrating [8], and often considered a major stumbling block for many students [15].", [["a major stumbling block", "PROBLEM", 103, 126]]], ["There is much evidence that drop-out and failure rates in introductory Computer Science courses such as CS1 and CS2 are high (30\u201340%) [3, 12, 16].IntroductionIntelligent Tutoring Systems have been proven to be beneficial solutions that can provide individualized, one-on-one instruction for all students [1], and improve the quality and effectiveness of computer programming instruction [14].", [["CS2", "CHEMICAL", 112, 115], ["CS1", "GENE_OR_GENE_PRODUCT", 104, 107], ["CS2", "GENE_OR_GENE_PRODUCT", 112, 115], ["failure rates", "PROBLEM", 41, 54], ["CS1", "TEST", 104, 107], ["CS2", "TEST", 112, 115], ["beneficial solutions", "TREATMENT", 210, 230], ["drop", "OBSERVATION_MODIFIER", 28, 32], ["high", "OBSERVATION_MODIFIER", 120, 124]]], ["Furthermore, the developed system relies on self-explanation theories of learning [5] by implementing instructional strategies such as eliciting self-explanations through Socratic questioning.IntroductionSocratic Tutor ITS uses a natural language understanding (NLU) engine [2] to evaluate students\u2019 responses with respect by computing a semantic similarity score to model/benchmark correct answers and well-known misconceptions created prior by experts.", [["instructional strategies", "TREATMENT", 102, 126]]], ["The developed system provides help to students using a three-level feedback strategy where at level one the tutor explains briefly the target concept and gives the student a second chance to retry answering the original question.", [["a three-level feedback strategy", "TREATMENT", 53, 84]]], ["At levels two and three, the tutor asks questions in the form of multiple-choice and fill-in-the-blank questions.IntroductionThis paper analyzes a comparative study of using the Socratic Tutor ITS for learning JAVA programming in Introductory to Computer Science courses (CS1 and CS2) focusing on arithmetic operations, nested", [["a comparative study", "TEST", 145, 164], ["the Socratic Tutor", "TREATMENT", 174, 192], ["arithmetic operations", "TREATMENT", 297, 318]]]], "2c3ac740ad80a760a8cb48b014d118043b76acd8": [["The array of pathogens responsible for the disproportionate number of childhood deaths that occur in sub-Saharan Africa and South Asia is not fully defined.", [["deaths", "DISEASE", 80, 86], ["pathogens", "PROBLEM", 13, 22], ["childhood deaths", "PROBLEM", 70, 86], ["pathogens", "OBSERVATION", 13, 22], ["disproportionate", "OBSERVATION_MODIFIER", 43, 59], ["number", "OBSERVATION_MODIFIER", 60, 66]]], ["Dramatic reductions in childhood morbidity and mortality associated with individual organisms, including polio, tetanus, measles, human immunodeficiency virus, and malaria [1] , have been achieved through successful targeted public health intervention strategies.", [["tetanus", "DISEASE", 112, 119], ["measles", "DISEASE", 121, 128], ["human immunodeficiency virus", "DISEASE", 130, 158], ["malaria", "DISEASE", 164, 171], ["human immunodeficiency virus", "ORGANISM", 130, 158], ["human", "SPECIES", 130, 135], ["immunodeficiency virus", "SPECIES", 136, 158], ["human immunodeficiency virus", "SPECIES", 130, 158], ["Dramatic reductions", "PROBLEM", 0, 19], ["childhood morbidity", "PROBLEM", 23, 42], ["mortality", "PROBLEM", 47, 56], ["individual organisms", "PROBLEM", 73, 93], ["polio", "PROBLEM", 105, 110], ["tetanus", "PROBLEM", 112, 119], ["measles", "PROBLEM", 121, 128], ["human immunodeficiency virus", "PROBLEM", 130, 158], ["malaria", "PROBLEM", 164, 171], ["intervention strategies", "TREATMENT", 239, 262], ["reductions", "OBSERVATION_MODIFIER", 9, 19], ["childhood", "OBSERVATION_MODIFIER", 23, 32], ["morbidity", "OBSERVATION", 33, 42]]], ["Such information can be used to strengthen existing public health measures such as vaccination, antimicrobial treatment guidelines, and appropriate infection control practices, and to prioritize the development of new tools and strategies.", [["infection", "DISEASE", 148, 157], ["public health measures", "TREATMENT", 52, 74], ["vaccination", "TREATMENT", 83, 94], ["antimicrobial treatment guidelines", "TREATMENT", 96, 130], ["appropriate infection control practices", "TREATMENT", 136, 175]]]]}